A patient may have limited or impaired mobility such that typical urination processes are challenging or impossible. For example, the patient may have surgery or a disability that impairs mobility. In another example, the patient may have restricted travel conditions such as those experience by pilots, drivers, and workers in hazardous areas. Additionally, fluid collection from the patient may be needed for monitoring purposes or clinical testing.
Bed pans and urinary catheters, such as a Foley catheter, may be used to address some of these circumstances. However, bed pans and urinary catheters have several problems associated therewith. For example, bed pans may be prone to discomfort, spills, and other hygiene issues. Urinary catheters be may be uncomfortable, painful, and may cause urinary tract infections.
Thus, users and manufacturers of fluid collection assemblies continue to seek new and improved devices, systems, and methods to collect urine.
Embodiments disclosed herein include fluid collection assemblies with at least one securement body, fluid collection systems including the same, and methods of using the same. In an embodiment, a fluid collection assembly is disclosed. The fluid collection assembly includes a fluid impermeable barrier at least defining a chamber, at least one opening, and a fluid outlet. The fluid collection assembly also includes at least one porous material disposed in the chamber and at least one securement body configured to limit movement of the fluid collection assembly relative to a region about a urethral opening of a patient. The at least one securement body includes at least one of a plurality of fibers exhibiting an average lateral dimension of about 5 μm or less, a plurality of suction cups, or at least one friction material exhibiting a coefficient of static friction that is greater than at least a portion of the at least one porous material.
In an embodiment, a fluid collection system is disclosed. The fluid collection system includes a fluid storage container configured to hold one or more bodily fluids therein. The fluid collection system also includes a fluid collection assembly. The fluid collection assembly includes a fluid impermeable barrier at least defining a chamber, at least one opening, and a fluid outlet. The fluid collection assembly also includes at least one porous material disposed in the chamber and at least one securement body configured to limit movement of the fluid collection assembly relative to a region about a urethral opening of a patient. The at least one securement body includes at least one of a plurality of fibers exhibiting an average lateral dimension of about 5 μm or less, a plurality of suction cups, or at least one friction material exhibiting a coefficient of static friction that is greater than at least a portion of the at least one porous material. The fluid collection system further includes a vacuum source in fluid communication with the fluid storage container and the fluid collection assembly. The vacuum source is configured to draw the one or more bodily fluids from the fluid collection assembly and deposit the one or more bodily fluids in the fluid storage container via one or more conduits.
Features from any of the disclosed embodiments may be used in combination with one another, without limitation. In addition, other features and advantages of the present disclosure will become apparent to those of ordinary skill in the art through consideration of the following detailed description and the accompanying drawings.
The drawings illustrate several embodiments of the present disclosure, wherein identical reference numerals refer to identical or similar elements or features in different views or embodiments shown in the drawings.
Embodiments disclosed herein include fluid collection assemblies with at least one securement body, fluid collection systems including the same, and methods of using the same. An example fluid collection assembly may include a male fluid collection assembly configured to receive one or more bodily fluids (e.g., urine, blood, sweat, etc.) from a male urethral opening or a female fluid collection assembly configured to receive the bodily fluids from a female urethral opening. The fluid collection assembly includes a fluid impermeable barrier that at least defines a chamber, at least one opening, and a fluid outlet. The fluid collection assembly also includes at least one porous material disposed in the chamber and at least one securement body. The securement body is disposed on one or more components of the fluid collection assembly and is configured to limit movement of the fluid collection assembly relative to a region about a urethral opening of the patient. For example, the securement body may be disposed on one or more of at least a portion of the fluid impermeable barrier, at least a portion of the porous material that extends across the opening, or a base. Examples of securement bodies include a plurality of fibers extending from at least one exterior surface of the fluid collection assembly, a plurality of suction cups, or a friction material that exhibits a coefficient of friction that is greater than at least a portion of the porous material.
During use, the fluid collection assembly is positioned adjacent to or receives the urethral opening of the patient. The patient may discharge one or more bodily fluids and the fluid collection assembly may receive the bodily fluids. However, movement of the fluid collection assembly may prevent the fluid collection assembly from receiving all or substantially all of the bodily fluids that are discharged by the patient. For example, movement of the fluid collection assembly may cause bodily fluids to leak. The leaked bodily fluids may create patient discomfort by causing the skin of the patient to remain moist, creating unsanitary conditions, requiring cleaning of the patient, and causing embarrassment to the patient.
Some conventional fluid collection assemblies rely on chemical adhesives or contact between the thighs of the patient and the fluid impermeable barrier to maintain the position of the fluid collection assembly and prevent bodily fluid leaks. However, the chemical adhesives may be painful to remove from the patient since such chemical adhesives may be attached to hair and sensitive regions of the patient (e.g., the region about the urethral opening). Further, the contact between the thighs of the patient and the fluid impermeable barrier may be unable to maintain the position of the fluid collection assembly because the patient is too thin (e.g., has gaps between the thighs that prevent contact with the fluid impermeable barrier) or the patient moves. The fluid collection assemblies that include at least one securement body (e.g., the plurality of fibers, the friction material, and/or the plurality of suction cups) are improvements over such conventional fluid collection assemblies. In an example, the securement body may engage the patient to limit movement of the fluid collection assembly but, unlike chemical adhesives, the securement body may be easily removed when certain forces are applied thereto. Further, the securement body may maintain the position of the fluid collection assembly even when the patient is too thin for the thighs of the patient to contact the fluid collection assembly and/or when the patient moves.
The sheath 102 includes a fluid impermeable barrier 108 that is at least partially formed from a first panel 110 and a second panel 112. The first panel 110 and the second panel 112 may be attached or integrally formed together (e.g., exhibits single piece construction). In an embodiment, as illustrated, the first panel 110 and the second panel 112 are distinct sheets. The fluid impermeable barrier 108 also defines a chamber 114 between the first panel 110 and the second panel 112, an opening 116 at a first end region 120 of the sheath 102, and an fluid outlet 118 at a second end region 122 of the sheath 102. The sheath 102 also includes at least one porous material 115 disposed in the chamber 114.
The inner surface(s) 124 of the fluid impermeable barrier 108 (e.g., inner surfaces of the first and second panels 110, 112) at least partially defines the chamber 114 within the fluid collection assembly 100. The fluid impermeable barrier 108 temporarily stores the bodily fluids in the chamber 114. The fluid impermeable barrier 108 may be formed of any suitable fluid impermeable material(s), such as a fluid impermeable polymer (e.g., silicone, polypropylene, polyethylene, polyethylene terephthalate, neoprene, a polycarbonate, etc.), a metal film, natural rubber, another suitable material, or combinations thereof. As such, the fluid impermeable barrier 108 substantially prevents the bodily fluids from passing through the fluid impermeable barrier 108. In an example, the fluid impermeable barrier 108 may be air permeable and fluid impermeable. In such an example, the fluid impermeable barrier 108 may be formed of a hydrophobic material that defines a plurality of pores. At least one or more portions of at least an outer surface 126 of the fluid impermeable barrier 108 may be formed from a soft and/or smooth material, thereby reducing chaffing.
In an embodiment, at least one of the first panel 110 or the second panel 112 is formed from an at least partially transparent fluid impermeable material, such as polyethylene, polypropylene, polycarbonate, or polyvinyl chloride. Forming at least one of the first panel 110 or the second panel 112 from an at least partially transparent fluid impermeable material allows a person (e.g., medical practitioner) to examiner the penis. In some embodiments, both the first panel 110 and the second panel 112 are formed from at least partially transparent fluid impermeable material. Selecting at least one of the first panel 110 or the second panel 112 to be formed from an at least partially transparent impermeable material allows the penis to be examined without detaching the entire fluid collection assembly 100 from the region about the penis. For example, the chamber 114 may include a penis receiving area 128 that is configured to receive the penis of the individual when the penis extends into the chamber 114. The penis receiving area 128 may be defined by at least the porous material 115 and at least a portion of the at least partially transparent material of the first panel 110 and/or the second panel 112. In other words, the porous material 115 is positioned in the chamber 114 such that the porous material 115 is not positioned between the penis and at least a portion of the transparent portion of the first panel 110 and/or second panel 112 when the penis is inserted into the chamber 114 through the opening 116. The porous material 115 is generally not transparent and, thus, the portion of the at least partially transparent material of the first panel 110 and/or the second panel 112 that defines the penis receiving area 128 forms a window which allows the person to view into the penis receiving area 128 and examine the penis.
The opening 116 defined by the fluid impermeable barrier 108 provides an ingress route for fluids to enter the chamber 114 when the penis is a buried penis and allow the penis to enter the chamber 114 (e.g., the penis receiving area 128) when the penis is not buried. The opening 116 may be defined by the fluid impermeable barrier 108 (e.g., an inner edge of the fluid impermeable barrier 108). For example, the opening 116 is formed in and extends through the fluid impermeable barrier 108 thereby enabling bodily fluids to enter the chamber 114 from outside of the fluid collection assembly 100.
The fluid impermeable barrier 108 defines an fluid outlet 118 sized to receive an conduit 130. The conduit 130 may be at least partially disposed in the chamber 114 or otherwise in fluid communication with the chamber 114 through the fluid outlet 118. The fluid outlet 118 may be sized and shaped to form an at least substantially fluid tight seal against the conduit 130 thereby substantially preventing the bodily fluids from escaping the chamber 114. In an embodiment, the fluid outlet 118 may be formed from a portion of the first panel 110 and the second panel 112 that are not attached or integrally formed together. In such an embodiment, the fluid impermeable barrier 108 may not include a cap exhibiting a rigidity that is greater than the portions of the fluid impermeable barrier 108 thereabout which may facilitate manufacturing of the fluid collection assembly 100 may decreasing the number of parts that are used to form the fluid collection assembly 100 and may decrease the time required to manufacture the fluid collection assembly 100. The lack of the cap may make securing the conduit 130 to the fluid outlet 118 using interference fit to be difficult though, it is noted, attaching the conduit 130 to the fluid outlet 118 may still be possible. As such, the conduit 130 may be attached to the fluid outlet 118 (e.g., to the first and second panels 110, 112) using an adhesive, a weld, or otherwise bonding the fluid outlet 118 to the fluid outlet 118. Attaching the conduit 130 to the fluid outlet 118 may prevent leaks and may prevent the conduit 130 from inadvertently becoming detached from the fluid outlet 118. In an example, the conduit 130 may be attached to the fluid outlet 118 in the same manufacturing step that attaches the first and second panels 110, 112 together.
As previously discussed, the sheath 102 includes at least one porous material 115 disclosed in the chamber 114. The porous material 115 may direct the bodily fluids to one or more selected regions of the chamber 114, such as away from the penis and towards the fluid outlet 118. In an embodiment, the porous material 115 includes a fluid permeable membrane extending across the opening 116 and a fluid permeable support since the fluid permeable membrane may be formed from a relatively foldable, flimsy, or otherwise easily deformable material. For example, the fluid permeable support may be positioned such that the fluid permeable membrane is disposed between the fluid permeable support and the fluid impermeable barrier 108. As such, the fluid permeable support may support and maintain the position of the fluid permeable membrane. The fluid permeable membrane may include fabric, such as a gauze (e.g., a silk, linen, or cotton gauze), another soft fabric, or another smooth fabric. The fluid permeable support may include any of the fluid permeable membrane materials disclosed above in a more dense or rigid form, a porous polymer (e.g., nylon, polyester, polyurethane, polyethylene, polypropylene, etc.) structure or an open cell foam, spun nylon fiber, a natural material (e.g., cotton, wool, silk, or combinations thereof), any other suitable material, or combinations thereof. In an embodiment, the porous material 115 may only include one of the fluid permeable membrane or the fluid permeable support. In an embodiment, the porous material 115 includes a first porous layer, a second porous layer, and a plurality of fibers forming a layer between the first and second layers.
In an embodiment, the porous material 115 may be configured to wick any bodily fluids away from the opening 116, thereby preventing the bodily fluids from escaping the chamber 114. The permeable properties referred to herein may be wicking, capillary action, diffusion, or other similar properties or processes, and are referred to herein as “permeable” and/or “wicking.” Such “wicking” may not include absorption of the bodily fluids into the wicking material. Put another way, substantially no absorption of the bodily fluids into the material may take place after the material is exposed to the bodily fluids and removed from the bodily fluids for a time. While no absorption is desired, the term “substantially no absorption” may allow for nominal amounts of absorption of the bodily fluids into the wicking material (e.g., absorbency), such as less than about 30 wt % of the dry weight of the porous material, less than 20 wt %, less than 15 wt %, less than 10 wt %, less than about 7 wt %, less than about 5 wt %, less than about 3 wt %, less than about 2 wt %, less than about 1 wt %, or less than about 0.5 wt % of the dry weight of the porous material. The wicking material may also wick the bodily fluids generally towards an interior of the chamber 114, as discussed in more detail below. In an embodiment, the porous material 115 may include at least one absorbent or adsorbent material.
In an embodiment, the porous material 115 may be a sheet. Forming the porous material 115 as a sheet may facilitate the manufacturing of the fluid collection assembly 100. For example, forming the porous material 115 as a sheet allows the first panel 110, the second panel 112, and the porous material 115 to each be sheets. During the manufacturing of the fluid collection assembly 100, the first panel 110, the second panel 112, and the porous material 115 may be stacked and then attached to each other in the same manufacturing step. For instance, the porous material 115 may exhibit a shape that is the same size or, more preferably, slightly smaller than the size of the first panel 110 and the second panel 112. As such, attaching the first panel 110 and the second panel 112 together along the outer edges thereof may also attach the porous material 115 to the first panel 110 and the second panel 112. The porous material 115 may be slightly smaller than the first panel 110 and the second panel 112 such that the first panel 110 and/or the second panel 112 extend around the porous material 115 such that the porous material 115 does not form a passageway through the fluid impermeable barrier 108 through which the bodily fluids may leak. Also, attaching the porous material 115 to the first panel 110 and/or the second panel 112 may prevent the porous material 115 from significantly moving in the chamber 114, such as preventing the porous material 115 from bunching together near the fluid outlet 118. In an example, the porous material 115 may be attached to the first panel 110 or the second panel 112 (e.g., via an adhesive) before or after attaching the first panel 110 to the second panel 112. In an example, the porous material 115 may merely be disposed in the chamber 114 without attaching the porous material 115 to at least one of the first panel 110 or the second panel 112. In an embodiment, as will be discussed in more detail below, the porous material 115 may exhibit shapes other than a sheet, such as a hollow generally cylindrical shape.
Generally, the sheath 102 is substantially flat when the penis is not in the penis receiving area 128 and the sheath 102 is resting on a flat surface. The sheath 102 is substantially flat because the fluid impermeable barrier 108 is formed from the first panel 110 and the second panel 112 instead of a generally tubular fluid impermeable barrier. Further, as previously discussed, the porous material 115 may be a sheet, which also causes the sheath 102 to be substantially flat. The sheath 102 may also be substantially flat because the fluid collection assembly 100 may not include relatively rigid rings or caps that exhibit a rigidity that is greater than the portions of the fluid impermeable barrier 108 thereabout since such rings and caps may inhibit the sheath 102 being substantially flat. It is noted that the sheath 102 is described as being substantially flat because at least one of the porous material 115 may cause a slight bulge to form in the sheath 102 depending on the thickness of the porous material 115, the fluid outlet 118 and/or conduit 130 may cause a bulge thereabout, or the base 104 may pull on portions of the sheath 102 thereabout. It is also noted that the sheath 102 may also be compliant and, as such, the sheath 102 may not be substantially flat during use since, during use, the sheath 102 may rest on a non-flat surface (e.g., may rest on the testicles, the perineum, and/or between the thighs) and the sheath 102 may conform to the surface of these shapes.
The ability of the sheath 102 to be substantially flat when the penis is not in the penis receiving area 128 and the sheath 102 is resting on a flat surface allows the fluid collection assembly 100 to be used with a buried and a non-buried penis. For example, when the fluid collection assembly 100 is being used with a buried penis, the penis does not extend into the penis receiving area 128 which causes the sheath 102 to lie relatively flat across the aperture 132 of the base 104. When the sheath 102 lies relatively flat across the aperture 132, the porous material 115 extends across the opening 116 and the aperature 132 and is in close proximity to the buried penis. As such, the porous material 115 prevents or inhibits pooling of bodily fluids discharged from the buried penis against the skin of the individual since the porous material 115 will receive and remove at least a significant portion of the bodily fluids that would otherwise pool against the skin of the individual. Thus, the skin of the individual remains dry thereby improving comfort of using the fluid collection assembly 100 and preventing skin degradation. However, unlike other conventional fluid collection assemblies that are configured to be used with buried penises, the fluid collection assembly 100 may still be used with a non-buried penis since the non-buried penis can still be received into the penis receiving area 128, even when the penis is fully erect. Additionally, the ability of the sheath 102 to be substantially flat allows the fluid collection assembly 100 to be used more discretely than if the sheath 102 was not substantially flat thereby avoiding possibly embarrassing scenarios.
When the sheath 102 is substantially flat, the porous material 115 occupies substantially all of the chamber 114 and the penis receiving area 128 is collapsed (shown as being non-collapsed in
As previously discussed, the first panel 110, the second panel 112, and the porous material 115 may be selected to be relatively flexible. The first panel 110, the second panel 112, and the porous material 115 are relatively flexible when the first panel 110, the second panel 112, and the porous material 115, respectively, are unable to maintain their shape when unsupported. The flexibility of the first panel 110, the second panel 112, and the porous material 115 may allow the sheath 102 to be substantially flat, as discussed above. The flexibility of the first panel 110, the second panel 112, and the porous material 115 may also allow the sheath 102 to conform to the shape of the penis even when the size and shape of the penis changes (e.g., becomes erect) and to minimize any unoccupied spaces in the chamber 114 in which bodily fluids may pool.
As previously discussed, the fluid collection assembly 100 includes a base 104 that is configured to be attached to the sheath 102. For example, the base 104 is configured to be permanently attached to the sheath 102. The base 104 is configured to be permanently attached to the sheath 102 when, for example, when the fluid collection assembly 100 is provided with the base 104 permanently attached to the sheath 102 or the base 104 is provided without being permanently attached to the sheath 102 but is configured to be permanently attached to the sheath 102 at some point in the future. Permanently attached means that the sheath 102 cannot be detached from the base 104 without damaging at least one of the sheath 102 or the base 104, using a blade to separate the sheath 102 from the base 104, and/or using chemicals to dissolve the adhesive that attaches the sheath 102 from the base 104. The base 104 may be permanently attached to the sheath 102 using an adhesive, sewing, heat sealing, RF welding, or US welding. In an embodiment, the base 104 is configured to be reversibly attached to the sheath 102.
As previously discussed, the base 104 includes an aperture 132. The base 104 is permanently attached to the first end region 120 of the sheath 102 such that the aperture 132 is aligned with the opening 116.
The base 104 is sized, shaped, and made of a material to be coupled to the skin that surrounds the penis (e.g., mons pubis, thighs, testicles, and/or perineum) and have the penis disposed therethrough. For example, the base 104 may define an aperture 132 configured to have the penis positioned therethrough. In an example, the base 104 may exhibit the general shape or contours of the skin surface that the base 104 is configured to be coupled with. The base 104 may be flexible, thereby allowing the base 104 to conform to any shape of the skin surface and mitigate the base 104 pulling the on skin surface. The base 104 may extend laterally past the sheath 102 thereby increasing the surface area of the skin of the individual to which the fluid collection assembly 100 may be attached compared to a substantially similar fluid collection assembly 100 that did not include a base.
The substrate 134 may be formed from any suitable material. In an embodiment, the substrate 134 may be formed from fluid impermeable material(s), such as any of the fluid impermeable materials disclosed herein. In such an embodiment, the substrate 134 inhibits bodily fluids from leaking therethrough. In an embodiment, the substrate 134 is formed from a porous material, such as a porous material that is air-permeable and water impermeable (e.g., a hydrophobic porous material). In such an embodiment, the substrate 134 may allow air to flow therethrough thereby encouraging fluid flow through the fluid collection assembly 100 and preventing a suction force provided to the fluid collection assembly 100 from giving the patient a hickie. In an embodiment, the substrate 134 may be formed from a flexible material and/or may exhibit a relatively thin thickness (e.g., less than about 2 mm, less than about 1 mm, less than about 0.5 mm, or in ranges of about 0.25 mm to about 0.75 mm, about 0.5 mm to about 1 mm, about 0.75 mm to about 1.5 mm, or about 1 mm to about 2 mm). The flexibility and/or thickness of the substrate 134 may allow the substrate 134 to be shaped to conform to the shape of the region about the urethral opening (e.g., mons pubis, testicles, etc.) without pulling on the region about the urethral opening.
The base 104 also include a securement body 106. The securement body 106 includes a support 140 that is distinct from the substrate 134. At least a portion of the support 140 is attached to at least a portion of bottom surface 138 of the substrate 134. The support 140 may be attached to the substrate 134 using any suitable technique, such as with an adhesive, ultrasonic welding, etc. Generally, the attachment between the substrate 134 and the support 140 is greater than a maximum attachment between the securement body 106 and the skin of the patient such that detaching the base 104 from the patient is unlikely to detach the support 140 from the substrate 134. It is noted that the securement body 106 and the support 140 may be attached to components of the fluid collection assembly 100 other than or in addition to the base 104, as will be discussed in more detail below.
The support 140 may be formed from any suitable material. In an embodiment, the support 140 may be formed from fluid impermeable material(s), such as any of the fluid impermeable materials disclosed herein. In such an embodiment, the support 140 inhibits bodily fluids from leaking therethrough. In an embodiment, the support 140 is formed from a porous material, such as a porous material that is air-permeable and water impermeable (e.g., a hydrophobic porous material). In such an embodiment, the support 140 may allow air to flow therethrough thereby encouraging fluid flow through the fluid collection assembly 100 and preventing a suction force provided to the fluid collection assembly 100 from giving the patient a hickie. In an embodiment, the support 140 may be formed from a flexible material and/or may exhibit a relatively thin thickness (e.g., less than about 2 mm, less than about 1 mm, less than about 0.5 mm, or in ranges of about 0.25 mm to about 0.75 mm, about 0.5 mm to about 1 mm, about 0.75 mm to about 1.5 mm, or about 1 mm to about 2 mm). The flexibility and/or thickness of the support 140 may allow the support 140 to be shaped to conform to the shape of the region about the urethral opening (e.g., mons pubis, testicles, etc.) without pulling on the region about the urethral opening.
The securement body 106 includes a plurality of fibers 142 extending from support 140. The plurality of fibers 142 are configured to attach the base 104 to the region about the urethral opening. The plurality of fibers 142 exhibit a large surface area due to the relatively small lateral dimensions d (e.g., diameters) thereof, as discussed in more detail below. The large surface area of the fibers 142 cause the fibers 142 to exhibit sufficiently large Van der Waal forces with the region about the urethral opening (e.g., the skin and hair about the urethral opening) that the fibers 142 securely attach the base 104 to the region about the urethral opening. In some embodiments, the fibers 142 may attach the base 104 to the region about the urethral opening as strongly as some chemical adhesives (e.g., hydrogels) when certain forces are applied to the base 104. However, the fibers 142 remain part of the base 104 when the base 104 is detached from the region about the urethral opening unlike chemical adhesives which may leave a film attached to the region about the urethral opening. In an example, since the fibers 142 remain part of the base 104, at least the base 104 may be reused. In such an example, the base 104 may be detached from the region about the urethral opening to allow for examination of the urethral opening and the region about the urethral opening (e.g., regardless if the panels are transparent) and, after examination, the base 104 may be reattached to the region about the urethral opening. Additionally or alternatively, after detaching the base 104 from the region about the urethral opening, the base 104 and, optionally, the sheath 104 may be washed and reused with the same or a new patient. In an example, the fibers 142 may be able to attach the base 104 to the region about the urethral opening when the region about the urethral opening is wet, dry, shaved, or hairy.
The fibers 142 may be selected to exhibit an average lateral dimension d. As used herein, the average lateral dimension d may refer to the average lateral dimension of one fiber 142 at a single location, the average lateral dimension of one fiber 142 averaged along a length thereof, or the average lateral dimension averaged across at least some (e.g., all) of the fibers 142. The average lateral dimension d may be selected to be less than about 10 μm, less than about 8 μm, less than about 6 μm, less than about 5 μm, less than about 4 μm, less than about 3 μm, less than about 2.5 μm, less than about 2 μm, less than about 1.5 μm, less than about 1 μm, less than about 750 nm, less than about 600 nm, less than about 500 nm, less than about 400 nm, less than about 300 nm, less than about 250 nm, less than about 200 nm, less than about 150 nm, less than about 100 nm, less than about 75 nm, less than about 50 nm, less than about 25 nm, less than about 10 nm, or in ranges of about 5 nm to about 25 nm, about 10 nm to about 50 nm, about 25 nm to about 75 nm, about 50 nm to about 100 nm, about 75 nm to about 150 nm, about 100 nm to about 200 nm, about 150 nm to about 300 nm, about 200 nm to about 400 nm, about 300 nm to about 500 nm, about 400 nm to about 600 nm, about 500 nm to about 750 nm, about 600 nm to about 1 μm, about 750 μm to about 1.5 μm, about 1 μm to about 2 μm, about 1.5 μm to about 3 μm, about 2 μm to about 4 μm, about 3 μm to about 5 μm, about 4 μm to about 7.5 μm, or about 5 μm to about 10 μm. The average lateral dimension d may be selected based on a number of factors.
In an example, the average lateral dimension d may be selected based on the desired adhesion between the securement body 106 and the region about the urethral opening. For instance, decreasing the average lateral dimension d increases the surface area of the fibers 142. The Vander der Waal forces between the fibers 142 and the region about the urethral opening increases as the surface area of the fibers 142 increase and the adhesion between the securement body 106 and the region about the urethral opening increases as the Vander de Waal forces increase. It is noted that the adhesion between the securement body 106 and the region about the urethral opening also depends on other factors, such as the number of fibers per unit of surface area of the support 140 and the length of the fibers 142.
In an example, the average lateral dimension d of the fibers 142 may be selected based on the material that forms the fibers 142. For instance, as previously discussed, the Vander der Waal forces between the fibers 142 and the region about the urethral opening depends on the surface area of the fibers 142 that are proximate to the region about the urethral opening. The surface area of the fibers 142 that are proximate to the region about the urethral opening may depend on the flexibility of the fibers 142. The flexibility of the fibers 142 depends inversely to the average lateral dimension d of the fibers 142 and inversely to the Young's modulus (i.e., modulus of elasticity) of the material that forms the fibers 142. As such, the average lateral dimension d may need to be increased as the Young's modulus of the material that forms the fibers 142 is decreased, and vice versa. In an embodiment, the fibers 142 are formed from a polymer, such as polyimide, polypropylene, polydimethylsiloxane, or any other suitable polymer. In such an embodiment, the average lateral dimension d of the fibers 142 may depend on the molecular weight of the polymer. In an embodiment, the fibers 142 are formed from carbon nanotubes. In such an embodiment, the fibers 142 may exhibit an average lateral dimension d that less than 100 nm, less than 50 nm, or more particularly less than 25 nm.
In an example, the average lateral dimension d of the fibers 142 may depend on the average length l of the fibers 142. For instance, increasing the average length l may increase the likelihood that the fibers 142 become tangled. Tangling the fibers 142 may prevent some of the fibers 142 from pressing against the region of the urethral opening that would press against the region about the urethral opening if not for the tangling. Thus, even though increasing the average length l generally increases the surface area of the fibers 142, increasing the average length l above a threshold value may cause the fibers 142 to become tangled and decrease the adhesion between the securement body 106 and the region about the urethral opening. The threshold value may be increased by increasing the average lateral dimension d of the fibers 142. Thus, increasing the average lateral dimension d allows the lengths of the fibers 142 to be increased without the accompanying issues of entanglement. It is noted that, as used herein, the average length l may refer to the length of a single fiber 142, the length averaged across some of the fibers 142, or the length averaged across all of the fibers 142.
In an embodiment, the average length l of the fibers 142 may be selected to be greater than about 500 nm, greater than about 750 nm, greater than about 1 μm, greater than about 2 μm, greater than about 3 μm, greater than about 5 μm, greater than about 7.5 μm, greater than about 10 μm, greater than about 15 μm, greater than about 25 μm, greater than about 50 μm, greater than about 75 μm, greater than about 100 μm, or in ranges of about 500 nm to about 1 μm, about 750 nm to about 1.5 μm, about 1 μm to about 2 μm, about 1.5 μm to about 3 μm, about 2 μm to about 5 μm, about 3 μm to about 7.5 μm, about 5 μm to about 10 μm, about 7.5 μm to about 15 μm, about 10 μm to about 25 μm, about 15 μm to about 50 μm, about 25 μm to about 75 μm, or about 50 μm to about 100 μm. As previously discussed, the average length l of the fibers 142 may be selected based on the average lateral dimension d and desired surface area of the fibers 142 that is proximate to the region about the urethral opening. The average length l of the fibers 142 may also be selected based on the material(s) that form the fibers 142 since increasing and decreasing the Young's modulus of the material(s) that form the fibers 142 increases and decreases, respectively, the entanglement threshold.
Generally, the average length l of the fibers 142 are greater than the average lateral dimension d. For example, the average length l of the fibers 142 may be selected to be greater than the average lateral dimension d by a factor that is at least about 5, at least about 10, at least about 20, at least about 30, at least about 50, at least about 75, at least about 100, at least about 150, at least about 200, at least about 300, at least about 500, or in ranges of about 5 to 20, about 20 to about 30, about 20 to about 30, about 30 to about 75, about 50 to about 100, about 75 to about 150, about 100 to about 200, about 150 to about 300, or about 200 to about 500.
The fibers 142 may extend from the support 140 at an average angle θ. The average angle θ is an oblique angle. The angle θ is the average smallest angle that may be measured from an outer surface 144 of the support 140 to a portion of the fibers 142 adjacent to the support 140 when no external force is pressing against the fibers 142. The average angle θ may be the angle θ measure between one, some, or all of the fibers 142. The angle θ may be about 1° to about 10°, about 5° to about 15°, about 10° to about 20°, about 15° to about 25°, about 20° to about 30°, about 25° to about 35°, about 30° to about 40°, about 35° to about 45°, about 40° to about 50°, about 45° to about 60°, about 55° to about 75°, or about 70° to about 89°. The average angle θ generally corresponds to the angle between the fibers 142 and the region about the urethral opening assuming the base 104 is sufficiently flexible that the base 104 generally corresponds to the region about the urethral opening. Decreasing the angle θ increases the surface area of the fibers 142 that are proximate to the region about the urethral opening which, in turn, increases the adhesion between the securement body 106 and the region about the urethral opening. Generally, decreasing the average angle θ to be less than about 45° and less than about 30° may allow the fibers 142 to be significantly better at resisting shear forces than if the average angle θ was greater than these values.
The average angle θ may be selected to facilitate attachment, detachment, and securement of the base 104 to the region about the urethral opening. In an example, referring to
It is noted that the average angle θ does not need to be selected such that the fibers 142 do not extend from the second region 148 to the first region 146. In an example, the average angle θ may be selected such that the fibers 142 extend from the first region 146 to the second region 148. In such an example, a large force pulling downward on the fluid collection assembly 100 may cause the securement body 106 to become detached from the patient which may be beneficial when the downward force is sufficient to cause patient pain if the securement body 106 did not become detached. In an example, the average angle θ may be selected such that the fibers 142 do not extend from the first region 146 to the second region 148 or from the second region 148 to the first region 146 (e.g., the fibers 142 extend in a sideways direction). In such an example, the securement body 106 may be used with a patient that remains mostly in-bed since the downward force applied to the fluid collection assembly 100 caused by standing is not likely to be a factor.
As discussed above, the average angle θ is relative to the outer surface 144 of the support 140. However, as will be discussed in more detail below, the fibers 142 may extend from at least one exterior surface of the fluid collection assembly 100 other than or in addition to the outer surface 144 of the support 140. For example, the fibers 142 may extend from the bottom surface 138 of the substrate 134 (as shown in
The securement body 106 may include at least 5,000 fibers per square centimeter of surface area of the outer surface 144 of the support 140 (“f/sc”), at least 10,000 f/sc, at least about 25,000 f/sc, at least about 50,000 f/sc, at least about 75,000 f/sc, at least about 100,000 f/sc, at least about 150,000 f/sc, at least about 200,000 f/sc, at least about 300,000 f/sc, at least about 500,000 f/sc, at least about 750,000 f/sc, at least about 1,000,000 f/sc, at least about 1,500,000 f/sc, at least about 2,500,000 f/sc, at least about 5,000,000 f/sc, at least about 10,000,000 f/sc, at least about 20,000,000 f/sc, or in ranges of about 10,000 f/sc to about 50,000 f/sc, about 25,000 f/sc to about 75,000 f/sc, about 50,000 f/sc to about 100,000 f/sc, about 75,000 f/sc to about 150,000 f/sc, about 100,000 f/sc to about 200,000 f/sc, about 150,000 f/sc to about 300,000 f/sc, about 200,000 f/sc to about 500,000 f/sc, about 300,000 f/sc to about 750,000 f/sc, about 500,000 f/sc to about 1,000,000 f/sc, about 750,000 f/sc to about 1,500,000 f/sc, about 1,000,000 f/sc to about 2,500,000 f/sc, about 1,500,000 f/sc to about 5,000,000 f/sc, about 2,500,000 f/sc to about 10,000,000 f/sc, or about 5,000,000 f/sc to about 20,000,000 f/sc. Increasing and decreasing number of fibers 142 per square centimeter of surface area of the outer surface 144 of the support 140 increases and decreases, respectively, the adhesion between the securement body 106 and the region about the urethral opening. As such, the number of fibers 142 per square centimeter of surface area of the outer surface 144 may be selected based on the desired adhesion, other factors that affect adhesion (e.g., average lateral dimension d, average length 1, etc.), and the maximum number of fibers 142 that may reasonably fit within the square centimeter.
In an embodiment, securement body 106 may include one or more branches 150 extending therefrom. The branches 150 may extend from or attached to a portion of the fibers 142 at or near the terminal end thereof. For illustrative purposes (i.e., to more clearly illustrated the fibers 142 and prevent clutter), only one of the fibers 142 are illustrated as having branches 150 extending therefrom. The branches 150 may increase the surface area of the fibers 142 which, in turn, increases the adhesion between the securement body 106 and the region about the urethral opening. The branches 150 exhibit an average diameter and an average length that is significantly less than the average lateral dimension d and the average length l of the fibers 142. For example, the average diameter and/or average length of the branches 150 may be less than the average lateral dimension d and/or average length l of the fibers 142, respectively, by at least about 2, at least about 5, at least about 10, at least about 15, at least about 20, at least about 30, at least about 40, at least about 50, or in ranges of about 2 to about 10, about 5 to about 15, about 10 to about 20, about 15 to about 30, about 20 to about 40, or about 30 to about 50. In an example, the average diameter of the branches 150 may exhibit be less than about less than about 2 μm, less than about 1.5 μm, less than about 1 μm, less than about 750 nm, less than about 600 nm, less than about 500 nm, less than about 400 nm, less than about 300 nm, less than about 250 nm, less than about 200 nm, less than about 150 nm, less than about 100 nm, less than about 75 nm, less than about 50 nm, less than about 25 nm, less than about 10 nm, less than about 5 nm or in ranges of about 1 nm to about 10 nm, about 5 nm to about 25 nm, about 10 nm to about 50 nm, about 25 nm to about 75 nm, about 50 nm to about 100 nm, about 75 nm to about 150 nm, about 100 nm to about 200 nm, about 150 nm to about 300 nm, about 200 nm to about 400 nm, about 300 nm to about 500 nm, about 400 nm to about 600 nm, about 500 nm to about 750 nm, about 600 nm to about 1 μm, about 750 μm to about 1.5 μm, or about 1 μm to about 2 μm. In an example, the length of the branches 150 may be less than about 500 nm, less than about 750 nm, less than about 1 μm, less than about 2 μm, less than about 3 μm, less than about 5 μm, less than about 7.5 μm, less than about 10 μm, less than about 15 μm, less than about 25 μm, less than about 50 μm, less than about 75 μm, less than about 100 μm, or in ranges of about 500 nm to about 1 μm, about 750 nm to about 1.5 μm, about 1 μm to about 2 μm, about 1.5 μm to about 3 μm, about 2 μm to about 5 μm, about 3 μm to about 7.5 μm, about 5 μm to about 10 μm, about 7.5 μm to about 15 μm, about 10 μm to about 25 μm, or about 15 μm to about 50 μm. In an embodiment, one or more of the branches 150 may branch into a plurality of additional branches.
Referring to
The base 104 may exhibit a different structure than the structure illustrated in
Referring to
Referring to
Referring back to
As previously discussed, the fluid collection assembly 100 includes a conduit 130. The conduit 130 may be the same or substantially similar to any of the assembly tubes disclosed herein. An inlet of the conduit 130 may be located at or near the second end region 122 of the sheath 102 which is expected to be the gravimetrically low point of the chamber 114 when worn by a user. Locating the inlet of the conduit 130 at or near the second end region 122 of the sheath 102 enables the conduit 130 to receive more of the bodily fluids than if the inlet of the conduit 130 was located elsewhere and reduce the likelihood of pooling (e.g., pooling of the bodily fluids may cause microbe growth and foul odors). For instance, the bodily fluids in porous material 115 flow into the porous material 115 due to capillary forces. However, the bodily fluids may exhibit a preference to flow in the direction of gravity, especially when at least a portion of the porous material 115 is saturated with the bodily fluids. Accordingly, the inlet of the conduit 130 may be located in the fluid collection assembly 100 in a position expected to be the gravimetrically low point in the fluid collection assembly 100 when worn by a user.
In an example, the conduit 130 is configured to be at least insertable into the chamber 114, such as into the penis receiving area 128. In such an example, the conduit 130 may include one or more markers (not shown) on an exterior thereof that are located to facilitate insertion of the conduit 130 into the chamber 114. For example, the conduit 130 may include one or more markings thereon that are configured to prevent over or under insertion of the conduit 130. In another example, the conduit 130 may include one or more markings thereon that are configured to facilitate correct rotation of the conduit 130 relative to the chamber 114. The one or more markings may include a line, a dot, a sticker, or any other suitable marking.
The conduit 130 may include a flexible material such as plastic tubing (e.g., medical tubing). Such plastic tubing may include a thermoplastic elastomer, polyvinyl chloride, ethylene vinyl acetate, polytetrafluoroethylene, etc., tubing. In some examples, the conduit 130 may include silicon or latex. In some examples, the conduit 130 may include one or more portions that are resilient, such as to by having one or more of a diameter or wall thickness that allows the conduit 130 to be flexible.
As described in more detail below, the conduit 130 is configured to be coupled to, and at least partially extend between, one or more of the fluid storage container (not shown) and the vacuum source (not shown). In some examples, the vacuum source may be remotely located from the fluid collection assembly 100. In such examples, the conduit 130 may be fluidly connected to the fluid storage container, which may be disposed between the vacuum source and the fluid collection assembly 100.
During operation, a male using the fluid collection assembly 100 may discharge bodily fluids (e.g., urine) into the chamber 114. The bodily fluids may pool or otherwise be collected in the chamber 114. At least some of the bodily fluids may be pulled through the interior of the conduit 130 via the inlet. The fluid may be drawn out of the fluid collection assembly 100 via the vacuum/suction provided by the vacuum source. Further examples of male fluid collection assemblies are disclosed in U.S. Provisional Patent Application No. 63/067,542 filed on Aug. 19, 2020, the disclosure of which is incorporated herein, in its entirety, by this reference.
The securement body disclosed herein may be used with other male fluid collection assemblies. For example,
The fluid collection assembly 200 includes a sheath 202 and a base 204 and a sheath 202. The sheath 202 includes (e.g., may be formed from) a fluid impermeable barrier 208 that is sized and shaped to fit into the hollowed region of the base 204. For example, the sheath 202 may be generally tubular or cup-shaped, as shown. The generally tubular or cup-shaped fluid impermeable barrier 208 may at least partially define the outer surface 226 of the sheath 202. The fluid impermeable barrier 208 may be similar or identical to the fluid impermeable barrier 108 as disclosed herein, in one or more aspects. For example, the fluid impermeable barrier 208 may be constructed of any of the materials disclosed herein for the fluid impermeable barrier 108. The fluid impermeable barrier 208 at least partially defines the chamber 214. For example, the inner surface 224 of the fluid impermeable barrier 208 at least partially defines the perimeter of the chamber 214. The chamber 214 may be similar or identical to the chamber 114 in one or more aspects. For example, the chamber 214 may at least temporarily retain fluids therein. As shown, the fluid collection assembly 200 may include the porous material 215 therein. The porous material 215 may be similar or identical to the porous material 115 in one or more aspects. In an example, the porous material 215 may include one or more of a fluid permeable membrane 252 or a fluid permeable support 254. In an example, the porous material 215 may include any of the other porous material disclosed herein. The fluid impermeable barrier 208 may also define an opening 216 extending through the fluid impermeable barrier 208 that is configured to have a male urethra positioned therethrough.
The sheath 202 also includes at least a portion of the conduit 230 therein, such as at least partially disposed in the chamber 214. For example, the conduit 230 may extend from the sheath 202 at the second end region 222 at least partially towards a first end region 220 at least proximate to the aperture 232. The first end region 220 may be disposed near or on the skin around the male urethra (e.g., on the penis or pubic area therearound).
In some examples, the fluid impermeable barrier 208 may be constructed of a material and/or have a thickness that allows the sheath 202 to collapse when placed under vacuum, such as to remove air around a penis in the fluid collection assembly 200 during use. In such examples, the conduit 230 may extend only to or into the second end region 222 in the chamber 214 (e.g., not through to the area adjacent the opening 216). In such examples, urine may be collected and removed from the fluid collection assembly 200 at the first end region 220. It is noted that the porous material 215 may not collapse when the sheath 202 collapses thereby allowing bodily fluids to flow through the fluid collection assembly 200.
In an example, portions of the chamber 214 may be substantially empty due to the varying sizes and rigidity of the male penis. However, in some examples, the outermost regions of the chamber 214 (e.g., periphery of the interior regions of the sheath 202) may include porous material 215 (e.g., one or more of the fluid permeable membrane 252 and fluid permeable support 254). For example, the porous material 215 may be bonded to the inner surface 224 of the fluid impermeable barrier 208. The porous material 215 may be positioned (e.g., at the distal end of the chamber 214) to blunt a stream of urine from the male urethra thereby limiting splashing and/or to direct the bodily fluids to a selected region of the chamber 214. Since the chamber 214 is substantially empty (e.g., substantially all of the chamber 214 forms a reservoir), the fluids are likely to pool at a gravimetrically low point of the chamber 214. The gravimetrically low point of the chamber 214 may be at an intersection of the skin of an patient and the fluid collection assembly 200, a corner formed in the sheath 202, or another suitable location depending on the orientation of the patient.
The porous material 215 may include any of the porous material(s) disclosed herein, In an example, as previously discussed, the porous material 215 may include one or more of the fluid permeable membrane 252 or the fluid permeable support 254. One or more of the fluid permeable membrane 252 or the fluid permeable support 254 may be disposed between the fluid impermeable barrier 208 and a penis inserted into the chamber 214. The fluid permeable membrane 252 may be positioned between the fluid impermeable barrier 208 and a penis inserted into the chamber 214, such as between the fluid permeable support 254 and penis of a patient as shown. The fluid permeable support 254 may be positioned between the fluid permeable membrane 252 and the fluid impermeable barrier 208. The inner surface 224, optionally including the end of the chamber 214 substantially opposite the opening 216, may be covered with one or both the fluid permeable membrane 252 or the fluid permeable support 254. The fluid permeable support 254 or the fluid permeable membrane 252 may be affixed (e.g., adhered) to the fluid impermeable barrier 208. The fluid permeable support 254 or the fluid permeable membrane 252 may be affixed to each other. In some examples, the porous material 215 only includes the fluid permeable membrane 252 or the fluid permeable support 254.
The base 204 is sized, shaped, and made of a material to be coupled to skin that surrounds the male urethra and have the male urethra positioned therethrough. For example, the base 204 may include an substrate 234 that defines an aperture 232 in the base 204. The substrate 234 is sized and shaped to be positioned around the male urethra (e.g., positioned around and/or over the penis) and the aperture 232 may be configured to have the male urethra positioned therethrough. The substrate 234 may also be sized, shaped, made of a material, or otherwise configured to be coupled (e.g., adhesively attached, such as with a hydrogel adhesive) to the skin around the male urethra (e.g., around the penis). In an example, the substrate 234 may exhibit the general shape or contours of the skin surface that the substrate 234 is selected to be coupled with. The substrate 234 may be flexible thereby allowing the substrate 234 to conform to any shape of the skin surface. The base 204 may include a longitudinally extending flange 255 extending from the substrate 234 and a laterally extending flange 257 extending inwardly from the longitudinal extending flange 255. The longitudinally extending flange 255 and the laterally extending flange 257 define a hollowed region that is configured to receive (e.g., seal against) the sheath 202.
The base 204 also includes at least one securement body 206. For example, the securement body 206 may be attached to at least a portion of a bottom surface 238 of the substrate 234. The securement body 206 may be the same or substantially similar to any of the securement body disclosed herein. For example, the securement body 206 includes a plurality of fibers (not shown) that are configured to be attach the base 204 to a region about the urethral opening. The fibers may be attached to a support that is attached to the bottom surface 238 of the substrate 234 (as shown in
In some examples, the fluid collection assembly 200 includes a cap 256 at a second end region 222. The cap 256 defines an interior channel through which the fluids may be removed from the fluid collection assembly 200. The interior channel is in fluid communication with the chamber 214. The cap 256 may be disposed over at least a portion of the second end region 222 of one or more of the fluid impermeable barrier 208 or the porous material 215. The cap 256 may be made of a polymer, rubber, or any other fluid impermeable material. The cap 256 may be attached to one or more of the fluid impermeable barrier 208, the porous material 215, or the conduit 130. The cap 256 may cover at least a portion of the second end region 222 of the fluid collection assembly 200. The cap 256 may laterally extend a distance from the sheath 202. The cap 256 defines a fluid outlet 218 that is sized and configured to receive and fluidly seal against the conduit 230, such as within the interior channel. The conduit 230 may extend a distance within or through the cap 256, such as to the porous material 215, through the porous material 215, or to a point set-off from the porous material 215. In the latter example, the interior channel of the cap 256 may define a reservoir 258 therein. In some examples (not shown), the cap 256 may be omitted.
The reservoir 258 is an unoccupied portion of fluid collection assembly 200 such as in the cap 256 and is void of other material. In some examples, the reservoir 258 is defined at least partially by the porous material 215 and the cap 256. During use, the fluids that are in the chamber 214 may flow through the porous material 215 to the reservoir 258. The reservoir 258 may store at least some of the fluids therein and/or position the fluids for removal by the conduit 230. In some examples, at least a portion of the porous material 215 may extend continuously between at least a portion of the opening of the interior channel and chamber 214 to wick any fluid from the opening directly to the reservoir 258.
The base 204, the sheath 202, the cap 256, and the conduit 230 may be attached together using any suitable method. For example, at least two of the base 204, the sheath 202, the cap 256, or the conduit 230 may be attached together using at least one of an interference fit, an adhesive, stitching, welding (e.g., ultrasonic welding), tape, any other suitable method, or combinations thereof.
In some examples (not shown), the fluid collection assembly 200 may have a one piece design, with one or more of the sheath 202, the base 204, and the cap 256 being a single, integrally formed piece.
Further examples of male fluid collection assemblies that may be used here are disclosed in U.S. patent application Ser. No. 16/433,773 filed on Jun. 6, 2019, the disclosure of which is incorporated herein, in its entirety, by this reference.
The securement body disclosed herein may be used with a female fluid collection assembly.
The fluid impermeable barrier 308 at least partially defines a chamber 314 (e.g., interior region) and an opening 316. For example, the interior surface(s) 324 of the fluid impermeable barrier 308 at least partially defines the chamber 314 within the fluid collection assembly 300. The fluid impermeable barrier 308 temporarily stores the bodily fluids in the chamber 314. The fluid impermeable barrier 308 may be formed of any suitable fluid impermeable material(s), such as any of the fluid impermeable materials disclosed herein. As such, the fluid impermeable barrier 308 substantially prevents the bodily fluids from passing through the fluid impermeable barrier 308. In an example, the fluid impermeable barrier 308 may be air permeable and fluid impermeable. In such an example, the fluid impermeable barrier 308 may be formed of a hydrophobic material that defines a plurality of pores. At least one or more portions of at least an outer surface 326 of the fluid impermeable barrier 308 may be formed from a soft and/or smooth material, thereby reducing chaffing.
In some examples, the fluid impermeable barrier 308 may be tubular (ignoring the opening 316), such as substantially cylindrical (as shown), oblong, prismatic, or flattened tubes. During use, the outer surface 326 of the fluid impermeable barrier 308 may contact the patient. The fluid impermeable barrier 308 may be sized and shaped to fit in the gluteal cleft between the legs of a female user.
The opening 316 provides an ingress route for fluids to enter the chamber 314. The opening 316 may be defined by the fluid impermeable barrier 308 such as by an inner edge of the fluid impermeable barrier 308. For example, the opening 316 is formed in and extends through the fluid impermeable barrier 308, from the outer surface 326 to the inner surface 324, thereby enabling bodily fluids to enter the chamber 314 from outside of the fluid collection assembly 300. The opening 316 may be an elongated hole in the fluid impermeable barrier 308. For example, the opening 316 may be defined as a cut-out in the fluid impermeable barrier 308. The opening 316 may be located and shaped to be positioned adjacent to a female urethra.
The fluid collection assembly 300 may be positioned proximate to the female urethral opening and the bodily fluids may enter the chamber 314 of the fluid collection assembly 300 via the opening 316. The fluid collection assembly 300 is configured to receive the bodily fluids into the chamber 314 via the opening 316. When in use, the opening 316 may have an elongated shape that extends from a first location below the urethral opening (e.g., at or near the anus or the vaginal opening) to a second location above the urethral opening (e.g., at or near the top of the vaginal opening or the pubic hair).
The opening 316 may have an elongated shape because the space between the legs of a female is relatively small when the legs of the female are closed, thereby only permitting the flow of the bodily fluids along a path that corresponds to the elongated shape of the opening 316 (e.g., longitudinally extending opening). The opening 316 in the fluid impermeable barrier 308 may exhibit a length that is measured along the longitudinal axis of the fluid collection assembly 300 that may be at least about 20% of the length of the fluid collection assembly 300, such as about 25% to about 50%, about 40% to about 60%, about 50% to about 75%, about 65% to about 85%, or about 75% to about 95% of the length of the fluid collection assembly 300.
The opening 316 in the fluid impermeable barrier 308 may exhibit a width that is measured transverse to the longitudinal axis of the fluid collection assembly 300 that may be at least about 30% of the circumference of the fluid collection assembly 300, such as about 25% to about 50%, about 40% to about 60%, about 50% to about 75%, about 65% to about 85%, or about 75% to about 300% of the circumference of the fluid collection assembly 300. The opening 316 may exhibit a width that is greater than 50% of the circumference of the fluid collection assembly 300 since the vacuum (e.g., suction) through the conduit 330 pulls the fluid through the porous material 315 and into the conduit 330. In some examples, the opening 316 may be vertically oriented (e.g., having a major axis parallel to the longitudinal axis of the fluid collection assembly 300). In some examples (not shown), the opening 316 may be horizontally oriented (e.g., having a major axis perpendicular to the longitudinal axis of the fluid collection assembly 300). In an example, the fluid impermeable barrier 308 may be configured to be attached to the patient, such as adhesively attached (e.g., with a hydrogel adhesive) to the patient. According to an example, a suitable adhesive is a hydrogel layer.
In some examples, the fluid impermeable barrier 308 may define an fluid outlet 318 sized to receive the conduit 330. The at least one conduit 330 may be disposed in the chamber 314 via the fluid outlet 318. The fluid outlet 318 may be sized and shaped to form an at least substantially fluid tight seal against the conduit 330 or the at least one tube thereby substantially preventing the bodily fluids from escaping the chamber 314.
The fluid impermeable barrier 308 may include markings thereon, such as one or more markings to aid a user in aligning the fluid collection assembly 300 on the patient. For example, a line on the fluid impermeable barrier 308 (e.g., opposite the opening 316) may allow a healthcare professional to align the opening 316 over the urethra of the patient. In examples, the markings may include one or more of alignment guide or an orientation indicator, such as a stripe or hashes. Such markings may be positioned to align the fluid collection assembly 300 to one or more anatomical features such as a pubic bone, etc.
The fluid collection assembly 300 includes porous material 315 disposed in the chamber 314. The porous material 315 may cover at least a portion (e.g., all) of the opening 316. The porous material 315 is exposed to the environment outside of the chamber 314 through the opening 316. In an embodiment, the porous material 315 may be configured to wick any bodily fluids away from the opening 316, thereby preventing the bodily fluids from escaping the chamber 314. In an embodiment, the porous material 315 may include at least one absorbent or adsorbent material.
The porous material 315 may include any of the porous material disclosed herein. For example, the porous material 315 may include a fluid permeable membrane 352 and a fluid permeable support 354 disposed in the chamber 314. The fluid permeable membrane 352 may cover at least a portion (e.g., all) of the opening 316. The fluid permeable membrane 352 may be composed to wick the bodily fluids away from the opening 316, thereby preventing the bodily fluids from escaping the chamber 314. The fluid permeable membrane 352 may include any of the fluid permeable membrane materials disclosed herein.
The fluid permeable support 354 is configured to support the fluid permeable membrane 352 since the fluid permeable membrane 352 may be formed from a relatively foldable, flimsy, or otherwise easily deformable material. For example, the fluid permeable support 354 may be positioned such that the fluid permeable membrane 352 is disposed between the fluid permeable support 354 and the fluid impermeable barrier 308. As such, the fluid permeable support 354 may support and maintain the position of the fluid permeable membrane 352. The fluid permeable support 354 may include any material that may wick the bodily fluids, such as any of the fluid permeable membrane materials or fluid permeable support materials disclosed herein. For example, the fluid permeable membrane material(s) may be utilized in a more dense or rigid form than in the fluid permeable membrane 352 when used as the fluid permeable support 354. The fluid permeable support 354 may be formed from any fluid permeable material that is less deformable than the fluid permeable membrane 352.
In some examples, the fluid permeable membrane 352 may be optional. For example, the porous material 315 may include only the fluid permeable support 354. In some examples, the fluid permeable support 354 may be optionally omitted from the fluid collection assembly 300. For example, the porous material 315 may only include the fluid permeable membrane 352.
The fluid permeable support 354 may have a greater ability to wick the bodily fluids than the fluid permeable membrane 352, such as to move the bodily fluids inwardly from the outer surface of the fluid collection assembly 300. In some examples, the porous ability of the fluid permeable support 354 and the fluid permeable membrane 352 may be substantially the same.
The fluid permeable membrane 352 and the fluid permeable support 354 may at least substantially completely fill the portions of the chamber 314 that are not occupied by the conduit 330. In some examples, the fluid permeable membrane 352 and the fluid permeable support 354 may not substantially completely fill the portions of the chamber 314 that are not occupied by the conduit 330. In such an example, the fluid collection assembly 300 includes the reservoir 358 disposed in the chamber 314.
The reservoir 358 is a substantially unoccupied portion of the chamber 314. The reservoir 358 may be defined between the fluid impermeable barrier 308 and one or both of the fluid permeable membrane 352 and fluid permeable support 354. The bodily fluids that are in the chamber 314 may flow through the porous material 315 to the reservoir 358. The fluid impermeable barrier 308 may retain the bodily fluids in the reservoir 358. While depicted in the first end region 320, the reservoir 358 may be located in any portion of the chamber 314 such as the second end region 322. The reservoir 358 may be located in a portion of the chamber 314 that is designed to be located in a gravimetrically low point of the fluid collection assembly when the fluid collection assembly is worn.
In some examples (not shown), the fluid collection assembly 300 may include multiple reservoirs, such as a first reservoir that is located at the portion of the chamber 314 closest to the inlet of the conduit 330 (e.g., first end region 320) and a second reservoir that is located at the portion of the of the chamber 314 that is at or near second end region 322). In another example, the fluid permeable support 354 is spaced from at least a portion of the conduit 330, and the reservoir 358 may be the space between the fluid permeable support 354 and the conduit 330.
The conduit 330 may be at least partially disposed in the chamber 314. The conduit 330 may be used to remove the bodily fluids from the chamber 314. The conduit 330 (e.g., a tube) includes an inlet of the conduit 330 and an outlet 312 positioned downstream from the inlet of the conduit 330. The outlet 312 may be operably coupled to a suction source, such as a vacuum pump for withdrawing fluid from the chamber 314 through the conduit 330. For example, the conduit 330 may extend into the fluid impermeable barrier 308 from the second end region 322 and may extend to the first end region 320 to a point proximate to the reservoir 358 therein such that the inlet of the conduit 330 is in fluid communication with the reservoir 358. The conduit 330 fluidly couples the chamber 314 with the fluid storage container (not shown) or the vacuum source (not shown).
The conduit 330 may extend through a bore in the fluid permeable membrane 352 and/or fluid permeable support 354, such as into the reservoir 358. For example, the inlet of the conduit 330 may be extend into or be positioned in the reservoir 358. In the illustrated embodiment, the conduit 330 is at least partially disposed in the reservoir 358. In some examples (not shown), the conduit 330 may enter the chamber 314 in the distal end region and the inlet of the conduit 330 of the conduit 330 may be disposed in the distal end region (e.g., in the reservoir 358). The bodily fluids collected in the fluid collection assembly 300 may be removed from the chamber 314 via the conduit 330.
In some examples, the inlet of the conduit 330 may not extend into the reservoir 358. In such examples, the inlet of the conduit 330 may be disposed within the porous material 315 (fluid permeable membrane 352 and/or fluid permeable support 354) or at a terminal end thereof. For example, an end of the conduit 330 may be coextensive with or recessed within the fluid permeable membrane 352 and/or fluid permeable support 354.
During use, the first end region 320 may be the gravimetrically low point of the chamber 314. As such, locating the inlet of the conduit 330 at or near a location expected to be the gravimetrically low point of the chamber 314 when worn by a patient enables the conduit 330 to receive more of the bodily fluids than if inlet of the conduit 330 was located elsewhere and reduce the likelihood of pooling (e.g., pooling of the bodily fluids may cause microbe growth and foul odors). For instance, as previously discussed, the bodily fluids in the fluid permeable membrane 352 and the fluid permeable support 354 may flow in any direction due to capillary forces. However, the bodily fluids may exhibit a preference to flow in the direction of gravity, especially when at least a portion of the fluid permeable membrane 352 and/or the fluid permeable support 354 is saturated with the bodily fluids. Accordingly, one or more of the inlet of the conduit 330 or the reservoir 358 may be located in the fluid collection assembly 300 in a position expected to be the gravimetrically low point in the fluid collection assembly 300 when worn by a patient, such as the first end region 320.
As previously discussed, the fluid collection assembly 300 may include at least one securement body 306. The securement body 306 may be configured to be attached to the skin of the patient, such as at least one of the thighs or the region about the urethral opening. As such, the securement body 206 may be attached to or formed on at least a portion of an outer surface 326 of the fluid impermeable barrier 308 that, during use, may contact the skin of the patient. The securement body 306 may be the same or substantially similar to any of the securement body disclosed herein. As such, the securement body 306 includes a plurality of fibers that are configured to be attach the securement body to the skin of a patient.
In an embodiment, the securement body 306 is distinct from the fluid impermeable barrier 308. In such an embodiment, the securement body 306 may include at least one of a plurality of fibers attached to or integrally formed with a support, similar to what is shown in
Other embodiments of fluid impermeable barriers, fluid permeable membranes, fluid permeable supports, chambers, and their shapes and configurations are disclosed in U.S. Pat. No. 10,973,678 filed on Jun. 2, 2017; U.S. Pat. No. 10,390,989 filed on Sep. 8, 2016; and U.S. Pat. No. 10,226,376 filed on Jun. 3, 2017, the disclosure of each of which is incorporated herein, in its entirety, by this reference.
The securement body illustrated in
The porous material 415 includes a contact surface 460 that is configured to contact the patient during use. The contact surface 460 may include the portion of the porous material 415 that extends across the opening 416.
The fluid collection 400 includes at least one securement body 406. The securement body 406 includes at least one friction material 461 disposed on at least a portion of the contact surface 460. The contact surface 460 exhibits a first coefficient of friction and the friction material 461 exhibits a second coefficient of friction that is greater than the first coefficient of friction. As such, the friction material 461 better prevents movement of the fluid collection assembly 400 when the opening is adjacent to the region about the urethral opening of the patient than if the fluid collection assembly 400 did not include the friction material 461. In is noted that, as used herein, the coefficient of friction refers to the coefficient of static friction of the material (e.g., the contact surface 460 or the friction material 461) against the against the skin of the patient when the skin is at least one of dry or moist.
The friction material 461 includes a material disposed on the contact surface 460 of the porous material 415. The material of the friction material 461 is different than the material that forms the porous material 415 which, at least in part, causes the friction material 461 to exhibit a coefficient of friction that is greater than the contact surface 460. In an example, the friction material 461 includes at least one elastomer, such as at least one of silicone, nitrile, rubber, neoprene, or another elastomer.
The friction material 461 may be disposed on the contact surface 460 using any suitable technique. In an example, the friction material 461 may include an adhesive on the surface of the friction material 461 that contacts the contact surface 460. In an example, the surface of the friction material 461 that contacts the contact surface 460 may be partially melted and the friction material 461 may be pressed into the contact surface 460. At least some of the melted portions of the friction material 461 may flow into and at least partially occupy some of the pores of the porous material 415 thereby attaching the friction material 461 to the porous material 415. In an example, the friction material 461 may be applied to the contact surface 460 while in a melted (e.g., liquid) state. Some of the melted friction material 461 may flow into and at least partially occupy some of the pores of the porous material 415 thereby attaching the friction material 461 to the porous material 415.
As previously discussed, the friction material 461 is disposed on the contact surface 460 of the porous material 415. As such, the friction material 461 may block portions of the porous material 415 that extend across the opening 416. In some embodiments, blocking portions of the porous material 415 that extend across the opening 416 may at least one of limit the amount of bodily fluids that may enter the chamber (not shown) or cause the bodily fluids to splash, either or which may cause bodily fluids to leak or otherwise inhibit the functionality of the fluid collection assembly 400. However, the friction material's 461 the ability to better maintain the position of the fluid collection assembly 400 against the region about the urethral opening still decreases the likelihood that the bodily fluids leak even though the friction material 461 may obstruct portions of the porous material 415 and cause splashing.
In an embodiment, the friction material 461 may define one or more passageways 462 (e.g., pores, voids, etc.) extending therethrough. The passageways 462 allow the bodily fluids to flow through the friction material 461 to the contact surface 460 of the porous material 415 and decrease splashing of the bodily fluids. Thus, the passageways 462 may further prevent bodily fluids from leaking from the fluid collection assembly 400. The passageways 462 may be formed using any suitable technique. In an example, the friction material 461 may be applied to the contact surface 460 in a manner that causes peaks and valleys to form and at least some of the valleys form the passageways 462. In an example, the friction material 461 may include one or more cutouts formed therein either before or after applying the friction material 461 to the contact surface 460. The cutouts may form the passageways 462. In an example, the friction material 461 may include a plurality of pores (e.g., interconnected pores) that form the passageways 462.
The friction material 461 illustrated in
The friction material 461 does not have to be arranged on the porous material 415 in the form of dots. For example,
Referring to
Referring to
Referring to
It is noted that the arrangement of the friction material illustrated in
The friction materials disclosed above include the friction materials disposed on the porous material of female fluid collection assemblies. However, it is noted that the friction materials disclosed herein may be disposed on the porous materials of any of the male fluid collection assemblies disclose herein. Such friction materials may help maintain the penis in the chambers of such male fluid collection assemblies when the penis would otherwise become buried thereby preventing or minimizing pooling of bodily fluids caused by buried penises. The arrangement of the friction material on the porous materials of the male fluid collection assemblies may be the same or substantially similar to the arrangement of any of the friction material disclosed above with regards to the female fluid collection assemblies.
The fluid collection assemblies disclosed herein may include securement body instead of or in addition to the fibers and the friction materials disclosed above. For example,
The fluid collection assembly 500a includes at least one securement body 506a. The securement body 506a include one or more suction cups 570a directly attached to or integrally formed with the base layer 564a. In particular, the suction cups 570a extend from the bottom surface 568a of the base layer 564a. The suction cups 570a are formed from a flexible material that is impermeable to air, such as nitrile, neoprene, polyurethane, silicone, rubber, vinyl, any other suitable polymer, or combinations thereof. The suction cups 570a may exhibit any concave shape. For example, the suction cups 570a may exhibit a conical or other cup-like shape having, for example, a circular or oblong opening.
The suction cups 570a may exhibit a maximum lateral dimension D (e.g., diameter). The maximum lateral dimension D of the suction cups 570a may be selected to be about 1 mm to about 3 mm, about 2 mm to about 4 mm, about 3 mm to about 5 mm, about 4 mm to about 6 mm, about 5 mm to about 7 mm, about 6 mm to about 8 mm, about 7 mm to about 9 mm, about 8 mm to about 1 cm, about 9 mm to about 1.2 cm, about 1 cm to about 1.4 cm, about 1.2 cm to about 1.6 cm, about 1.4 cm to about 1.8 cm, about 1.6 cm to about 2 cm, about 1.8 cm to about 2.25 cm, about 2 cm to about 2.5 cm, about 2.25 cm to about 2.75 cm, about 2.5 cm to about 3 cm, about 2.75 cm to about 3.5 cm, or about 3 cm to about 4 cm. The maximum lateral dimension D of the suction cups 570a may be selected based on a number of factors. Generally, the maximum lateral dimension D may be selected based on two competing factors, namely increasing the force required to detach the suction cups 570a and minimizing hickies and general discomfort caused by the suction cups 570a. For example, generally increasing the lateral dimension D may increase the force required to detach the suction cups 570a but also increases the likelihood of hickies and/or patient discomfort, especially if the fluid collection assembly 500a is used for a prolonged period of time. However, decreasing the maximum lateral dimension D may allow the fluid collection assembly 500a to include more suction cups 570a which may at least partially offset the decrease force required to detach the suction cups 570a.
The suction force may be applied to the outlet of the conduit 630 by the vacuum source 676 either directly or indirectly. The suction force may be applied indirectly via the fluid storage container 674. For example, the outlet of the conduit 630 may be disposed within the fluid storage container 674 and an additional conduit 630 may extend from the fluid storage container 674 to the vacuum source 676. Accordingly, the vacuum source 676 may apply suction to the fluid collection assembly 600 via the fluid storage container 674. The suction force may be applied directly via the vacuum source 676. For example, the outlet of the conduit 630 may be disposed within the vacuum source 676. An additional conduit 630 may extend from the vacuum source 676 to a point outside of the fluid collection assembly 600, such as to the fluid storage container 674. In such examples, the vacuum source 676 may be disposed between the fluid collection assembly 600 and the fluid storage container 674.
The fluid collection assembly 600 may be similar or identical to any of the fluid collection assemblies disclosed herein in one or more aspects. The fluid collection assembly 600 may be shaped and sized to be positioned adjacent to a female urethral opening or have a male urethral opening positioned therethrough (e.g., receive a penis therein). For example, the fluid collection assembly 600 may include a fluid impermeable barrier at least partially defining a chamber (e.g., interior region) of the fluid collection assembly 600. The fluid impermeable barrier also defines at least one opening extending therethrough from the external environment. The opening may be positioned adjacent to a female urethral opening or have a male urethral opening positioned therethrough. The fluid collection assembly 600 may include porous material disposed in the chamber such as one or more of a fluid permeable support and a fluid permeable membrane. The fluid collection assembly 600 includes one or more of any of the securement bodies disclosed herein.
The fluid storage container 674 is sized and shaped to retain the bodily fluids therein. The fluid storage container 674 may include a bag (e.g., drainage bag), a bottle or cup (e.g., collection jar), or any other enclosed container for storing bodily fluids such as urine. In some examples, the conduit 630 may extend from the fluid collection assembly 600 and attach to the fluid storage container 674 at a first point therein. An additional conduit 630 may attach to the fluid storage container 674 at a second point thereon and may extend and attach to the vacuum source 676. Accordingly, a vacuum (e.g., suction) may be drawn through fluid collection assembly 600 via the fluid storage container 674. Fluid, such as urine, may be drained from the fluid collection assembly 600 using the vacuum source 676.
The vacuum source 676 may include one or more of a manual vacuum pump, and electric vacuum pump, a diaphragm pump, a centrifugal pump, a displacement pump, a magnetically driven pump, a peristaltic pump, or any pump configured to produce a vacuum. The vacuum source 676 may provide a vacuum or suction to remove fluid from the fluid collection assembly 600. In some examples, the vacuum source 676 may be powered by one or more of a power cord (e.g., connected to a power socket), one or more batteries, or even manual power (e.g., a hand operated vacuum pump). In some examples, the vacuum source 676 may be sized and shaped to fit outside of, on, or within the fluid collection assembly 600. For example, the vacuum source 676 may include one or more miniaturized pumps or one or more micro pumps. The vacuum sources 676 disclosed herein may include one or more of a switch, a button, a plug, a remote, or any other device suitable to activate the vacuum source 676.
While various aspects and embodiments have been disclosed herein, other aspects and embodiments are contemplated. The various aspects and embodiments disclosed herein are for purposes of illustration and are not intended to be limiting.
Terms of degree (e.g., “about,” “substantially,” “generally,” etc.) indicate structurally or functionally insignificant variations. In an example, when the term of degree is included with a term indicating quantity, the term of degree is interpreted to mean±10%, ±5%, or ±2% of the term indicating quantity. In an example, when the term of degree is used to modify a shape, the term of degree indicates that the shape being modified by the term of degree has the appearance of the disclosed shape. For instance, the term of degree may be used to indicate that the shape may have rounded corners instead of sharp corners, curved edges instead of straight edges, one or more protrusions extending therefrom, is oblong, is the same as the disclosed shape, etc.
This application claims priority to U.S. Provisional Patent Application No. 63/134,450 filed on Jan. 6, 2021, the disclosure of which is incorporated herein, in its entirety, by this reference.
Number | Name | Date | Kind |
---|---|---|---|
737443 | Mooers | Aug 1903 | A |
1032841 | Koenig | Jul 1912 | A |
1178644 | Johnson | Apr 1916 | A |
1387726 | Karge | Aug 1921 | A |
1742080 | Jones | Dec 1929 | A |
1979899 | Obrien et al. | Nov 1934 | A |
2241010 | Chipley | May 1941 | A |
2262772 | Peder | Nov 1941 | A |
2326881 | Packer | Aug 1943 | A |
2379346 | Farrell | Jun 1945 | A |
2485555 | Bester | Oct 1949 | A |
2571357 | Charles | Oct 1951 | A |
2613670 | Edward | Oct 1952 | A |
2616426 | Adele | Nov 1952 | A |
2644234 | Earl | Jul 1953 | A |
2648335 | Chambers | Aug 1953 | A |
2859786 | Tupper | Nov 1958 | A |
2944551 | Carl | Jul 1960 | A |
2968046 | Duke | Jan 1961 | A |
2971512 | Reinhardt | Feb 1961 | A |
3032038 | Swinn | May 1962 | A |
3077883 | Hill | Feb 1963 | A |
3087938 | Hans et al. | Apr 1963 | A |
3169528 | Knox et al. | Feb 1965 | A |
3171506 | Therkel | Mar 1965 | A |
3194238 | Breece | Jul 1965 | A |
3198994 | Hildebrandt et al. | Aug 1965 | A |
3221742 | Egon | Dec 1965 | A |
3312221 | Overment | Apr 1967 | A |
3312981 | McGuire et al. | Apr 1967 | A |
3349768 | Keane | Oct 1967 | A |
3362590 | Gene | Jan 1968 | A |
3366116 | Huck | Jan 1968 | A |
3398848 | Donovan | Aug 1968 | A |
3400717 | Bruce et al. | Sep 1968 | A |
3406688 | Bruce | Oct 1968 | A |
3424163 | Gravdahl | Jan 1969 | A |
3425471 | Yates | Feb 1969 | A |
3511241 | Lee | May 1970 | A |
3512185 | Ellis | May 1970 | A |
3520300 | Flower | Jul 1970 | A |
3528423 | Lee | Sep 1970 | A |
3613123 | Langstrom | Oct 1971 | A |
3648700 | Warner | Mar 1972 | A |
3651810 | Ormerod | Mar 1972 | A |
3661155 | Lindan | May 1972 | A |
3683918 | Pizzella | Aug 1972 | A |
3699815 | Holbrook | Oct 1972 | A |
3726277 | Hirschman | Apr 1973 | A |
3742952 | Magers et al. | Jul 1973 | A |
3757355 | Allen et al. | Sep 1973 | A |
3788324 | Lim | Jan 1974 | A |
3843016 | Bornhorst et al. | Oct 1974 | A |
3863638 | Rogers et al. | Feb 1975 | A |
3863798 | Kurihara et al. | Feb 1975 | A |
3864759 | Horiuchi | Feb 1975 | A |
3865109 | Elmore et al. | Feb 1975 | A |
3881486 | Fenton | May 1975 | A |
3881489 | Hartwell | May 1975 | A |
3915189 | Holbrook et al. | Oct 1975 | A |
3998228 | Poidomani | Dec 1976 | A |
3999550 | Martin | Dec 1976 | A |
4015604 | Csillag | Apr 1977 | A |
4020843 | Kanall | May 1977 | A |
4022213 | Stein | May 1977 | A |
4027776 | Douglas | Jun 1977 | A |
4064962 | Hunt | Dec 1977 | A |
4116197 | Bermingham | Sep 1978 | A |
4180178 | Turner | Dec 1979 | A |
4187953 | Turner | Feb 1980 | A |
4194508 | Anderson | Mar 1980 | A |
4200102 | Duhamel et al. | Apr 1980 | A |
4202058 | Anderson | May 1980 | A |
4203503 | Bertotti et al. | May 1980 | A |
4209076 | Bertotti et al. | Jun 1980 | A |
4223677 | Anderson | Sep 1980 | A |
4233025 | Larson et al. | Nov 1980 | A |
4233978 | Hickey | Nov 1980 | A |
4246901 | Frosch et al. | Jan 1981 | A |
4253542 | Ruspa et al. | Mar 1981 | A |
4257418 | Hessner | Mar 1981 | A |
4270539 | Frosch et al. | Jun 1981 | A |
4281655 | Terauchi | Aug 1981 | A |
4292916 | Bradley et al. | Oct 1981 | A |
4330239 | Gannaway | May 1982 | A |
4352356 | Tong | Oct 1982 | A |
4360933 | Kimura et al. | Nov 1982 | A |
4365363 | Windauer | Dec 1982 | A |
4375841 | Vielbig | Mar 1983 | A |
4387726 | Denard | Jun 1983 | A |
4403991 | Hill | Sep 1983 | A |
4425130 | Desmarais | Jan 1984 | A |
4446986 | Bowen et al. | May 1984 | A |
4453938 | Brendling | Jun 1984 | A |
4457314 | Knowles | Jul 1984 | A |
4476879 | Jackson | Oct 1984 | A |
4526688 | Schmidt et al. | Jul 1985 | A |
4528703 | Kraus | Jul 1985 | A |
D280438 | Wendt | Sep 1985 | S |
4551141 | McNeil | Nov 1985 | A |
4553968 | Komis | Nov 1985 | A |
4581026 | Schneider | Apr 1986 | A |
4589516 | Inoue et al. | May 1986 | A |
4601716 | Smith | Jul 1986 | A |
4610675 | Triunfol | Sep 1986 | A |
4620333 | Ritter | Nov 1986 | A |
4626250 | Schneider | Dec 1986 | A |
4627846 | Ternstroem | Dec 1986 | A |
4631061 | Martin | Dec 1986 | A |
4650477 | Johnson | Mar 1987 | A |
4655754 | Richmond et al. | Apr 1987 | A |
4656675 | Fajnsztajn | Apr 1987 | A |
4681570 | Dalton | Jul 1987 | A |
4681577 | Stern et al. | Jul 1987 | A |
4692160 | Nussbaumer | Sep 1987 | A |
4707864 | Ikematsu et al. | Nov 1987 | A |
4713065 | Koot | Dec 1987 | A |
4713066 | Komis | Dec 1987 | A |
4723953 | Pratt et al. | Feb 1988 | A |
4735841 | Sourdet | Apr 1988 | A |
4743236 | Manschot | May 1988 | A |
4747166 | Kuntz | May 1988 | A |
4752944 | Conrads et al. | Jun 1988 | A |
4769215 | Ehrenkranz | Sep 1988 | A |
4771484 | Mozell | Sep 1988 | A |
4772280 | Rooyakkers | Sep 1988 | A |
4784654 | Beecher | Nov 1988 | A |
4790830 | Hamacher | Dec 1988 | A |
4790835 | Elias | Dec 1988 | A |
4791686 | Taniguchi et al. | Dec 1988 | A |
4795449 | Schneider et al. | Jan 1989 | A |
4798603 | Meyer et al. | Jan 1989 | A |
4799928 | Crowley | Jan 1989 | A |
4804377 | Hanifl et al. | Feb 1989 | A |
4812053 | Bhattacharjee | Mar 1989 | A |
4813943 | Smith | Mar 1989 | A |
4820297 | Kaufman et al. | Apr 1989 | A |
4846818 | Keldahl et al. | Jul 1989 | A |
4846909 | Klug et al. | Jul 1989 | A |
4865595 | Heyden | Sep 1989 | A |
4880417 | Yabrov et al. | Nov 1989 | A |
4882794 | Stewart | Nov 1989 | A |
4883465 | Brennan | Nov 1989 | A |
4886498 | Newton | Dec 1989 | A |
4886508 | Washington | Dec 1989 | A |
4886509 | Mattsson | Dec 1989 | A |
4889532 | Metz et al. | Dec 1989 | A |
4889533 | Beecher | Dec 1989 | A |
4890691 | Ching-ho | Jan 1990 | A |
4903254 | Haas | Feb 1990 | A |
4904248 | Vaillancourt | Feb 1990 | A |
4905692 | More | Mar 1990 | A |
4936838 | Cross et al. | Jun 1990 | A |
4955922 | Terauchi | Sep 1990 | A |
4957487 | Gerow | Sep 1990 | A |
4965460 | Tanaka et al. | Oct 1990 | A |
4986823 | Anderson et al. | Jan 1991 | A |
4987849 | Sherman | Jan 1991 | A |
5002541 | Conkling et al. | Mar 1991 | A |
5004463 | Nigay | Apr 1991 | A |
5031248 | Kemper | Jul 1991 | A |
5045077 | Blake | Sep 1991 | A |
5045283 | Patel | Sep 1991 | A |
5049144 | Payton | Sep 1991 | A |
5053339 | Patel | Oct 1991 | A |
5057092 | Webster | Oct 1991 | A |
5058088 | Haas et al. | Oct 1991 | A |
5071347 | McGuire | Dec 1991 | A |
5078707 | Peter | Jan 1992 | A |
5084037 | Barnett | Jan 1992 | A |
5100396 | Zamierowski | Mar 1992 | A |
5112324 | Wallace | May 1992 | A |
5147301 | Ruvio | Sep 1992 | A |
5176667 | Debring | Jan 1993 | A |
5195997 | Carns | Mar 1993 | A |
5196654 | Diflora et al. | Mar 1993 | A |
5203699 | McGuire | Apr 1993 | A |
5244458 | Takasu | Sep 1993 | A |
5246454 | Peterson | Sep 1993 | A |
5267988 | Farkas | Dec 1993 | A |
5275307 | Freese | Jan 1994 | A |
5282795 | Finney | Feb 1994 | A |
5294983 | Ersoz et al. | Mar 1994 | A |
5295983 | Kubo | Mar 1994 | A |
5300052 | Kubo | Apr 1994 | A |
5304749 | Crandell | Apr 1994 | A |
5312383 | Kubalak | May 1994 | A |
5318550 | Cermak et al. | Jun 1994 | A |
5330459 | Lavon et al. | Jul 1994 | A |
5340840 | Park et al. | Aug 1994 | A |
5382244 | Telang | Jan 1995 | A |
5409014 | Napoli et al. | Apr 1995 | A |
5411495 | Willingham | May 1995 | A |
5423784 | Metz | Jun 1995 | A |
5456246 | Schmieding et al. | Oct 1995 | A |
5466229 | Elson et al. | Nov 1995 | A |
5478334 | Bernstein | Dec 1995 | A |
5499977 | Marx | Mar 1996 | A |
5543042 | Filan et al. | Aug 1996 | A |
D373928 | Green | Sep 1996 | S |
5582604 | Ahr et al. | Dec 1996 | A |
5592950 | Kopelowicz | Jan 1997 | A |
5605161 | Cross | Feb 1997 | A |
5618277 | Goulter | Apr 1997 | A |
5628735 | Skow | May 1997 | A |
5636643 | Argenta et al. | Jun 1997 | A |
5637104 | Ball et al. | Jun 1997 | A |
5674212 | Osborn et al. | Oct 1997 | A |
5678564 | Lawrence et al. | Oct 1997 | A |
5678654 | Uzawa | Oct 1997 | A |
5687429 | Rahlff | Nov 1997 | A |
5695485 | Duperret et al. | Dec 1997 | A |
5700254 | Mcdowall et al. | Dec 1997 | A |
5701612 | Daneshvar | Dec 1997 | A |
5705777 | Flanigan et al. | Jan 1998 | A |
5752944 | Dann et al. | May 1998 | A |
5763333 | Suzuki et al. | Jun 1998 | A |
5772644 | Bark et al. | Jun 1998 | A |
5792132 | Garcia | Aug 1998 | A |
5827243 | Palestrant | Oct 1998 | A |
5827247 | Kay | Oct 1998 | A |
5827250 | Fujioka et al. | Oct 1998 | A |
5827257 | Fujioka et al. | Oct 1998 | A |
D401699 | Herchenbach et al. | Nov 1998 | S |
5859393 | Cummins et al. | Jan 1999 | A |
5865378 | Hollinshead et al. | Feb 1999 | A |
5876393 | Ahr et al. | Mar 1999 | A |
5887291 | Bellizzi | Mar 1999 | A |
5891125 | Plumley | Apr 1999 | A |
5894608 | Birbara | Apr 1999 | A |
D409303 | Oepping | May 1999 | S |
5911222 | Lawrence et al. | Jun 1999 | A |
5957904 | Holland | Sep 1999 | A |
5968026 | Osborn et al. | Oct 1999 | A |
5972505 | Phillips et al. | Oct 1999 | A |
6007526 | Passalaqua et al. | Dec 1999 | A |
6039060 | Rower | Mar 2000 | A |
6050983 | Moore et al. | Apr 2000 | A |
6059762 | Boyer et al. | May 2000 | A |
6063064 | Tuckey et al. | May 2000 | A |
6098625 | Winkler | Aug 2000 | A |
6105174 | Karlsten et al. | Aug 2000 | A |
6113582 | Dwork | Sep 2000 | A |
6117163 | Bierman | Sep 2000 | A |
6123398 | Arai et al. | Sep 2000 | A |
6129718 | Wada et al. | Oct 2000 | A |
6131964 | Sareshwala | Oct 2000 | A |
6152902 | Christian et al. | Nov 2000 | A |
6164569 | Hollinshead et al. | Dec 2000 | A |
6177606 | Etheredge et al. | Jan 2001 | B1 |
6209142 | Mattsson et al. | Apr 2001 | B1 |
6220050 | Cooksey | Apr 2001 | B1 |
6244311 | Hand et al. | Jun 2001 | B1 |
6248096 | Dwork et al. | Jun 2001 | B1 |
6263887 | Dunn | Jul 2001 | B1 |
6283246 | Nishikawa | Sep 2001 | B1 |
6311339 | Kraus | Nov 2001 | B1 |
6336919 | Davis et al. | Jan 2002 | B1 |
6338729 | Wada et al. | Jan 2002 | B1 |
6352525 | Wakabayashi | Mar 2002 | B1 |
6394988 | Hashimoto | May 2002 | B1 |
6398742 | Kim | Jun 2002 | B1 |
6406463 | Brown | Jun 2002 | B1 |
6409712 | Dutari et al. | Jun 2002 | B1 |
6416500 | Wada et al. | Jul 2002 | B1 |
6423045 | Wise et al. | Jul 2002 | B1 |
6428521 | Droll | Aug 2002 | B1 |
6428522 | Dipalma et al. | Aug 2002 | B1 |
6446454 | Lee et al. | Sep 2002 | B1 |
6475198 | Lipman et al. | Nov 2002 | B1 |
6479726 | Cole et al. | Nov 2002 | B1 |
6491673 | Palumbo et al. | Dec 2002 | B1 |
6508794 | Palumbo et al. | Jan 2003 | B1 |
6524292 | Dipalma et al. | Feb 2003 | B1 |
6540729 | Wada et al. | Apr 2003 | B1 |
6547771 | Robertson et al. | Apr 2003 | B2 |
6569133 | Cheng et al. | May 2003 | B2 |
D476518 | Doppelt | Jul 2003 | S |
6592560 | Snyder et al. | Jul 2003 | B2 |
6610038 | Dipalma et al. | Aug 2003 | B1 |
6618868 | Minnick | Sep 2003 | B2 |
6620142 | Flueckiger | Sep 2003 | B1 |
6629651 | Male et al. | Oct 2003 | B1 |
6635038 | Scovel | Oct 2003 | B2 |
6652495 | Walker | Nov 2003 | B1 |
6666850 | Ahr et al. | Dec 2003 | B1 |
6685684 | Falconer | Feb 2004 | B1 |
6695828 | Dipalma et al. | Feb 2004 | B1 |
6699174 | Bennett | Mar 2004 | B1 |
6700034 | Lindsay et al. | Mar 2004 | B1 |
6702793 | Sweetser et al. | Mar 2004 | B1 |
6706027 | Harvie et al. | Mar 2004 | B2 |
6732384 | Scott | May 2004 | B2 |
6736977 | Hall et al. | May 2004 | B1 |
6740066 | Wolff et al. | May 2004 | B2 |
6764477 | Chen et al. | Jul 2004 | B1 |
6783519 | Samuelsson | Aug 2004 | B2 |
6796974 | Palumbo et al. | Sep 2004 | B2 |
6814547 | Childers et al. | Nov 2004 | B2 |
6849065 | Schmidt et al. | Feb 2005 | B2 |
6857137 | Otto | Feb 2005 | B2 |
6885690 | Aggerstam et al. | Apr 2005 | B2 |
6888044 | Fell et al. | May 2005 | B2 |
6893425 | Dunn et al. | May 2005 | B2 |
6912737 | Ernest et al. | Jul 2005 | B2 |
6918899 | Harvie | Jul 2005 | B2 |
6979324 | Bybordi et al. | Dec 2005 | B2 |
7018366 | Easter | Mar 2006 | B2 |
7066411 | Male et al. | Jun 2006 | B2 |
7122023 | Hinoki | Oct 2006 | B1 |
7125399 | Miskie | Oct 2006 | B2 |
7131964 | Harvie | Nov 2006 | B2 |
7135012 | Harvie | Nov 2006 | B2 |
7141043 | Harvie | Nov 2006 | B2 |
D533972 | La | Dec 2006 | S |
7160273 | Greter et al. | Jan 2007 | B2 |
7171699 | Ernest et al. | Feb 2007 | B2 |
7171871 | Kozak | Feb 2007 | B2 |
7179951 | Krishnaswamy-Mirle et al. | Feb 2007 | B2 |
7181781 | Trabold et al. | Feb 2007 | B1 |
7186245 | Cheng et al. | Mar 2007 | B1 |
7192424 | Cooper | Mar 2007 | B2 |
7219764 | Forbes | May 2007 | B1 |
7220250 | Suzuki et al. | May 2007 | B2 |
D562975 | Otto | Feb 2008 | S |
7335189 | Harvie | Feb 2008 | B2 |
7358282 | Krueger et al. | Apr 2008 | B2 |
7390320 | Machida et al. | Jun 2008 | B2 |
7438706 | Koizumi et al. | Oct 2008 | B2 |
7488310 | Yang | Feb 2009 | B2 |
7491194 | Oliwa | Feb 2009 | B1 |
D591106 | Dominique et al. | Apr 2009 | S |
7513381 | Heng et al. | Apr 2009 | B2 |
7520872 | Biggie et al. | Apr 2009 | B2 |
D593801 | Wilson et al. | Jun 2009 | S |
7540364 | Sanderson | Jun 2009 | B2 |
7549511 | Marocco | Jun 2009 | B2 |
7549512 | Newberry | Jun 2009 | B2 |
7585293 | Vermaak | Sep 2009 | B2 |
7588560 | Dunlop | Sep 2009 | B1 |
7637905 | Saadat et al. | Dec 2009 | B2 |
7665359 | Barber | Feb 2010 | B2 |
7682347 | Parks et al. | Mar 2010 | B2 |
7687004 | Allen | Mar 2010 | B2 |
7695459 | Gilbert et al. | Apr 2010 | B2 |
7695460 | Wada et al. | Apr 2010 | B2 |
7699818 | Gilbert | Apr 2010 | B2 |
7699831 | Bengtson et al. | Apr 2010 | B2 |
7722584 | Tanaka et al. | May 2010 | B2 |
7727206 | Gorres | Jun 2010 | B2 |
7740620 | Gilbert et al. | Jun 2010 | B2 |
7749205 | Tazoe et al. | Jul 2010 | B2 |
7755497 | Wada et al. | Jul 2010 | B2 |
7766887 | Burns et al. | Aug 2010 | B2 |
D625407 | Koizumi et al. | Oct 2010 | S |
7806879 | Brooks et al. | Oct 2010 | B2 |
7811272 | Lindsay | Oct 2010 | B2 |
7815067 | Matsumoto et al. | Oct 2010 | B2 |
7833169 | Hannon | Nov 2010 | B2 |
7857806 | Karpowicz et al. | Dec 2010 | B2 |
7866942 | Harvie | Jan 2011 | B2 |
7871385 | Levinson et al. | Jan 2011 | B2 |
7875010 | Frazier et al. | Jan 2011 | B2 |
7901389 | Mombrinie | Mar 2011 | B2 |
7927320 | Goldwasser et al. | Apr 2011 | B2 |
7927321 | Marland | Apr 2011 | B2 |
7931634 | Swiecicki et al. | Apr 2011 | B2 |
7939706 | Okabe et al. | May 2011 | B2 |
7946443 | Stull et al. | May 2011 | B2 |
7947025 | Buglino et al. | May 2011 | B2 |
7963419 | Burney et al. | Jun 2011 | B2 |
7976519 | Bubb et al. | Jul 2011 | B2 |
7993318 | Olsson et al. | Aug 2011 | B2 |
8015627 | Baker et al. | Sep 2011 | B2 |
8016071 | Martinus et al. | Sep 2011 | B1 |
8028460 | Williams | Oct 2011 | B2 |
8047398 | Dimartino et al. | Nov 2011 | B2 |
8083094 | Caulfield et al. | Dec 2011 | B2 |
8128608 | Thevenin | Mar 2012 | B2 |
8181651 | Pinel | May 2012 | B2 |
8181819 | Burney et al. | May 2012 | B2 |
8211063 | Bierman et al. | Jul 2012 | B2 |
8221369 | Parks et al. | Jul 2012 | B2 |
8241262 | Mahnensmith | Aug 2012 | B2 |
8277426 | Wilcox et al. | Oct 2012 | B2 |
8287508 | Sanchez | Oct 2012 | B1 |
8303554 | Tsai et al. | Nov 2012 | B2 |
8322565 | Caulfield et al. | Dec 2012 | B2 |
8337477 | Parks et al. | Dec 2012 | B2 |
D674241 | Bickert et al. | Jan 2013 | S |
8343122 | Gorres | Jan 2013 | B2 |
8343125 | Kawazoe et al. | Jan 2013 | B2 |
8353074 | Krebs | Jan 2013 | B2 |
8353886 | Bester et al. | Jan 2013 | B2 |
D676241 | Merrill | Feb 2013 | S |
8388588 | Wada et al. | Mar 2013 | B2 |
D679807 | Burgess et al. | Apr 2013 | S |
8425482 | Khoubnazar | Apr 2013 | B2 |
8434586 | Pawelski et al. | May 2013 | B2 |
8449510 | Martini et al. | May 2013 | B2 |
D684260 | Lund et al. | Jun 2013 | S |
8470230 | Caulfield et al. | Jun 2013 | B2 |
8479941 | Matsumoto et al. | Jul 2013 | B2 |
8479949 | Henkel | Jul 2013 | B2 |
8500719 | Simpson et al. | Aug 2013 | B1 |
8512301 | Ma | Aug 2013 | B2 |
8529530 | Koch et al. | Sep 2013 | B2 |
8535284 | Joder et al. | Sep 2013 | B2 |
8546639 | Wada et al. | Oct 2013 | B2 |
8551075 | Bengtson | Oct 2013 | B2 |
8568376 | Delattre et al. | Oct 2013 | B2 |
D694404 | Burgess et al. | Nov 2013 | S |
8585683 | Bengtson et al. | Nov 2013 | B2 |
8586583 | Hamblin et al. | Nov 2013 | B2 |
8652112 | Johannison et al. | Feb 2014 | B2 |
8669412 | Fernkvist et al. | Mar 2014 | B2 |
D702973 | Norland et al. | Apr 2014 | S |
8703032 | Menon et al. | Apr 2014 | B2 |
D704330 | Cicatelli | May 2014 | S |
D704510 | Mason et al. | May 2014 | S |
D705423 | Walsh Cutler | May 2014 | S |
D705926 | Burgess et al. | May 2014 | S |
8714394 | Wulf | May 2014 | B2 |
8715267 | Bengtson et al. | May 2014 | B2 |
8757425 | Copeland | Jun 2014 | B2 |
8777032 | Biesecker et al. | Jul 2014 | B2 |
8808260 | Koch et al. | Aug 2014 | B2 |
8864730 | Conway et al. | Oct 2014 | B2 |
8881923 | Higginson | Nov 2014 | B2 |
8882731 | Suzuki et al. | Nov 2014 | B2 |
8936585 | Carson et al. | Jan 2015 | B2 |
D729581 | Boroski | May 2015 | S |
9028460 | Medeiros | May 2015 | B2 |
9056698 | Noer | Jun 2015 | B2 |
9078792 | Ruiz | Jul 2015 | B2 |
9145879 | Pirovano et al. | Sep 2015 | B2 |
9173602 | Gilbert | Nov 2015 | B2 |
9173799 | Tanimoto et al. | Nov 2015 | B2 |
9187220 | Biesecker et al. | Nov 2015 | B2 |
9199772 | Krippendorf | Dec 2015 | B2 |
9233020 | Matsumiya | Jan 2016 | B2 |
9248058 | Conway et al. | Feb 2016 | B2 |
9308118 | Dupree et al. | Apr 2016 | B1 |
9309029 | Incorvia et al. | Apr 2016 | B2 |
9333281 | Giezendanner et al. | May 2016 | B2 |
9381108 | Longoni et al. | Jul 2016 | B2 |
9382047 | Schmidtner et al. | Jul 2016 | B2 |
9402424 | Roy | Aug 2016 | B2 |
9456937 | Ellis | Oct 2016 | B2 |
9480595 | Baham et al. | Nov 2016 | B2 |
9517865 | Albers et al. | Dec 2016 | B2 |
D777941 | Piramoon | Jan 2017 | S |
9533806 | Ding et al. | Jan 2017 | B2 |
9550611 | Hodge | Jan 2017 | B2 |
9555930 | Campbell et al. | Jan 2017 | B2 |
9623159 | Locke | Apr 2017 | B2 |
D789522 | Burgess et al. | Jun 2017 | S |
9687849 | Bruno et al. | Jun 2017 | B2 |
9694949 | Hendricks et al. | Jul 2017 | B2 |
9709048 | Kinjo | Jul 2017 | B2 |
9713547 | Lee et al. | Jul 2017 | B2 |
9732754 | Huang et al. | Aug 2017 | B2 |
9752564 | Arceno et al. | Sep 2017 | B2 |
9788992 | Harvie | Oct 2017 | B2 |
D804907 | Sandoval | Dec 2017 | S |
9868564 | McGirr et al. | Jan 2018 | B2 |
D814239 | Arora | Apr 2018 | S |
D817484 | Lafond | May 2018 | S |
10037640 | Gordon | Jul 2018 | B2 |
10058470 | Phillips | Aug 2018 | B2 |
10098990 | Koch et al. | Oct 2018 | B2 |
D835264 | Mozzicato et al. | Dec 2018 | S |
D835779 | Mozzicato et al. | Dec 2018 | S |
D840533 | Mozzicato et al. | Feb 2019 | S |
D840534 | Mozzicato et al. | Feb 2019 | S |
10225376 | Perez Martinez | Mar 2019 | B2 |
10226376 | Sanchez et al. | Mar 2019 | B2 |
10258517 | Maschino et al. | Apr 2019 | B1 |
D848612 | Mozzicato et al. | May 2019 | S |
10307305 | Hodges | Jun 2019 | B1 |
10335121 | Desai | Jul 2019 | B2 |
D856512 | Cowart et al. | Aug 2019 | S |
10376406 | Newton | Aug 2019 | B2 |
10376407 | Newton | Aug 2019 | B2 |
10390989 | Sanchez et al. | Aug 2019 | B2 |
D858144 | Fu | Sep 2019 | S |
10406039 | Mllarreal | Sep 2019 | B2 |
10407222 | Allen | Sep 2019 | B2 |
10478356 | Griffin | Nov 2019 | B2 |
10500108 | Maschino et al. | Dec 2019 | B1 |
10538366 | Pentelovitch et al. | Jan 2020 | B2 |
10569938 | Zhao et al. | Feb 2020 | B2 |
10577156 | Dagnelie et al. | Mar 2020 | B2 |
RE47930 | Cho | Apr 2020 | E |
10618721 | Vazin | Apr 2020 | B2 |
D884390 | Wang | May 2020 | S |
10669079 | Freedman et al. | Jun 2020 | B2 |
D892315 | Airy | Aug 2020 | S |
10730672 | Bertram et al. | Aug 2020 | B2 |
10737848 | Philip et al. | Aug 2020 | B2 |
10765854 | Law et al. | Sep 2020 | B2 |
10766670 | Kittmann | Sep 2020 | B2 |
10799386 | Harrison | Oct 2020 | B1 |
10806642 | Tagomori et al. | Oct 2020 | B2 |
D901214 | Hu | Nov 2020 | S |
10849799 | Nishikawa et al. | Dec 2020 | B2 |
10857025 | Davis et al. | Dec 2020 | B2 |
10865017 | Cowart et al. | Dec 2020 | B1 |
10889412 | West et al. | Jan 2021 | B2 |
10913581 | Stahlecker | Feb 2021 | B2 |
D912244 | Rehm et al. | Mar 2021 | S |
10952889 | Newton et al. | Mar 2021 | B2 |
10973378 | Ryu et al. | Apr 2021 | B2 |
10973678 | Newton et al. | Apr 2021 | B2 |
10974874 | Ragias et al. | Apr 2021 | B2 |
11000401 | Ecklund et al. | May 2021 | B2 |
D923365 | Wang | Jun 2021 | S |
11026829 | Harvie | Jun 2021 | B2 |
11027900 | Liu | Jun 2021 | B2 |
11045346 | Argent et al. | Jun 2021 | B2 |
D928946 | Sanchez et al. | Aug 2021 | S |
11090183 | Sanchez et al. | Aug 2021 | B2 |
11160695 | Febo et al. | Nov 2021 | B2 |
11160697 | Maschino et al. | Nov 2021 | B2 |
11168420 | Kinugasa et al. | Nov 2021 | B2 |
11179506 | Barr et al. | Nov 2021 | B2 |
11226376 | Yamauchi et al. | Jan 2022 | B2 |
11253407 | Miao et al. | Feb 2022 | B2 |
11326586 | Milner et al. | May 2022 | B2 |
11369508 | Ecklund et al. | Jun 2022 | B2 |
11369524 | Hubbard et al. | Jun 2022 | B2 |
11376152 | Sanchez et al. | Jul 2022 | B2 |
11382786 | Sanchez et al. | Jul 2022 | B2 |
11382788 | Hjorth et al. | Jul 2022 | B2 |
11389318 | Radl et al. | Jul 2022 | B2 |
11395871 | Radl et al. | Jul 2022 | B2 |
11399990 | Suyama | Aug 2022 | B2 |
11426303 | Davis et al. | Aug 2022 | B2 |
11504265 | Godinez et al. | Nov 2022 | B2 |
11529252 | Glithero et al. | Dec 2022 | B2 |
11547788 | Radl et al. | Jan 2023 | B2 |
11806266 | Sanchez et al. | Nov 2023 | B2 |
11839567 | Davis et al. | Dec 2023 | B2 |
D1010109 | Ecklund et al. | Jan 2024 | S |
11857716 | Lee et al. | Jan 2024 | B2 |
11865030 | Davis et al. | Jan 2024 | B2 |
11890221 | Ulreich et al. | Feb 2024 | B2 |
11925575 | Newton | Mar 2024 | B2 |
11938053 | Austermann et al. | Mar 2024 | B2 |
11944740 | Hughett et al. | Apr 2024 | B2 |
12023457 | Mann et al. | Jul 2024 | B2 |
12042422 | Davis et al. | Jul 2024 | B2 |
20010037097 | Cheng et al. | Nov 2001 | A1 |
20010054426 | Knudson et al. | Dec 2001 | A1 |
20020019614 | Woon | Feb 2002 | A1 |
20020026161 | Grundke | Feb 2002 | A1 |
20020087131 | Wolff et al. | Jul 2002 | A1 |
20020091364 | Prabhakar | Jul 2002 | A1 |
20020189992 | Schmidt et al. | Dec 2002 | A1 |
20020193760 | Thompson | Dec 2002 | A1 |
20030004436 | Schmidt et al. | Jan 2003 | A1 |
20030032931 | Grundke et al. | Feb 2003 | A1 |
20030032944 | Cawood | Feb 2003 | A1 |
20030073964 | Palumbo et al. | Apr 2003 | A1 |
20030120178 | Heki | Jun 2003 | A1 |
20030157859 | Ishikawa | Aug 2003 | A1 |
20030181880 | Schwartz | Sep 2003 | A1 |
20030195484 | Harvie | Oct 2003 | A1 |
20030204173 | Burns et al. | Oct 2003 | A1 |
20030233079 | Parks et al. | Dec 2003 | A1 |
20040006321 | Cheng et al. | Jan 2004 | A1 |
20040015141 | Cheng et al. | Jan 2004 | A1 |
20040056122 | Male et al. | Mar 2004 | A1 |
20040084465 | Luburic | May 2004 | A1 |
20040127872 | Petryk et al. | Jul 2004 | A1 |
20040128749 | Scott | Jul 2004 | A1 |
20040143229 | Easter | Jul 2004 | A1 |
20040147863 | Diaz et al. | Jul 2004 | A1 |
20040147894 | Mizutani et al. | Jul 2004 | A1 |
20040158221 | Mizutani et al. | Aug 2004 | A1 |
20040176731 | Cheng et al. | Sep 2004 | A1 |
20040176746 | Forral | Sep 2004 | A1 |
20040191919 | Unger et al. | Sep 2004 | A1 |
20040200936 | Opperthauser | Oct 2004 | A1 |
20040207530 | Nielsen | Oct 2004 | A1 |
20040236292 | Tazoe et al. | Nov 2004 | A1 |
20040243075 | Harvie | Dec 2004 | A1 |
20040254547 | Okabe et al. | Dec 2004 | A1 |
20050010182 | Parks et al. | Jan 2005 | A1 |
20050033248 | Machida et al. | Feb 2005 | A1 |
20050065471 | Kuntz | Mar 2005 | A1 |
20050070861 | Okabe et al. | Mar 2005 | A1 |
20050070862 | Tazoe et al. | Mar 2005 | A1 |
20050082300 | Modrell et al. | Apr 2005 | A1 |
20050097662 | Leimkuhler et al. | May 2005 | A1 |
20050101924 | Elson et al. | May 2005 | A1 |
20050119630 | Harvie | Jun 2005 | A1 |
20050137557 | Swiecicki et al. | Jun 2005 | A1 |
20050154360 | Harvie | Jul 2005 | A1 |
20050177070 | Levinson et al. | Aug 2005 | A1 |
20050197639 | Mombrinie | Sep 2005 | A1 |
20050273920 | Marinas | Dec 2005 | A1 |
20050277904 | Chase et al. | Dec 2005 | A1 |
20050279359 | Leblanc et al. | Dec 2005 | A1 |
20060004332 | Marx | Jan 2006 | A1 |
20060015080 | Mahnensmith | Jan 2006 | A1 |
20060015081 | Suzuki et al. | Jan 2006 | A1 |
20060016778 | Park | Jan 2006 | A1 |
20060069359 | Dipalma et al. | Mar 2006 | A1 |
20060079854 | Kay et al. | Apr 2006 | A1 |
20060111648 | Vermaak | May 2006 | A1 |
20060155214 | Wightman | Jul 2006 | A1 |
20060171997 | Gruenbacher et al. | Aug 2006 | A1 |
20060200102 | Cooper | Sep 2006 | A1 |
20060229575 | Boiarski | Oct 2006 | A1 |
20060229576 | Conway et al. | Oct 2006 | A1 |
20060231648 | Male et al. | Oct 2006 | A1 |
20060235266 | Nan | Oct 2006 | A1 |
20060235359 | Marland | Oct 2006 | A1 |
20060241553 | Harvie | Oct 2006 | A1 |
20060269439 | White | Nov 2006 | A1 |
20060277670 | Baker et al. | Dec 2006 | A1 |
20070006368 | Key et al. | Jan 2007 | A1 |
20070010797 | Nishtala et al. | Jan 2007 | A1 |
20070016152 | Karpowicz et al. | Jan 2007 | A1 |
20070038194 | Wada et al. | Feb 2007 | A1 |
20070055209 | Patel et al. | Mar 2007 | A1 |
20070073252 | Forgrave | Mar 2007 | A1 |
20070117880 | Elson et al. | May 2007 | A1 |
20070118993 | Bates | May 2007 | A1 |
20070135786 | Schmidt et al. | Jun 2007 | A1 |
20070137718 | Rushlander et al. | Jun 2007 | A1 |
20070149935 | Dirico | Jun 2007 | A1 |
20070191804 | Coley | Aug 2007 | A1 |
20070203464 | Green et al. | Aug 2007 | A1 |
20070214553 | Carromba et al. | Sep 2007 | A1 |
20070225663 | Watt et al. | Sep 2007 | A1 |
20070225666 | Otto | Sep 2007 | A1 |
20070225668 | Otto | Sep 2007 | A1 |
20070266486 | Ramirez | Nov 2007 | A1 |
20070282309 | Bengtson et al. | Dec 2007 | A1 |
20080004576 | Tanaka et al. | Jan 2008 | A1 |
20080015526 | Reiner et al. | Jan 2008 | A1 |
20080015527 | House | Jan 2008 | A1 |
20080033386 | Okabe et al. | Feb 2008 | A1 |
20080041869 | Backaert | Feb 2008 | A1 |
20080091153 | Harvie | Apr 2008 | A1 |
20080091158 | Yang | Apr 2008 | A1 |
20080114327 | Barge | May 2008 | A1 |
20080167634 | Kouta et al. | Jul 2008 | A1 |
20080183157 | Walters | Jul 2008 | A1 |
20080215031 | Belfort et al. | Sep 2008 | A1 |
20080234642 | Patterson et al. | Sep 2008 | A1 |
20080269703 | Collins et al. | Oct 2008 | A1 |
20080281282 | Finger et al. | Nov 2008 | A1 |
20080287894 | Van Den Heuvel et al. | Nov 2008 | A1 |
20080312550 | Nishtala et al. | Dec 2008 | A1 |
20090025717 | Pinel | Jan 2009 | A1 |
20090048570 | Jensen | Feb 2009 | A1 |
20090056003 | Ivie et al. | Mar 2009 | A1 |
20090069761 | Vogel | Mar 2009 | A1 |
20090069765 | Wortham | Mar 2009 | A1 |
20090120179 | Nylander et al. | May 2009 | A1 |
20090192482 | Dodge et al. | Jul 2009 | A1 |
20090234312 | Otoole et al. | Sep 2009 | A1 |
20090251510 | Noro et al. | Oct 2009 | A1 |
20090264840 | Mrginio | Oct 2009 | A1 |
20090270822 | Medeiros | Oct 2009 | A1 |
20090281510 | Fisher | Nov 2009 | A1 |
20100004612 | Thevenin | Jan 2010 | A1 |
20100058660 | Williams | Mar 2010 | A1 |
20100121289 | Parks et al. | May 2010 | A1 |
20100158168 | Murthy et al. | Jun 2010 | A1 |
20100160882 | Lowe | Jun 2010 | A1 |
20100174250 | Hu et al. | Jul 2010 | A1 |
20100185168 | Graauw et al. | Jul 2010 | A1 |
20100198172 | Wada et al. | Aug 2010 | A1 |
20100211032 | Tsai et al. | Aug 2010 | A1 |
20100234820 | Tsai et al. | Sep 2010 | A1 |
20100241104 | Gilbert | Sep 2010 | A1 |
20100263113 | Shelton et al. | Oct 2010 | A1 |
20100310845 | Bond et al. | Dec 2010 | A1 |
20110028920 | Johannison | Feb 2011 | A1 |
20110028922 | Kay et al. | Feb 2011 | A1 |
20110034889 | Smith | Feb 2011 | A1 |
20110036837 | Shang | Feb 2011 | A1 |
20110040267 | Wada et al. | Feb 2011 | A1 |
20110040271 | Rogers et al. | Feb 2011 | A1 |
20110054426 | Stewart et al. | Mar 2011 | A1 |
20110060299 | Wada et al. | Mar 2011 | A1 |
20110060300 | Weig et al. | Mar 2011 | A1 |
20110077495 | Gilbert | Mar 2011 | A1 |
20110077606 | Wilcox et al. | Mar 2011 | A1 |
20110087337 | Forsell | Apr 2011 | A1 |
20110137273 | Muellejans et al. | Jun 2011 | A1 |
20110145993 | Rader et al. | Jun 2011 | A1 |
20110152802 | Dicamillo et al. | Jun 2011 | A1 |
20110164147 | Takahashi et al. | Jul 2011 | A1 |
20110172620 | Khambatta | Jul 2011 | A1 |
20110172625 | Wada et al. | Jul 2011 | A1 |
20110202024 | Cozzens | Aug 2011 | A1 |
20110238023 | Slayton | Sep 2011 | A1 |
20110240648 | Tucker | Oct 2011 | A1 |
20110251572 | Nishtala et al. | Oct 2011 | A1 |
20110265889 | Tanaka et al. | Nov 2011 | A1 |
20110276020 | Mitsui | Nov 2011 | A1 |
20120029452 | Roedsten | Feb 2012 | A1 |
20120035577 | Tomes et al. | Feb 2012 | A1 |
20120041400 | Christensen | Feb 2012 | A1 |
20120059328 | Dikeman et al. | Mar 2012 | A1 |
20120066825 | Birbara et al. | Mar 2012 | A1 |
20120103347 | Wheaton et al. | May 2012 | A1 |
20120137420 | Gordon et al. | Jun 2012 | A1 |
20120165768 | Sekiyama et al. | Jun 2012 | A1 |
20120165786 | Chappa et al. | Jun 2012 | A1 |
20120210503 | Anzivino et al. | Aug 2012 | A1 |
20120233761 | Huang | Sep 2012 | A1 |
20120245541 | Suzuki et al. | Sep 2012 | A1 |
20120245542 | Suzuki et al. | Sep 2012 | A1 |
20120245547 | Wilcox et al. | Sep 2012 | A1 |
20120253303 | Suzuki et al. | Oct 2012 | A1 |
20120271259 | Ulert | Oct 2012 | A1 |
20120296305 | Barraza Khaled et al. | Nov 2012 | A1 |
20120316522 | Carter et al. | Dec 2012 | A1 |
20120330256 | Wilcox et al. | Dec 2012 | A1 |
20130006206 | Wada et al. | Jan 2013 | A1 |
20130045651 | Esteves et al. | Feb 2013 | A1 |
20130053804 | Soerensen et al. | Feb 2013 | A1 |
20130096523 | Chang et al. | Apr 2013 | A1 |
20130110059 | Kossow et al. | May 2013 | A1 |
20130138064 | Stroebech et al. | May 2013 | A1 |
20130150813 | Gordon et al. | Jun 2013 | A1 |
20130218112 | Thompson | Aug 2013 | A1 |
20130245496 | Wells et al. | Sep 2013 | A1 |
20130245586 | Jha | Sep 2013 | A1 |
20130292537 | Dirico | Nov 2013 | A1 |
20130330501 | Aizenberg | Dec 2013 | A1 |
20140005647 | Shuffler et al. | Jan 2014 | A1 |
20140031774 | Bengtson | Jan 2014 | A1 |
20140039432 | Dunbar et al. | Feb 2014 | A1 |
20140157499 | Suzuki et al. | Jun 2014 | A1 |
20140171889 | Hopman et al. | Jun 2014 | A1 |
20140182051 | Tanimoto et al. | Jul 2014 | A1 |
20140196189 | Lee et al. | Jul 2014 | A1 |
20140276501 | Cisko | Sep 2014 | A1 |
20140303582 | Wright et al. | Oct 2014 | A1 |
20140316381 | Reglin | Oct 2014 | A1 |
20140325746 | Block | Nov 2014 | A1 |
20140348139 | Gomez Martinez | Nov 2014 | A1 |
20140352050 | Yao et al. | Dec 2014 | A1 |
20140371628 | Desai | Dec 2014 | A1 |
20150045757 | Lee et al. | Feb 2015 | A1 |
20150047114 | Ramirez | Feb 2015 | A1 |
20150048089 | Robertson | Feb 2015 | A1 |
20150135423 | Sharpe et al. | May 2015 | A1 |
20150157300 | Ealovega et al. | Jun 2015 | A1 |
20150209194 | Heyman | Jul 2015 | A1 |
20150290425 | Macy et al. | Oct 2015 | A1 |
20150320583 | Harvie | Nov 2015 | A1 |
20150329255 | Rzepecki | Nov 2015 | A1 |
20150342799 | Michiels et al. | Dec 2015 | A1 |
20150359660 | Harvie | Dec 2015 | A1 |
20150366699 | Nelson | Dec 2015 | A1 |
20160029998 | Brister et al. | Feb 2016 | A1 |
20160030228 | Jones | Feb 2016 | A1 |
20160038356 | Yao et al. | Feb 2016 | A1 |
20160058322 | Brister et al. | Mar 2016 | A1 |
20160060001 | Wada et al. | Mar 2016 | A1 |
20160100976 | Conway et al. | Apr 2016 | A1 |
20160106604 | Timm | Apr 2016 | A1 |
20160113809 | Kim | Apr 2016 | A1 |
20160183689 | Miner | Jun 2016 | A1 |
20160256022 | Le | Sep 2016 | A1 |
20160270982 | Raycheck et al. | Sep 2016 | A1 |
20160278662 | Brister et al. | Sep 2016 | A1 |
20160357400 | Penha et al. | Dec 2016 | A1 |
20160366699 | Zhang et al. | Dec 2016 | A1 |
20160367226 | Newton et al. | Dec 2016 | A1 |
20160367411 | Justiz et al. | Dec 2016 | A1 |
20160367726 | Gratzer | Dec 2016 | A1 |
20160374848 | Sanchez et al. | Dec 2016 | A1 |
20170007438 | Harvie | Jan 2017 | A1 |
20170014560 | Minskoff et al. | Jan 2017 | A1 |
20170100276 | Joh | Apr 2017 | A1 |
20170128638 | Giezendanner et al. | May 2017 | A1 |
20170136209 | Burnett et al. | May 2017 | A1 |
20170143534 | Sanchez | May 2017 | A1 |
20170165100 | Jackson et al. | Jun 2017 | A1 |
20170165405 | Muser et al. | Jun 2017 | A1 |
20170189225 | Voorhees et al. | Jul 2017 | A1 |
20170202692 | Laniado | Jul 2017 | A1 |
20170216081 | Accosta | Aug 2017 | A1 |
20170246026 | Laniado | Aug 2017 | A1 |
20170252014 | Siller Gonzalez et al. | Sep 2017 | A1 |
20170252202 | Sanchez et al. | Sep 2017 | A9 |
20170266031 | Sanchez et al. | Sep 2017 | A1 |
20170266658 | Bruno et al. | Sep 2017 | A1 |
20170281399 | Vanmiddendorp et al. | Oct 2017 | A1 |
20170312116 | Laniado | Nov 2017 | A1 |
20170325788 | Ealovega et al. | Nov 2017 | A1 |
20170333244 | Laniado | Nov 2017 | A1 |
20170042748 | Griffin | Dec 2017 | A1 |
20170348139 | Newton et al. | Dec 2017 | A1 |
20170354532 | Holt | Dec 2017 | A1 |
20170354551 | Gawley et al. | Dec 2017 | A1 |
20170367873 | Grannum | Dec 2017 | A1 |
20180002075 | Lee | Jan 2018 | A1 |
20180008451 | Stroebech | Jan 2018 | A1 |
20180008804 | Laniado | Jan 2018 | A1 |
20180021218 | Brosch et al. | Jan 2018 | A1 |
20180028349 | Newton et al. | Feb 2018 | A1 |
20180037384 | Archeny et al. | Feb 2018 | A1 |
20180049910 | Newton | Feb 2018 | A1 |
20180064572 | Wiltshire | Mar 2018 | A1 |
20180104131 | Killian | Apr 2018 | A1 |
20180127187 | Sewell | May 2018 | A1 |
20180193215 | Davies et al. | Jul 2018 | A1 |
20180200101 | Su | Jul 2018 | A1 |
20180228642 | Davis et al. | Aug 2018 | A1 |
20180256384 | Kasirye | Sep 2018 | A1 |
20180271694 | Fernandez et al. | Sep 2018 | A1 |
20180317892 | Catlin | Nov 2018 | A1 |
20180325748 | Sharma et al. | Nov 2018 | A1 |
20190001030 | Braga et al. | Jan 2019 | A1 |
20190021899 | Vlet | Jan 2019 | A1 |
20190038451 | Harvie | Feb 2019 | A1 |
20190046102 | Kushnir et al. | Feb 2019 | A1 |
20190059938 | Holsten | Feb 2019 | A1 |
20190091059 | Gabriel | Mar 2019 | A1 |
20190100362 | Meyers et al. | Apr 2019 | A1 |
20190133814 | Tammen et al. | May 2019 | A1 |
20190142624 | Sanchez et al. | May 2019 | A1 |
20190224036 | Sanchez et al. | Jul 2019 | A1 |
20190247222 | Ecklund et al. | Aug 2019 | A1 |
20190247223 | Brun et al. | Aug 2019 | A1 |
20190282391 | Johannes | Sep 2019 | A1 |
20190314189 | Acosta | Oct 2019 | A1 |
20190314190 | Sanchez et al. | Oct 2019 | A1 |
20190321587 | Mcmenamin et al. | Oct 2019 | A1 |
20190344934 | Faerber et al. | Nov 2019 | A1 |
20190365307 | Laing et al. | Dec 2019 | A1 |
20190365561 | Newton et al. | Dec 2019 | A1 |
20200008985 | Nguyen et al. | Jan 2020 | A1 |
20200016012 | Dutkiewicz | Jan 2020 | A1 |
20200030595 | Boukidjian et al. | Jan 2020 | A1 |
20200046544 | Godinez et al. | Feb 2020 | A1 |
20200055638 | Lau et al. | Feb 2020 | A1 |
20200070392 | Huber et al. | Mar 2020 | A1 |
20200085609 | Schelch et al. | Mar 2020 | A1 |
20200085610 | Cohn et al. | Mar 2020 | A1 |
20200086090 | Von Weymarn-Schärli et al. | Mar 2020 | A1 |
20200107518 | Hiroshima et al. | Apr 2020 | A1 |
20200129322 | Leuckel | Apr 2020 | A1 |
20200171217 | Braga et al. | Jun 2020 | A9 |
20200206039 | Mclain | Jul 2020 | A1 |
20200214910 | Varona et al. | Jul 2020 | A1 |
20200216898 | Hubbell | Jul 2020 | A1 |
20200216989 | Kinugasa et al. | Jul 2020 | A1 |
20200229964 | Staali et al. | Jul 2020 | A1 |
20200231343 | Freedman et al. | Jul 2020 | A1 |
20200232841 | Satish et al. | Jul 2020 | A1 |
20200246172 | Ho | Aug 2020 | A1 |
20200246203 | Tulk et al. | Aug 2020 | A1 |
20200255189 | Liu | Aug 2020 | A1 |
20200261280 | Heyman | Aug 2020 | A1 |
20200276046 | Staali et al. | Sep 2020 | A1 |
20200306075 | Newton et al. | Oct 2020 | A1 |
20200315837 | Radl et al. | Oct 2020 | A1 |
20200315838 | Eckert | Oct 2020 | A1 |
20200315872 | Viens et al. | Oct 2020 | A1 |
20200315874 | Viens et al. | Oct 2020 | A1 |
20200331672 | Bertram et al. | Oct 2020 | A1 |
20200345332 | Duval | Nov 2020 | A1 |
20200353135 | Gregory et al. | Nov 2020 | A1 |
20200367677 | Silsby et al. | Nov 2020 | A1 |
20200369444 | Silsby et al. | Nov 2020 | A1 |
20200375781 | Staali et al. | Dec 2020 | A1 |
20200375810 | Carlin et al. | Dec 2020 | A1 |
20200385179 | Mccourt | Dec 2020 | A1 |
20200390591 | Glithero et al. | Dec 2020 | A1 |
20200390592 | Merrill | Dec 2020 | A1 |
20200405521 | Glasroe | Dec 2020 | A1 |
20210008771 | Huber et al. | Jan 2021 | A1 |
20210009323 | Markarian et al. | Jan 2021 | A1 |
20210020072 | Moehring et al. | Jan 2021 | A1 |
20210059853 | Davis et al. | Mar 2021 | A1 |
20210061523 | Bytheway | Mar 2021 | A1 |
20210069005 | Sanchez et al. | Mar 2021 | A1 |
20210069008 | Blabas et al. | Mar 2021 | A1 |
20210069009 | Im | Mar 2021 | A1 |
20210069030 | Nishikawa et al. | Mar 2021 | A1 |
20210077993 | Nazareth et al. | Mar 2021 | A1 |
20210113749 | Radl et al. | Apr 2021 | A1 |
20210121318 | Pinlac | Apr 2021 | A1 |
20210137724 | Ecklund et al. | May 2021 | A1 |
20210138190 | Erbey et al. | May 2021 | A1 |
20210154055 | Mllarreal | May 2021 | A1 |
20210170079 | Radl et al. | Jun 2021 | A1 |
20210178390 | Oueslati et al. | Jun 2021 | A1 |
20210186742 | Newton et al. | Jun 2021 | A1 |
20210212865 | Wallajapet et al. | Jul 2021 | A1 |
20210220162 | Jamison | Jul 2021 | A1 |
20210220163 | Mayrand | Jul 2021 | A1 |
20210228400 | Glithero | Jul 2021 | A1 |
20210228401 | Becker et al. | Jul 2021 | A1 |
20210228795 | Hughett et al. | Jul 2021 | A1 |
20210229877 | Ragias et al. | Jul 2021 | A1 |
20210236323 | Austermann et al. | Aug 2021 | A1 |
20210236324 | Sweeney | Aug 2021 | A1 |
20210251814 | Jönegren et al. | Aug 2021 | A1 |
20210267787 | Nazemi | Sep 2021 | A1 |
20210275343 | Sanchez et al. | Sep 2021 | A1 |
20210275344 | Wing | Sep 2021 | A1 |
20210290454 | Yamada | Sep 2021 | A1 |
20210315727 | Jiang | Oct 2021 | A1 |
20210353450 | Sharma et al. | Nov 2021 | A1 |
20210361469 | Liu et al. | Nov 2021 | A1 |
20210369495 | Cheng et al. | Dec 2021 | A1 |
20210386925 | Hartwell et al. | Dec 2021 | A1 |
20210393433 | Godinez et al. | Dec 2021 | A1 |
20220023091 | Ecklund et al. | Jan 2022 | A1 |
20220031523 | Pierpoint | Feb 2022 | A1 |
20220039995 | Johannes et al. | Feb 2022 | A1 |
20220047410 | Walthall | Feb 2022 | A1 |
20220062027 | Mitchell et al. | Mar 2022 | A1 |
20220062028 | Mitchell et al. | Mar 2022 | A1 |
20220062029 | Johannes et al. | Mar 2022 | A1 |
20220066825 | Saraf et al. | Mar 2022 | A1 |
20220071811 | Cheng et al. | Mar 2022 | A1 |
20220071826 | Kulkarni et al. | Mar 2022 | A1 |
20220104965 | Vaninetti et al. | Apr 2022 | A1 |
20220104976 | Hoeger et al. | Apr 2022 | A1 |
20220104981 | Jones | Apr 2022 | A1 |
20220117773 | Davis et al. | Apr 2022 | A1 |
20220117774 | Meyer et al. | Apr 2022 | A1 |
20220117775 | Jones et al. | Apr 2022 | A1 |
20220133524 | Davis | May 2022 | A1 |
20220151817 | Mann | May 2022 | A1 |
20220160949 | Simiele et al. | May 2022 | A1 |
20220168159 | Triado et al. | Jun 2022 | A1 |
20220193312 | Lee et al. | Jun 2022 | A1 |
20220211536 | Johannes et al. | Jul 2022 | A1 |
20220218510 | Metzger et al. | Jul 2022 | A1 |
20220229053 | Levin et al. | Jul 2022 | A1 |
20220241106 | Johannes et al. | Aug 2022 | A1 |
20220247407 | Yamamoto et al. | Aug 2022 | A1 |
20220248836 | Cagle et al. | Aug 2022 | A1 |
20220257407 | Johannes et al. | Aug 2022 | A1 |
20220265460 | Coker | Aug 2022 | A1 |
20220265462 | Alder et al. | Aug 2022 | A1 |
20220270711 | Feala et al. | Aug 2022 | A1 |
20220273482 | Johannes et al. | Sep 2022 | A1 |
20220280357 | Jagannathan et al. | Sep 2022 | A1 |
20220287689 | Johannes | Sep 2022 | A1 |
20220296408 | Evans et al. | Sep 2022 | A1 |
20220305191 | Joseph et al. | Sep 2022 | A1 |
20220313222 | Austermann et al. | Oct 2022 | A1 |
20220313474 | Kriscovich et al. | Oct 2022 | A1 |
20220331170 | Erdem et al. | Oct 2022 | A1 |
20220339024 | Johannes et al. | Oct 2022 | A1 |
20220354685 | Davis et al. | Nov 2022 | A1 |
20220362049 | Austermann et al. | Nov 2022 | A1 |
20220370231 | Wang et al. | Nov 2022 | A1 |
20220370234 | Hughett et al. | Nov 2022 | A1 |
20220370235 | Johannes et al. | Nov 2022 | A1 |
20220370237 | Parmar et al. | Nov 2022 | A1 |
20220387001 | Askenazi et al. | Dec 2022 | A1 |
20220395390 | Brooks | Dec 2022 | A1 |
20220395391 | Saunders et al. | Dec 2022 | A1 |
20230018845 | Lee | Jan 2023 | A1 |
20230020563 | Sharma et al. | Jan 2023 | A1 |
20230031640 | Hughett et al. | Feb 2023 | A1 |
20230037159 | Brennan et al. | Feb 2023 | A1 |
20230052238 | Oluwasogo | Feb 2023 | A1 |
20230062944 | Vollenberg et al. | Mar 2023 | A1 |
20230062994 | Ecklund et al. | Mar 2023 | A1 |
20230070347 | Watson et al. | Mar 2023 | A1 |
20230073708 | Xu et al. | Mar 2023 | A1 |
20230089032 | Hughett et al. | Mar 2023 | A1 |
20230099821 | Radl et al. | Mar 2023 | A1 |
20230099991 | Bianchi et al. | Mar 2023 | A1 |
20230105001 | Whittome et al. | Apr 2023 | A1 |
20230110577 | Choi | Apr 2023 | A1 |
20230138269 | Abdelal et al. | May 2023 | A1 |
20230145365 | Martin et al. | May 2023 | A1 |
20230155253 | Mn et al. | May 2023 | A1 |
20230210504 | Kuroda et al. | Jul 2023 | A1 |
20230210685 | Fallows et al. | Jul 2023 | A1 |
20230218426 | Hughett | Jul 2023 | A1 |
20230240884 | Davis et al. | Aug 2023 | A1 |
20230248562 | Sanchez et al. | Aug 2023 | A1 |
20230248564 | Mann et al. | Aug 2023 | A1 |
20230255812 | Sanchez et al. | Aug 2023 | A1 |
20230255813 | Sanchez et al. | Aug 2023 | A1 |
20230255815 | Newton | Aug 2023 | A1 |
20230263650 | Sanchez et al. | Aug 2023 | A1 |
20230263655 | Johannes et al. | Aug 2023 | A1 |
20230277362 | Davis et al. | Sep 2023 | A1 |
20230285178 | Sanchez et al. | Sep 2023 | A1 |
20230293339 | James | Sep 2023 | A1 |
20230301846 | Greenwood | Sep 2023 | A1 |
20230355423 | Stevenson et al. | Nov 2023 | A1 |
20230404791 | Ecklund et al. | Dec 2023 | A1 |
20240008444 | Su et al. | Jan 2024 | A1 |
20240009023 | Johannes et al. | Jan 2024 | A1 |
20240024170 | Scott | Jan 2024 | A1 |
20240041638 | Johannes et al. | Feb 2024 | A1 |
20240058161 | Ulreich et al. | Feb 2024 | A1 |
20240065881 | Kuroda et al. | Feb 2024 | A1 |
20240099874 | Sanchez et al. | Mar 2024 | A1 |
20240110318 | Bendt et al. | Apr 2024 | A1 |
20240123134 | Kharkar et al. | Apr 2024 | A1 |
Number | Date | Country |
---|---|---|
2018216821 | Aug 2019 | AU |
2021299304 | Feb 2023 | AU |
2165286 | Sep 1999 | CA |
2354132 | Jun 2000 | CA |
2359091 | Sep 2003 | CA |
2488867 | Aug 2007 | CA |
3050918 | Aug 2018 | CA |
3098571 | Nov 2019 | CA |
2269203 | Dec 1997 | CN |
1332620 | Jan 2002 | CN |
1434693 | Aug 2003 | CN |
1533755 | Oct 2004 | CN |
1602825 | Apr 2005 | CN |
1720888 | Jan 2006 | CN |
2936204 | Aug 2007 | CN |
101262836 | Sep 2008 | CN |
101522148 | Sep 2009 | CN |
102159159 | Aug 2011 | CN |
202184840 | Apr 2012 | CN |
102481441 | May 2012 | CN |
202463712 | Oct 2012 | CN |
103533968 | Jan 2014 | CN |
103717180 | Apr 2014 | CN |
204562697 | Aug 2015 | CN |
105411783 | Mar 2016 | CN |
105451693 | Mar 2016 | CN |
105534632 | May 2016 | CN |
205849719 | Jan 2017 | CN |
106726089 | May 2017 | CN |
107847384 | Mar 2018 | CN |
107920912 | Apr 2018 | CN |
108420590 | Aug 2018 | CN |
209285902 | Aug 2019 | CN |
110381883 | Oct 2019 | CN |
211198839 | Aug 2020 | CN |
112566550 | Mar 2021 | CN |
112603184 | Apr 2021 | CN |
114007493 | Feb 2022 | CN |
114375187 | Apr 2022 | CN |
116096332 | May 2023 | CN |
79818 | Oct 1893 | DE |
1516466 | Jun 1969 | DE |
2721330 | Nov 1977 | DE |
2742298 | Mar 1978 | DE |
9407554.9 | May 1995 | DE |
4443710 | Jun 1995 | DE |
4416094 | Nov 1995 | DE |
4236097 | Oct 1996 | DE |
19619597 | Nov 1997 | DE |
102005037762 | Sep 2006 | DE |
102011103783 | Dec 2012 | DE |
202015104597 | Jul 2016 | DE |
102020121462 | Jan 2022 | DE |
9600118 | Nov 1996 | DK |
0032138 | Jul 1981 | EP |
0068712 | Jan 1983 | EP |
0140470 | May 1985 | EP |
066070 | Sep 1985 | EP |
0140471 | May 1988 | EP |
0274753 | Jul 1988 | EP |
0119143 | Nov 1988 | EP |
0483592 | May 1992 | EP |
0610638 | Aug 1994 | EP |
0613355 | Sep 1994 | EP |
0613355 | Jan 1997 | EP |
0787472 | Aug 1997 | EP |
0966936 | Dec 1999 | EP |
0987293 | Mar 2000 | EP |
1063953 | Jan 2001 | EP |
0653928 | Oct 2002 | EP |
1332738 | Aug 2003 | EP |
1382318 | Jan 2004 | EP |
1089684 | Oct 2004 | EP |
1616542 | Jan 2006 | EP |
1382318 | May 2006 | EP |
1063953 | Jan 2007 | EP |
1872752 | Jan 2008 | EP |
2180907 | May 2010 | EP |
2380532 | Oct 2011 | EP |
2389908 | Nov 2011 | EP |
2601916 | Jun 2013 | EP |
2676643 | Dec 2013 | EP |
2997950 | Mar 2016 | EP |
2879534 | Mar 2017 | EP |
3424471 | Jan 2019 | EP |
3169292 | Nov 2019 | EP |
3753492 | Dec 2020 | EP |
3788992 | Mar 2021 | EP |
3576689 | Mar 2022 | EP |
3752110 | Mar 2022 | EP |
3787570 | Mar 2022 | EP |
4025163 | Jul 2022 | EP |
3463180 | Mar 2023 | EP |
3569205 | Jun 2023 | EP |
4382082 | Jun 2024 | EP |
871820 | Jul 1961 | GB |
1011517 | Dec 1965 | GB |
1467144 | Mar 1977 | GB |
2106395 | Apr 1983 | GB |
2106784 | Apr 1983 | GB |
2148126 | May 1985 | GB |
2171315 | Aug 1986 | GB |
2181953 | May 1987 | GB |
2148126 | Jul 1987 | GB |
2191095 | Dec 1987 | GB |
2199750 | Jul 1988 | GB |
2260907 | May 1993 | GB |
2462267 | Feb 2010 | GB |
2469496 | Oct 2010 | GB |
2490327 | Oct 2012 | GB |
2507318 | Apr 2014 | GB |
2612752 | May 2023 | GB |
201800009129 | Apr 2020 | IT |
S498638 | Jan 1974 | JP |
S5410596 | Jan 1979 | JP |
S5410596 | May 1979 | JP |
S55155618 | Dec 1980 | JP |
S5888596 | Jun 1983 | JP |
S63107780 | Jul 1988 | JP |
H0267530 | Mar 1990 | JP |
H02103871 | Apr 1990 | JP |
H02131422 | May 1990 | JP |
H02131422 | Nov 1990 | JP |
H0460220 | Feb 1992 | JP |
H04060220 | May 1992 | JP |
H05123349 | May 1993 | JP |
H05123350 | May 1993 | JP |
3087938 | Oct 1995 | JP |
H085630 | Jan 1996 | JP |
H1040141 | Feb 1998 | JP |
H10225430 | Aug 1998 | JP |
H11113946 | Apr 1999 | JP |
H11290365 | Oct 1999 | JP |
2000116690 | Apr 2000 | JP |
2000185068 | Jul 2000 | JP |
2001054531 | Feb 2001 | JP |
2001070331 | Mar 2001 | JP |
2001224616 | Aug 2001 | JP |
2001276107 | Oct 2001 | JP |
2001276108 | Oct 2001 | JP |
2002028173 | Jan 2002 | JP |
2003505152 | Feb 2003 | JP |
2003126242 | May 2003 | JP |
2003180722 | Jul 2003 | JP |
2003528691 | Sep 2003 | JP |
2004057578 | Feb 2004 | JP |
2004130056 | Apr 2004 | JP |
2004267530 | Sep 2004 | JP |
2005052219 | Mar 2005 | JP |
2005066011 | Mar 2005 | JP |
2005066325 | Mar 2005 | JP |
2005102978 | Apr 2005 | JP |
2005518237 | Jun 2005 | JP |
3749097 | Dec 2005 | JP |
2006026108 | Feb 2006 | JP |
3123547 | Jun 2006 | JP |
2006136492 | Jun 2006 | JP |
2006204868 | Aug 2006 | JP |
2007044494 | Feb 2007 | JP |
3132659 | May 2007 | JP |
2007209687 | Aug 2007 | JP |
4039641 | Nov 2007 | JP |
2008005975 | Jan 2008 | JP |
2009509570 | Mar 2009 | JP |
2009165887 | Jul 2009 | JP |
2010504150 | Feb 2010 | JP |
2010081981 | Apr 2010 | JP |
4640772 | Dec 2010 | JP |
2010536439 | Dec 2010 | JP |
2011500225 | Jan 2011 | JP |
2011030962 | Feb 2011 | JP |
4747166 | May 2011 | JP |
2011087823 | May 2011 | JP |
4801218 | Aug 2011 | JP |
2011218130 | Nov 2011 | JP |
2011224070 | Nov 2011 | JP |
3175719 | Apr 2012 | JP |
2012523869 | Oct 2012 | JP |
2013238608 | Nov 2013 | JP |
2014521960 | Aug 2014 | JP |
2015092945 | May 2015 | JP |
3198994 | Jul 2015 | JP |
2016521191 | Jul 2016 | JP |
2017014698 | Jan 2017 | JP |
2019525811 | Sep 2019 | JP |
2019170942 | Oct 2019 | JP |
2019533492 | Nov 2019 | JP |
2021120686 | Aug 2021 | JP |
2021522009 | Aug 2021 | JP |
2021522013 | Aug 2021 | JP |
7129493 | Aug 2022 | JP |
2023532132 | Jul 2023 | JP |
200290061 | Sep 2002 | KR |
20030047451 | Jun 2003 | KR |
20140039485 | Apr 2014 | KR |
101432639 | Aug 2014 | KR |
20180106659 | Oct 2018 | KR |
20180108774 | Oct 2018 | KR |
2068717 | Jun 2013 | PT |
505542 | Sep 1997 | SE |
8101957 | Jul 1981 | WO |
8804558 | Jun 1988 | WO |
9104714 | Apr 1991 | WO |
9104714 | Jun 1991 | WO |
9220299 | Feb 1993 | WO |
9307839 | Apr 1993 | WO |
9309736 | May 1993 | WO |
9309736 | Jun 1993 | WO |
9514448 | Jun 1995 | WO |
9600096 | Jan 1996 | WO |
9634636 | Nov 1996 | WO |
9817211 | Apr 1998 | WO |
9830336 | Jul 1998 | WO |
0000112 | Jan 2000 | WO |
0000113 | Jan 2000 | WO |
0025651 | May 2000 | WO |
0033773 | Jun 2000 | WO |
0057784 | Oct 2000 | WO |
0069377 | Nov 2000 | WO |
0079497 | Dec 2000 | WO |
0145618 | Jun 2001 | WO |
0145621 | Jun 2001 | WO |
02094160 | Nov 2002 | WO |
03013967 | Feb 2003 | WO |
03024824 | Mar 2003 | WO |
03055423 | Jul 2003 | WO |
03071931 | Sep 2003 | WO |
03079942 | Oct 2003 | WO |
03071931 | Feb 2004 | WO |
2004019836 | Mar 2004 | WO |
2004024046 | Mar 2004 | WO |
2004026195 | Apr 2004 | WO |
2005051252 | Jun 2005 | WO |
2005074571 | Sep 2005 | WO |
2005089687 | Sep 2005 | WO |
2005107661 | Nov 2005 | WO |
2006021220 | Mar 2006 | WO |
2006037140 | Apr 2006 | WO |
2007005851 | Jan 2007 | WO |
2007007845 | Jan 2007 | WO |
2007042823 | Apr 2007 | WO |
2007055651 | May 2007 | WO |
2006098950 | Nov 2007 | WO |
2007134608 | Nov 2007 | WO |
2007128156 | Feb 2008 | WO |
2008026106 | Mar 2008 | WO |
2008078117 | Jul 2008 | WO |
2008104019 | Sep 2008 | WO |
2008141471 | Nov 2008 | WO |
2009004368 | Jan 2009 | WO |
2009004369 | Jan 2009 | WO |
2009052496 | Apr 2009 | WO |
2009052502 | Apr 2009 | WO |
2009007702 | Jul 2009 | WO |
2009101738 | Aug 2009 | WO |
2010058192 | May 2010 | WO |
2010030122 | Jul 2010 | WO |
2010101915 | Jan 2011 | WO |
2011018132 | Feb 2011 | WO |
2011018133 | Feb 2011 | WO |
2011024864 | Mar 2011 | WO |
2011054118 | May 2011 | WO |
2011079132 | Jun 2011 | WO |
2011107972 | Sep 2011 | WO |
2011108972 | Sep 2011 | WO |
2011117292 | Sep 2011 | WO |
2011123219 | Oct 2011 | WO |
2011132043 | Oct 2011 | WO |
2012012908 | Feb 2012 | WO |
2012065274 | May 2012 | WO |
2012097462 | Jul 2012 | WO |
2012098796 | Jul 2012 | WO |
2012101288 | Aug 2012 | WO |
2012175916 | Dec 2012 | WO |
2013018435 | Feb 2013 | WO |
2013033429 | Mar 2013 | WO |
2013055434 | Apr 2013 | WO |
2013082397 | Jun 2013 | WO |
2013103291 | Jul 2013 | WO |
2013131109 | Sep 2013 | WO |
2013167478 | Nov 2013 | WO |
2013177716 | Dec 2013 | WO |
2014041534 | Mar 2014 | WO |
2014046420 | Mar 2014 | WO |
2014118518 | Aug 2014 | WO |
2014160852 | Oct 2014 | WO |
2015023599 | Feb 2015 | WO |
2015052348 | Apr 2015 | WO |
2015068384 | May 2015 | WO |
2015169403 | Nov 2015 | WO |
2015170307 | Nov 2015 | WO |
2015197462 | Dec 2015 | WO |
2016051385 | Apr 2016 | WO |
2016055989 | Apr 2016 | WO |
2016071894 | May 2016 | WO |
2016103242 | Jun 2016 | WO |
2016116915 | Jul 2016 | WO |
2016124203 | Aug 2016 | WO |
2016139448 | Sep 2016 | WO |
2016166562 | Oct 2016 | WO |
2016167535 | Oct 2016 | WO |
2016191574 | Dec 2016 | WO |
2016200088 | Dec 2016 | WO |
2016200361 | Dec 2016 | WO |
2016204731 | Dec 2016 | WO |
2017001532 | Jan 2017 | WO |
2017001846 | Jan 2017 | WO |
2017075226 | May 2017 | WO |
2017152198 | Sep 2017 | WO |
2017153357 | Sep 2017 | WO |
2017162559 | Sep 2017 | WO |
2017205446 | Nov 2017 | WO |
2017209779 | Dec 2017 | WO |
2017210524 | Dec 2017 | WO |
2018022414 | Feb 2018 | WO |
2018044781 | Mar 2018 | WO |
2018056953 | Mar 2018 | WO |
2018090550 | May 2018 | WO |
2018138513 | Aug 2018 | WO |
2018144318 | Aug 2018 | WO |
2018144463 | Aug 2018 | WO |
2018150263 | Aug 2018 | WO |
2018150268 | Aug 2018 | WO |
2018152156 | Aug 2018 | WO |
2018183791 | Oct 2018 | WO |
2018150267 | Nov 2018 | WO |
2018235026 | Dec 2018 | WO |
2018235065 | Dec 2018 | WO |
2019004404 | Jan 2019 | WO |
2019041005 | Mar 2019 | WO |
2019044217 | Mar 2019 | WO |
2019044218 | Mar 2019 | WO |
2019044219 | Mar 2019 | WO |
2019050959 | Mar 2019 | WO |
2019065541 | Apr 2019 | WO |
2019096845 | May 2019 | WO |
2019150385 | Aug 2019 | WO |
2019161094 | Aug 2019 | WO |
2019188566 | Oct 2019 | WO |
2019190593 | Oct 2019 | WO |
2019212949 | Nov 2019 | WO |
2019212950 | Nov 2019 | WO |
2019212951 | Nov 2019 | WO |
2019212952 | Nov 2019 | WO |
2019212954 | Nov 2019 | WO |
2019212955 | Nov 2019 | WO |
2019212956 | Nov 2019 | WO |
2019214787 | Nov 2019 | WO |
2019214788 | Nov 2019 | WO |
2019226826 | Nov 2019 | WO |
2019239433 | Dec 2019 | WO |
2020000994 | Jan 2020 | WO |
2020020618 | Jan 2020 | WO |
2020038822 | Feb 2020 | WO |
2020088409 | May 2020 | WO |
2020049394 | Jun 2020 | WO |
2020120657 | Jun 2020 | WO |
2020152575 | Jul 2020 | WO |
2020182923 | Sep 2020 | WO |
2020204967 | Oct 2020 | WO |
2020205939 | Oct 2020 | WO |
2020209898 | Oct 2020 | WO |
2020242790 | Dec 2020 | WO |
2020251893 | Dec 2020 | WO |
2020256865 | Dec 2020 | WO |
2021007144 | Jan 2021 | WO |
2021007345 | Jan 2021 | WO |
2021010844 | Jan 2021 | WO |
2021016026 | Jan 2021 | WO |
2021016300 | Jan 2021 | WO |
2021025919 | Feb 2021 | WO |
2021034886 | Feb 2021 | WO |
2021041123 | Mar 2021 | WO |
2021046501 | Mar 2021 | WO |
2021086868 | May 2021 | WO |
2021094352 | May 2021 | WO |
2021094639 | May 2021 | WO |
2021097067 | May 2021 | WO |
2021102296 | May 2021 | WO |
2021107025 | Jun 2021 | WO |
2021138411 | Jul 2021 | WO |
2021138414 | Jul 2021 | WO |
2021154686 | Aug 2021 | WO |
2021155206 | Aug 2021 | WO |
2021170075 | Sep 2021 | WO |
2021173436 | Sep 2021 | WO |
2021188817 | Sep 2021 | WO |
2021195384 | Sep 2021 | WO |
2021205995 | Oct 2021 | WO |
2021207621 | Oct 2021 | WO |
2021211568 | Oct 2021 | WO |
2021211801 | Oct 2021 | WO |
2021211914 | Oct 2021 | WO |
2021216419 | Oct 2021 | WO |
2021216422 | Oct 2021 | WO |
2021231532 | Nov 2021 | WO |
2021247523 | Dec 2021 | WO |
2021257202 | Dec 2021 | WO |
2022006256 | Jan 2022 | WO |
2022031943 | Feb 2022 | WO |
2022035745 | Feb 2022 | WO |
2022051360 | Mar 2022 | WO |
2022054613 | Mar 2022 | WO |
2022066704 | Mar 2022 | WO |
2022067392 | Apr 2022 | WO |
2022069950 | Apr 2022 | WO |
2022071429 | Apr 2022 | WO |
2022076322 | Apr 2022 | WO |
2022076427 | Apr 2022 | WO |
2022086898 | Apr 2022 | WO |
2022090199 | May 2022 | WO |
2022098536 | May 2022 | WO |
2022099087 | May 2022 | WO |
2022101999 | May 2022 | WO |
2022115692 | Jun 2022 | WO |
2022125685 | Jun 2022 | WO |
2022140545 | Jun 2022 | WO |
2022145231 | Jul 2022 | WO |
2022150360 | Jul 2022 | WO |
2022150463 | Jul 2022 | WO |
2022159392 | Jul 2022 | WO |
2022170182 | Aug 2022 | WO |
2022182385 | Sep 2022 | WO |
2022187152 | Sep 2022 | WO |
2022192188 | Sep 2022 | WO |
2022192347 | Sep 2022 | WO |
2022204000 | Sep 2022 | WO |
2022216507 | Oct 2022 | WO |
2022222030 | Oct 2022 | WO |
2023286058 | Jan 2023 | WO |
2023014639 | Feb 2023 | WO |
2023014641 | Feb 2023 | WO |
2023018475 | Feb 2023 | WO |
2023023777 | Mar 2023 | WO |
2023034453 | Mar 2023 | WO |
2023038945 | Mar 2023 | WO |
2023038950 | Mar 2023 | WO |
2023049109 | Mar 2023 | WO |
2023049175 | Mar 2023 | WO |
2023086394 | May 2023 | WO |
2023149884 | Aug 2023 | WO |
2023149902 | Aug 2023 | WO |
2023149903 | Aug 2023 | WO |
2023154390 | Aug 2023 | WO |
2023191764 | Oct 2023 | WO |
2023244238 | Dec 2023 | WO |
2024058788 | Mar 2024 | WO |
Entry |
---|
US 9,908,683 B2, 03/2018, Sandhausen et al. (withdrawn) |
International Search Report and Written Opinion from International Application No. PCT/US2022/015781 mailed May 6, 2022. |
International Search Report and Written Opinion from International Application No. PCT/US2022/016942 mailed Jun. 8, 2022. |
International Search Report and Written Opinion from International Application No. PCT/US2022/018159 mailed Dec. 12, 2022. |
International Search Report and Written Opinion from International Application No. PCT/US2022/018170 mailed May 31, 2022. |
International Search Report and Written Opinion from International Application No. PCT/US2022/019254 mailed Jun. 7, 2022. |
International Search Report and Written Opinion from International Application No. PCT/US2022/019480 mailed Jun. 13, 2022. |
Non-Final Office Action for U.S. Appl. No. 17/501,591 mailed Apr. 25, 2023. |
Non-Final Office Action for U.S. Appl. No. 17/653,137 mailed Apr. 7, 2023. |
Non-Final Office Action for U.S. Appl. No. 17/655,464 mailed Mar. 14, 2023. |
Non-Final Office Action for U.S. Appl. No. 17/662,700 mailed Jul. 22, 2022. |
Non-Final Office Action for U.S. Appl. No. 29/741,751 mailed Jan. 18, 2022. |
Notice of Allowance for U.S. Appl. No. 16/449,039 mailed Dec. 15, 2022. |
Notice of Allowance for U.S. Appl. No. 16/899,956 mailed Apr. 19, 2022. |
Notice of Allowance for U.S. Appl. No. 16/899,956 mailed Aug. 10, 2022. |
Advisory Action for U.S. Appl. No. 16/245,726 mailed Apr. 19, 2023. |
Advisory Action for U.S. Appl. No. 16/369,676 mailed Mar. 24, 2023. |
Advisory Action for U.S. Appl. No. 16/433,773 mailed Feb. 15, 2023. |
Advisory Action for U.S. Appl. No. 16/452,258 mailed Oct. 26, 2022. |
Advisory Action for U.S. Appl. No. 16/478,180 mailed Sep. 21, 2022. |
Advisory Action for U.S. Appl. No. 16/904,868 mailed Jun. 15, 2022. |
Advisory Action for U.S. Appl. No. 16/905,400 mailed Feb. 16, 2022. |
Advisory Action for U.S. Appl. No. 17/662,700 mailed Jan. 30, 2023. |
Final Office Action for U.S. Appl. No. 16/245,726 mailed Nov. 25, 2022. |
Final Office Action for U.S. Appl. No. 16/369,676 mailed Dec. 5, 2022. |
Final Office Action for U.S. Appl. No. 16/433,773 mailed Oct. 25, 2022. |
Final Office Action for U.S. Appl. No. 16/449,039 mailed Aug. 1, 2022. |
Final Office Action for U.S. Appl. No. 16/452,145 mailed Mar. 25, 2022. |
Final Office Action for U.S. Appl. No. 16/452,258 mailed Jun. 14, 2022. |
Final Office Action for U.S. Appl. No. 16/478,180 mailed Jun. 22, 2022. |
Final Office Action for U.S. Appl. No. 16/478,180 mailed May 31, 2023. |
Final Office Action for U.S. Appl. No. 16/904,868 mailed Mar. 10, 2022. |
Final Office Action for U.S. Appl. No. 17/051,399 mailed Mar. 9, 2023. |
Final Office Action for U.S. Appl. No. 17/051,550 mailed May 23, 2023. |
Final Office Action for U.S. Appl. No. 17/451,345 mailed May 3, 2023. |
Final Office Action for U.S. Appl. No. 17/662,700 mailed Sep. 30, 2022. |
International Search Report and Written Opinion from International Application No. PCT/IB2021/057173 mailed Nov. 5, 2021. |
International Search Report and Written Opinion from International Application No. PCT/US2020/057562 mailed Jan. 27, 2021. |
International Search Report and Written Opinion from International Application No. PCT/US2021/026607 mailed Jul. 29, 2021. |
International Search Report and Written Opinion from International Application No. PCT/US2021/039866 mailed Oct. 7, 2021. |
International Search Report and Written Opinion from International Application No. PCT/US2021/045188 mailed Jan. 26, 2022. |
International Search Report and Written Opinion from International Application No. PCT/US2021/047536 mailed Dec. 23, 2021. |
International Search Report and Written Opinion from International Application No. PCT/US2021/048211 mailed Dec. 22, 2021. |
International Search Report and Written Opinion from International Application No. PCT/US2021/048661 mailed Feb. 14, 2022. |
International Search Report and Written Opinion from International Application No. PCT/US2021/049404 mailed Jan. 18, 2022. |
International Search Report and Written Opinion from International Application No. PCT/US2021/051456 mailed Jan. 19, 2022. |
International Search Report and Written Opinion from International Application No. PCT/US2021/053593 mailed Apr. 11, 2022. |
International Search Report and Written Opinion from International Application No. PCT/US2021/055515 mailed Jan. 28, 2022. |
International Search Report and Written Opinion from International Application No. PCT/US2021/056566 mailed Feb. 11, 2022. |
International Search Report and Written Opinion from International Application No. PCT/US2021/060993 mailed Mar. 18, 2022. |
International Search Report and Written Opinion from International Application No. PCT/US2021/062440 mailed Mar. 28, 2022. |
International Search Report and Written Opinion from International Application No. PCT/US2022/011108 mailed Apr. 22, 2022. |
International Search Report and Written Opinion from International Application No. PCT/US2022/011281 mailed Apr. 25, 2022. |
International Search Report and Written Opinion from International Application No. PCT/US2022/011419 mailed Jun. 7, 2022. |
International Search Report and Written Opinion from International Application No. PCT/US2022/011421 mailed Jun. 13, 2022. |
International Search Report and Written Opinion from International Application No. PCT/US2022/012794 mailed May 3, 2022. |
International Search Report and Written Opinion from International Application No. PCT/US2022/014285 mailed Sep. 28, 2022. |
International Search Report and Written Opinion from International Application No. PCT/US2022/014749 mailed Sep. 28, 2022. |
International Search Report and Written Opinion from International Application No. PCT/US2022/015026 mailed Oct. 31, 2022. |
International Search Report and Written Opinion from International Application No. PCT/US2022/015045 mailed Sep. 9, 2022. |
International Search Report and Written Opinion from International Application No. PCT/US2022/015073 mailed Sep. 8, 2022. |
International Search Report and Written Opinion from International Application No. PCT/US2022/015418 mailed Nov. 11, 2022. |
International Search Report and Written Opinion from International Application No. PCT/US2022/015420 mailed Nov. 18, 2022. |
International Search Report and Written Opinion from International Application No. PCT/US2022/015471 mailed May 16, 2022. |
International Search Report and Written Opinion from International Application No. PCT/US2022/015492 mailed Apr. 26, 2022. |
International Search Report and Written Opinion from International Application No. PCT/US2022/021103 mailed Jun. 23, 2022. |
International Search Report and Written Opinion from International Application No. PCT/US2022/022111 mailed Oct. 26, 2022. |
International Search Report and Written Opinion from International Application No. PCT/US2022/023594 mailed Jul. 12, 2022. |
International Search Report and Written Opinion from International Application No. PCT/US2022/026667 mailed Aug. 22, 2022. |
International Search Report and Written Opinion from International Application No. PCT/US2022/030685 mailed Oct. 31, 2022. |
International Search Report and Written Opinion from International Application No. PCT/US2022/031032 mailed Sep. 9, 2022. |
International Search Report and Written Opinion from International Application No. PCT/US2022/032424 mailed Oct. 11, 2022. |
International Search Report and Written Opinion from International Application No. PCT/US2022/034457 mailed Oct. 12, 2022. |
International Search Report and Written Opinion from International Application No. PCT/US2022/034744 mailed Dec. 9, 2022. |
International Search Report and Written Opinion from International Application No. PCT/US2022/039018 mailed Jan. 10, 2023. |
International Search Report and Written Opinion from International Application No. PCT/US2022/039022 mailed Jan. 10, 2023. |
International Search Report and Written Opinion from International Application No. PCT/US2022/039711 mailed Jan. 12, 2023. |
International Search Report and Written Opinion from International Application No. PCT/US2022/039714 mailed Nov. 22, 2022. |
International Search Report and Written Opinion from International Application No. PCT/US2022/041085 mailed Mar. 16, 2023. |
International Search Report and Written Opinion from International Application No. PCT/US2022/041688 mailed Nov. 21, 2022. |
International Search Report and Written Opinion from International Application No. PCT/US2022/042719 mailed Dec. 5, 2022. |
International Search Report and Written Opinion from International Application No. PCT/US2022/042725 mailed Dec. 19, 2022. |
International Search Report and Written Opinion from International Application No. PCT/US2022/044107 mailed Dec. 23, 2022. |
International Search Report and Written Opinion from International Application No. PCT/US2022/044212 mailed Jan. 20, 2023. |
International Search Report and Written Opinion from International Application No. PCT/US2022/044243 mailed Feb. 24, 2023. |
Issue Notification for U.S. Appl. No. 16/899,956 mailed Mar. 29, 2023. |
Issue Notification for U.S. Appl. No. 16/905,400 mailed Nov. 30, 2022. |
Issue Notification for U.S. Appl. No. 17/088,272 mailed Jun. 15, 2022. |
Issue Notification for U.S. Appl. No. 17/330,657 mailed Jun. 22, 2022. |
Non-Final Office Action for U.S. Appl. No. 16/245,726 mailed Jan. 21, 2022. |
Non-Final Office Action for U.S. Appl. No. 16/369,676 mailed Mar. 31, 2022. |
Non-Final Office Action for U.S. Appl. No. 16/433,773 mailed Apr. 11, 2023. |
Non-Final Office Action for U.S. Appl. No. 16/433,773 mailed Apr. 21, 2022. |
Non-Final Office Action for U.S. Appl. No. 16/449,039 mailed Apr. 27, 2023. |
Non-Final Office Action for U.S. Appl. No. 16/452,145 mailed Mar. 28, 2023. |
Non-Final Office Action for U.S. Appl. No. 16/452,258 mailed Apr. 26, 2023. |
Non-Final Office Action for U.S. Appl. No. 16/478,180 mailed Dec. 20, 2022. |
Non-Final Office Action for U.S. Appl. No. 16/904,868 mailed Mar. 15, 2023. |
Non-Final Office Action for U.S. Appl. No. 16/905,400 mailed Apr. 27, 2022. |
Non-Final Office Action for U.S. Appl. No. 17/051,550 mailed Dec. 15, 2022. |
Non-Final Office Action for U.S. Appl. No. 17/051,585 mailed Mar. 29, 2023. |
Non-Final Office Action for U.S. Appl. No. 17/179,116 mailed Mar. 24, 2023. |
Non-Final Office Action for U.S. Appl. No. 17/444,792 mailed Feb. 10, 2023. |
Non-Final Office Action for U.S. Appl. No. 17/446,256 mailed Apr. 13, 2023. |
Non-Final Office Action for U.S. Appl. No. 17/448,811 mailed Mar. 1, 2023. |
Non-Final Office Action for U.S. Appl. No. 17/450,864 mailed May 10, 2023. |
Non-Final Office Action for U.S. Appl. No. 17/451,345 mailed Dec. 7, 2022. |
Non-Final Office Action for U.S. Appl. No. 17/451,354 mailed May 3, 2023. |
Non-Final Office Action for U.S. Appl. No. 17/453,260 mailed Mar. 14, 2023. |
Notice of Allowance for U.S. Appl. No. 16/899,956 mailed Dec. 1, 2022. |
Notice of Allowance for U.S. Appl. No. 16/899,956 mailed Dec. 29, 2021. |
Notice of Allowance for U.S. Appl. No. 16/905,400 mailed Aug. 17, 2022. |
Notice of Allowance for U.S. Appl. No. 17/088,272 mailed Mar. 4, 2022. |
Notice of Allowance for U.S. Appl. No. 17/330,657 mailed Mar. 16, 2022. |
Notice of Allowance for U.S. Appl. No. 17/461,036 mailed Feb. 22, 2023. |
Notice of Allowance for U.S. Appl. No. 17/461,036 mailed Oct. 6, 2022. |
Notice of Allowance for U.S. Appl. No. 17/662,700 mailed Mar. 28, 2023. |
Notice of Allowance for U.S. Appl. No. 17/663,046 mailed Jan. 30, 2023. |
Notice of Allowance for U.S. Appl. No. 29/741,751 mailed Jun. 9, 2022. |
Restriction Requirement for U.S. Appl. No. 17/326,980 mailed Mar. 20, 2023. |
Restriction Requirement for U.S. Appl. No. 17/446,256 mailed Jan. 23, 2023. |
Restriction Requirement for U.S. Appl. No. 17/646,771 mailed Apr. 6, 2023. |
Text Messages to Lorena Eckert Re Prototype PureWick Holder dated Apr. 16, 2022. |
U.S. Application No. 15/384, 196 filed Dec. 19, 2016. |
U.S. Appl. No. 17/394,055, filed Aug. 4, 2021. |
U.S. Appl. No. 17/597,408, filed Jan. 5, 2022. |
U.S. Appl. No. 17/597,673, filed Jan. 18, 2022. |
U.S. Appl. No. 17/631,619, filed Jan. 31, 2022. |
U.S. Appl. No. 17/653,314, filed Mar. 3, 2022. |
U.S. Appl. No. 17/653,920, filed Mar. 8, 2022. |
U.S. Appl. No. 17/655,464, filed Mar. 18, 2022. |
U.S. Appl. No. 17/657,474, filed Mar. 31, 2022. |
U.S. Appl. No. 17/661,090, filed Apr. 28, 2022. |
U.S. Appl. No. 17/662,700, filed May 10, 2022. |
U.S. Appl. No. 17/663,046, filed May 12, 2022. |
U.S. Appl. No. 17/664,914, filed May 25, 2022. |
U.S. Appl. No. 17/749,340, filed May 20, 2022. |
U.S. Appl. No. 17/754,736, filed Apr. 11, 2022. |
U.S. Appl. No. 17/756,201, filed May 19, 2022. |
U.S. Appl. No. 17/758,152 filed Jun. 29, 2022. |
U.S. Appl. No. 17/758,316, filed Jul. 1, 2022. |
U.S. Appl. No. 17/759,697, filed Jul. 28, 2022. |
U.S. Appl. No. 17/878,268, filed Aug. 1, 2022. |
U.S. Appl. No. 17/907,125, filed Sep. 23, 2022. |
U.S. Appl. No. 17/912,147, filed Sep. 16, 2022. |
U.S. Appl. No. 17/929,887, filed Sep. 6, 2022. |
U.S. Appl. No. 17/930,238, filed Sep. 7, 2022. |
U.S. Appl. No. 17/933,590, filed Sep. 20, 2022. |
U.S. Appl. No. 17/996,064, filed Oct. 12, 2022. |
U.S. Appl. No. 17/996,155, filed Oct. 13, 2022. |
U.S. Appl. No. 17/996,253, filed Oct. 14, 2022. |
U.S. Appl. No. 17/996,468, filed Oct. 18, 2022. |
U.S. Appl. No. 17/996,556, filed Oct. 19, 2022. |
U.S. Appl. No. 18/003,029, filed Dec. 22, 2022. |
U.S. Appl. No. 18/006,807, filed Jan. 25, 2023. |
U.S. Appl. No. 18/007,105, filed Jan. 27, 2023. |
U.S. Appl. No. 18/041,109, filed Feb. 9, 2023. |
U.S. Appl. No. 18/042,842, filed Feb. 24, 2023. |
U.S. Appl. No. 18/043,618, filed Mar. 1, 2023. |
U.S. Appl. No. 18/115,444, filed Feb. 28, 2023. |
U.S. Appl. No. 18/134,857, filed Apr. 14, 2023. |
U.S. Appl. No. 18/140,163 filed Apr. 27, 2023. |
U.S. Appl. No. 18/140,751, filed Apr. 28, 2023. |
U.S. Appl. No. 18/164,800, filed Feb. 6, 2023. |
U.S. Appl. No. 18/198,464, filed May 17, 2023. |
U.S. Appl. No. 18/246,121 filed Mar. 21, 2023. |
U.S. Appl. No. 18/247,986, filed Apr. 5, 2023. |
U.S. Appl. No. 18/299,788, filed Apr. 13, 2023. |
U.S. Appl. No. 62/923,279, filed Oct. 18, 2019. |
U.S. Appl. No. 62/926,767, filed Oct. 28, 2019. |
U.S. Appl. No. 62/935,337, filed Nov. 14, 2019. |
U.S. Appl. No. 62/967,158, filed Jan. 26, 2020. |
U.S. Appl. No. 62/967,977, filed Jan. 30, 2020. |
U.S. Appl. No. 62/991,754, filed Mar. 19, 2020. |
U.S. Appl. No. 63/008,112, filed Apr. 10, 2020. |
U.S. Appl. No. 63/094,646, filed Oct. 21, 2020. |
U.S. Appl. No. 63/138,878, filed Jan. 19, 2021. |
U.S. Appl. No. 63/191,558, filed May 21, 2021. |
U.S. Appl. No. 63/192,289, filed May 24, 2021. |
U.S. Appl. No. 63/208,262, filed Jun. 8, 2021. |
U.S. Appl. No. 63/230,897, filed Aug. 9, 2021. |
U.S. Appl. No. 63/241,328, filed Sep. 7, 2021. |
U.S. Appl. No. 63/299,208, filed Jan. 13, 2022. |
U.S. Appl. No. 63/308,190, filed Feb. 9, 2022. |
PureWick Corporation v. Sage Products, LLC Transcripts vol. 5, Apr. 1, 2022, 72 pages. |
PureWick Corporation v. Sage Products, LLC Transcripts vol. 1, Mar. 28, 2022, 99 pages. |
PureWick Corporation v. Sage Products, LLC Transcripts vol. 2, Mar. 29, 2022, 106 pages. |
PureWick Corporation v. Sage Products, LLC Transcripts vol. 3, Mar. 30, 2022, 115 pages. |
PureWick Corporation v. Sage Products, LLC Transcripts vol. 4, Mar. 31, 2022, 117 pages. |
“AMXD Control Starter Kit”, Omni Medical Systems, Inc., 1 page. |
“AMXDmax Advanced Mission Extender Device User & Maintenance Guide”, Omni Medical, Jan. 11, 2010, 10 pages. |
“AMXDmax Development History 2002-2014”, Omni Medical Systems, Inc., 2 pages. |
“Combat Force Multiplier in Flight Bladder Relief Cockpit Essential Equipment Brochure”, Omni Medical, 20 pages. |
“GSA Price List”, Omni Medical, Apr. 2011, 2 pages. |
“How is Polypropylene Fiber Made”, https:www.yarnsandfibers.com/textile-resources/synthetic-fibers/polypropylene-fiber/polypropylene-fiber-production-raw-materials/how-is-polypropylene-fiber-made/ last accessed 2020, Oct. 7, 2020, 3 pages. |
“Letter to Mark Harvie of Omni Measurement Systems”, Department of Veterans Affairs, Nov. 1, 2007, 11 pages. |
“Revised AMXDmax Advanced Mission Extender Device User & Maintenance Guide”, Omni Medical Systems, Oct. 8, 2019, 52 pages. |
“Rising Warrior Insulated Gallon Jug Cover”, https://www.amazon.com/Rising-Warrior-Insulated-Sleeve, 2021, 2 pages. |
“Urine Bag Cover-Catheter Bag Cover 2000 ml Volume-Medline Style-Multiple Sclerosis-Spine Injury-Suprapublic Catheter-Bladder Incontinence”, https://www.etsy.com/listing/1142934658/urine-bag-cover-caatheter-bag-cover-2000, 2022, 1 page. |
“Vinyl Dust Cover, Janome #741811000, Janome, Sewing Parts Online”, https://www.sewingpartsonline.com/vinyl-dust-cover-janome-74181000, 2020, 2 pages. |
Ali , “Sustainability Assessment: Seventh Generation Diapers versus gDiapers”, The University of Vermont, Dec. 6, 2011, pp. 1-31. |
Autumn , et al., “Frictional adhesion: a new angle on gecko attachment”, The Journal of Experimental Biology, 2006, pp. 3569-3579. |
Cañas , et al., “Effect of nano- and micro-roughness on adhesion of bioinspired micropatterned surfaces”, Acta Biomaterialia 8, 2012, pp. 282-288. |
Chaudhary , et al., “Bioinspired dry adhesive: Poly(dimethylsiloxane) grafted with poly(2-ethylhexyl acrylate) brushes”, European Polymer Journal, 2015, pp. 432-440. |
Dai , et al., “Non-sticky and Non-slippery Biomimetic Patterned Surfaces”, Journal of Bionic Engineering, Mar. 2020, pp. 326-334. |
Espinoza-Ramirez , “Nanobiodiversity and Biomimetic Adhesives Development: From Nature to Production and Application”, Journal of Biomaterials and Nanobiotechnology, pp. 78-101, 2019. |
Hwang , et al., “Multifunctional Smart Skin Adhesive Patches for Advanced Health Care”, Adv. Healthcare Mater, 2018, pp. 1-20. |
Jagota , et al., “Adhesion, friction, and compliance of bio-mimetic and bio-inspired structured interfaces”, Materials Science and Engineering, 2011, pp. 253-292. |
Jeong , et al., “A nontransferring dry adhesive with hierarchical polymer nanohairs”, PNAS, Apr. 7, 2009, pp. 5639-5644. |
Jeong , et al., “Nanohairs and nanotubes: Efficient structural elements for gecko-inspired artificial dry adhesives”, Science Direct, 2009, pp. 335-346. |
Karp , et al., “Dry solution to a sticky problem”, Nature., 2011, pp. 42-43. |
Lee , et al., “Continuous Fabrication of Wide-Tip Microstructures for Bio-Inspired Dry Adhesives via Tip Inking Process”, Journal of Chemistry, Jan. 2, 2019, pp. 1-5. |
Parness , et al., “A microfabricated wedge-shaped adhesive array displaying gecko-like dynamic adhesion, directionality”, J.R. Soc. Interface, 2009, pp. 1223-1232. |
Pieper , et al., “An external urine-collection device for women: A clinical trial”, Journal of ER Nursing, vol. 20, No. 2, Mar./Apr. 1993, pp. 51-55. |
Tsipenyuk , et al., “Use of biomimetic hexagonal surface texture in friction against lubricated skin”, Journal of The Royal Society—Interface, 2014, pp. 1-6. |
Vinas , “A Solution For An Awkward—But Serious—Subject”, http://www.aero-news.net/index.cfm?do=main.textpost&id=69ae2bb1-838b-4098-a7b5-7flbb2505688 last accessed Feb. 8, 2021, 3 pages. |
Advisory Action for U.S. Appl. No. 14/722,613 mailed Mar. 4, 2019. |
Advisory Action for U.S. Appl. No. 14/952,591 mailed Jun. 1, 2018. |
Advisory Action for U.S. Appl. No. 15/238,427 mailed Apr. 10, 2019. |
Advisory Action for U.S. Appl. No. 16/899,956 mailed Jul. 9, 2021. |
Advisory Action for U.S. Appl. No. 16/904,868 mailed Jul. 2, 2021. |
Advisory Action for U.S. Appl. No. 16/905,400 mailed Jun. 9, 2021. |
Corrected International Search Report and Written Opinion for International Application No. PCT/US2017/043025 mailed Jan. 11, 2018. |
Corrected Notice of Allowability for U.S. Appl. No. 15/221,106 mailed Jul. 2, 2019. |
Corrected Notice of Allowability for U.S. Appl. No. 15/612,325 mailed Mar. 17, 2021. |
Corrected Notice of Allowability for U.S. Appl. No. 17/330,657 mailed Dec. 9, 2021. |
Final Office Action for U.S. Appl. No. 14/722,613 mailed on Nov. 29, 2018. |
Final Office Action for U.S. Appl. No. 14/947,759 mailed Apr. 8, 2016. |
Final Office Action for U.S. Appl. No. 14/952,591 mailed Feb. 23, 2018. |
Final Office Action for U.S. Appl. No. 14/952,591 mailed Nov. 1, 2019. |
Final Office Action for U.S. Appl. No. 14/952,591 mailed Nov. 27, 2020. |
Final Office Action for U.S. Appl. No. 15/171,968 mailed Feb. 14, 2020. |
Final Office Action for U.S. Appl. No. 15/171,968 mailed Mar. 19, 2019. |
Final Office Action for U.S. Appl. No. 15/221,106 mailed Jan. 23, 2019. |
Final Office Action for U.S. Appl. No. 15/238,427 mailed Jan. 2, 2019. |
Final Office Action for U.S. Appl. No. 15/260,103 mailed Feb. 14, 2019. |
Final Office Action for U.S. Appl. No. 15/612,325 mailed Sep. 17, 2020. |
Final Office Action for U.S. Appl. No. 16/899,956 mailed Apr. 19, 2021. |
Final Office Action for U.S. Appl. No. 16/904,868 mailed Mar. 26, 2021. |
Final Office Action for U.S. Appl. No. 16/905,400 mailed Apr. 6, 2021. |
Final Office Action for U.S. Appl. No. 16/905,400 mailed Dec. 9, 2021. |
Final Office Action for U.S. Appl. No. 17/088,272 mailed May 25, 2021. |
Final Office Action for U.S. Appl. No. 29/624,661 mailed Feb. 18, 2020. |
International Search Report and Written Opinion from International Application No. PCT/US2016/049274 mailed Dec. 1, 2016. |
International Search Report and Written Opinion from International Application No. PCT/US2017/035625 mailed Aug. 15, 2017. |
International Search Report and Written Opinion from International Application No. PCT/US2017/043025 mailed Oct. 18, 2017. |
International Search Report and Written Opinion from International Application No. PCT/US2018/015968 mailed Apr. 6, 2018. |
International Search Report and Written Opinion from International Application No. PCT/US2019/029608 mailed Sep. 3, 2019. |
International Search Report and Written Opinion from International Application No. PCT/US2019/029609 mailed Sep. 3, 2019. |
International Search Report and Written Opinion from International Application No. PCT/US2019/029610 mailed Sep. 3, 2019. |
International Search Report and Written Opinion from International Application No. PCT/US2019/029611 mailed Jul. 3, 2019. |
International Search Report and Written Opinion from International Application No. PCT/US2019/029613 mailed Jul. 3, 2019. |
International Search Report and Written Opinion from International Application No. PCT/US2019/029614 mailed Sep. 26, 2019. |
International Search Report and Written Opinion from International Application No. PCT/US2019/029616 mailed Aug. 30, 2019. |
International Search Report and Written Opinion from International Application No. PCT/US2020/023572 mailed Jul. 6, 2020. |
International Search Report and Written Opinion from International Application No. PCT/US2020/033064 mailed Aug. 31, 2020. |
International Search Report and Written Opinion from International Application No. PCT/US2020/033122 mailed Aug. 31, 2020. |
International Search Report and Written Opinion from International Application No. PCT/US2020/040860 mailed Oct. 2, 2020. |
International Search Report and Written Opinion from International Application No. PCT/US2020/041242 mailed Nov. 17, 2020. |
International Search Report and Written Opinion from International Application No. PCT/US2020/041249 mailed Oct. 2, 2020. |
International Search Report and Written Opinion from International Application No. PCT/US2020/042262 mailed Oct. 14, 2020. |
International Search Report and Written Opinion from International Application No. PCT/US2020/043059 mailed Oct. 6, 2020. |
International Search Report and Written Opinion from International Application No. PCT/US2020/044024 mailed Nov. 12, 2020. |
International Search Report and Written Opinion from International Application No. PCT/US2020/046914 mailed Dec. 1, 2020. |
International Search Report and Written Opinion from International Application No. PCT/US2020/055680 mailed Dec. 15, 2020. |
International Search Report and Written Opinion from International Application No. PCT/US2020/061563 mailed Feb. 19, 2021. |
International Search Report and Written Opinion from International Application No. PCT/US2020/065234 mailed Apr. 12, 2021. |
International Search Report and Written Opinion from International Application No. PCT/US2020/067451 mailed Mar. 25, 2021. |
International Search Report and Written Opinion from International Application No. PCT/US2020/067454 mailed Mar. 29, 2021. |
International Search Report and Written Opinion from International Application No. PCT/US2020/067455 mailed Mar. 26, 2021. |
International Search Report and Written Opinion from International Application No. PCT/US2021/015024 mailed May 18, 2021. |
International Search Report and Written Opinion from International Application No. PCT/US2021/015787 mailed May 27, 2021. |
International Search Report and Written Opinion from International Application No. PCT/US2021/023001 mailed Jun. 21, 2021. |
International Search Report and Written Opinion from International Application No. PCT/US2021/024162 mailed Jul. 8, 2021. |
International Search Report and Written Opinion from International Application No. PCT/US2021/027061 mailed Jul. 19, 2021. |
International Search Report and Written Opinion from International Application No. PCT/US2021/027104 mailed Jul. 6, 2021. |
International Search Report and Written Opinion from International Application No. PCT/US2021/027314 mailed Jul. 6, 2021. |
International Search Report and Written Opinion from International Application No. PCT/US2021/027422 mailed Aug. 12, 2021. |
International Search Report and Written Opinion from International Application No. PCT/US2021/027425 mailed Aug. 11, 2021. |
International Search Report and Written Opinion from International Application No. PCT/US2021/027913 mailed Jul. 12, 2021. |
International Search Report and Written Opinion from International Application No. PCT/US2021/027917 mailed Aug. 19, 2021. |
International Search Report and Written Opinion from International Application No. PCT/US2021/035181 mailed Sep. 16, 2021. |
International Search Report and Written Opinion from International Application No. PCT/US2021/043893 mailed Nov. 22, 2021. |
International Search Report and Written Opinion from International Application No. PCT/US2021/044699 mailed Nov. 22, 2021. |
Issue Notification for U.S. Appl. No. 14/952,591 mailed Jul. 28, 2021. |
Issue Notification for U.S. Appl. No. 15/171,968 mailed Mar. 3, 2021. |
Issue Notification for U.S. Appl. No. 15/221,106 mailed Jul. 24, 2019. |
Issue Notification for U.S. Appl. No. 15/238,427 mailed Jul. 24, 2019. |
Issue Notification for U.S. Appl. No. 15/260,103 mailed Aug. 7, 2019. |
Issue Notification for U.S. Appl. No. 15/611,587 mailed Feb. 20, 2019. |
Issue Notification for U.S. Appl. No. 15/612,325 mailed Mar. 24, 2021. |
Issue Notification for U.S. Appl. No. 29/624,661 mailed Aug. 4, 2021. |
Non-Final Office Action for U.S. Appl. No. 14/592,591 mailed Mar. 20, 2020. |
Non-Final Office Action for U.S. Appl. No. 14/722,613 mailed Jun. 13, 2019. |
Non-Final Office Action for U.S. Appl. No. 14/947,759 mailed Mar. 17, 2016. |
Non-Final Office Action for U.S. Appl. No. 14/952,591 mailed Aug. 1, 2017. |
Non-Final Office Action for U.S. Appl. No. 14/952,591 mailed Mar. 20, 2020. |
Non-Final Office Action for U.S. Appl. No. 14/952,591 mailed Mar. 21, 2019. |
Non-Final Office Action for U.S. Appl. No. 14/952,591 mailed Sep. 28, 2018. |
Non-Final Office Action for U.S. Appl. No. 15/171,968 mailed May 11, 2020. |
Non-Final Office Action for U.S. Appl. No. 15/171,968 mailed Aug. 20, 2019. |
Non-Final Office Action for U.S. Appl. No. 15/171,968 mailed Jun. 12, 2018. |
Non-Final Office Action for U.S. Appl. No. 15/221,106 mailed Jun. 5, 2018. |
Non-Final Office Action for U.S. Appl. No. 15/238,427 mailed Aug. 8, 2018. |
Non-Final Office Action for U.S. Appl. No. 15/260,103 mailed Sep. 26, 2018. |
Non-Final Office Action for U.S. Appl. No. 15/611,587 mailed Dec. 29, 2017. |
Non-Final Office Action for U.S. Appl. No. 15/611,587 mailed Jul. 13, 2018. |
Non-Final Office Action for U.S. Appl. No. 15/612,325 mailed Mar. 19, 2020. |
Non-Final Office Action for U.S. Appl. No. 16/449,039 mailed Dec. 8, 2021. |
Non-Final Office Action for U.S. Appl. No. 16/452,145 mailed Sep. 28, 2021. |
Non-Final Office Action for U.S. Appl. No. 16/452,258 mailed Sep. 28, 2021. |
Non-Final Office Action for U.S. Appl. No. 16/478,180 mailed Oct. 22, 2021. |
Non-Final Office Action for U.S. Appl. No. 16/899,956 mailed Oct. 16, 2020. |
Non-Final Office Action for U.S. Appl. No. 16/899,956 mailed Sep. 2, 2021. |
Non-Final Office Action for U.S. Appl. No. 16/904,868 mailed Nov. 25, 2020. |
Non-Final Office Action for U.S. Appl. No. 16/904,868 mailed Oct. 5, 2021. |
Non-Final Office Action for U.S. Appl. No. 16/905,400 mailed Dec. 2, 2020. |
Non-Final Office Action for U.S. Appl. No. 16/905,400 mailed Jul. 22, 2021. |
Non-Final Office Action for U.S. Appl. No. 17/088,272 mailed Jan. 25, 2021. |
Non-Final Office Action for U.S. Appl. No. 17/330,657 mailed Aug. 11, 2021. |
Non-Final Office Action for U.S. Appl. No. 29/624,661 mailed Jul. 18, 2019. |
Non-Final Office Action for U.S. Appl. No. 29/694,002 mailed Jun. 24, 2020. |
Notice of Allowance for U.S. Appl. No. 14/952,591 mailed Apr. 5, 2021. |
Notice of Allowance for U.S. Appl. No. 14/952,591 mailed Jul. 8, 2021. |
Notice of Allowance for U.S. Appl. No. 15/171,968 mailed Feb. 16, 2021. |
Notice of Allowance for U.S. Appl. No. 15/171,968 mailed Nov. 6, 2020. |
Notice of Allowance for U.S. Appl. No. 15/221,106 mailed May 1, 2019. |
Notice of Allowance for U.S. Appl. No. 15/238,427 mailed May 23, 2019. |
Notice of Allowance for U.S. Appl. No. 15/260,103 mailed Jun. 7, 2019. |
Notice of Allowance for U.S. Appl. No. 15/611,587 mailed Dec. 21, 2018. |
Notice of Allowance for U.S. Appl. No. 15/612,325 mailed Feb. 19, 2021. |
Notice of Allowance for U.S. Appl. No. 15/612,325 mailed Jan. 21, 2021. |
Notice of Allowance for U.S. Appl. No. 17/088,272 mailed Aug. 5, 2021. |
Notice of Allowance for U.S. Appl. No. 17/088,272 mailed Nov. 24, 2021. |
Notice of Allowance for U.S. Appl. No. 17/330,657 mailed Nov. 26, 2021. |
Notice of Allowance for U.S. Appl. No. 29/624,661 mailed Apr. 28, 2021. |
Notice of Allowance for U.S. Appl. No. 29/624,661 mailed Jul. 10, 2020. |
Notice of Allowance for U.S. Appl. No. 29/624,661 mailed May 14, 2020. |
Notice of Allowance for U.S. Appl. No. 29/624,661 mailed Sep. 29, 2020. |
Notice of Allowance for U.S. Appl. No. 29/694,002 mailed Apr. 29, 2021. |
Notice of Allowance for U.S. Appl. No. 29/694,002 mailed Jan. 29, 2021. |
Notice of Allowance for U.S. Appl. No. 29/694,002 mailed Oct. 16, 2020. |
Notice to File Missing Parts for U.S. Appl. No. 17/179,116 mailed Mar. 3, 2021. |
Restriction Requirement for U.S. Appl. No. 16/433,773 mailed Dec. 7, 2021. |
Restriction Requirement for U.S. Appl. No. 16/478,180 mailed May 25, 2021. |
U.S. Appl. No. 14/433,773, filed Apr. 3, 2020. |
U.S. Appl. No. 14/625,469, filed Feb. 28, 2015. |
U.S. Appl. No. 14/947,759, filed Nov. 20, 2015. |
U.S. Appl. No. 14/952,591, filed Nov. 25, 2015. |
U.S. Appl. No. 15/171,968, filed Jun. 2, 2016. |
U.S. Appl. No. 15/221,106, filed Jul. 27, 2016. |
U.S. Appl. No. 15/260,103, filed Sep. 8, 2016. |
U.S. Appl. No. 15/611,587, filed Jun. 1, 2017. |
U.S. Appl. No. 15/612,325, filed Jun. 2, 2017. |
U.S. Appl. No. 16/245,726, filed Jan. 11, 2019. |
U.S. Appl. No. 16/369,676, filed Mar. 29, 2019. |
U.S. Appl. No. 16/433,773, filed Jun. 6, 2019. |
U.S. Appl. No. 16/449,039, filed Jun. 21, 2019. |
U.S. Appl. No. 16/452,145, filed Jun. 25, 2019. |
U.S. Appl. No. 16/452,258, filed Jun. 25, 2019. |
U.S. Appl. No. 16/478,180, filed Jul. 16, 2019. |
U.S. Appl. No. 16/904,868, filed Jun. 18, 2020. |
U.S. Appl. No. 16/905,400, filed Jun. 18, 2020. |
U.S. Appl. No. 17/051,550, filed Oct. 29, 2020. |
U.S. Appl. No. 17/051,554, filed Oct. 29, 2020. |
U.S. Appl. No. 17/051,585, filed Oct. 29, 2020. |
U.S. Appl. No. 17/051,600, filed Oct. 29, 2020. |
U.S. Appl. No. 17/088,272, filed Nov. 3, 2020. |
U.S. Appl. No. 17/179,116, filed Feb. 18, 2021. |
U.S. Appl. No. 17/330,657, filed May 26, 2021. |
U.S. Appl. No. 17/378,015, filed Jul. 16, 2021. |
U.S. Appl. No. 17/412,864, filed Aug. 26, 2021. |
U.S. Appl. No. 17/444,825, filed Aug. 10, 2021. |
U.S. Appl. No. 17/446,256, filed Aug. 27, 2021. |
U.S. Appl. No. 17/446,654, filed Sep. 1, 2021. |
U.S. Appl. No. 17/447,123, filed Sep. 8, 2021. |
U.S. Appl. No. 17/450,864, filed Oct. 14, 2021. |
U.S. Appl. No. 17/451,345, filed Oct. 19, 2021. |
U.S. Appl. No. 17/451,354, filed Oct. 19, 2021. |
U.S. Appl. No. 17/453,260, filed Nov. 2, 2021. |
U.S. Appl. No. 17/453,560, filed Nov. 4, 2021. |
U.S. Appl. No. 17/461,036 mailed Aug. 30, 2021. |
U.S. Appl. No. 17/494,578, filed Oct. 5, 2021. |
U.S. Appl. No. 17/501,591, filed Oct. 14, 2021. |
U.S. Appl. No. 17/595,747, filed Nov. 23, 2021. |
U.S. Appl. No. 17/614,173, filed Nov. 24, 2021. |
U.S. Appl. No. 17/645,821, filed Dec. 23, 2021. |
U.S. Appl. No. 29/741,751, filed Jul. 15, 2020. |
U.S. Appl. No. 61/955,537, filed Mar. 19, 2014. |
U.S. Appl. No. 62/082,279, filed Nov. 20, 2014. |
U.S. Appl. No. 62/084,078, filed Nov. 25, 2014. |
U.S. Appl. No. 62/414,963, filed Oct. 31, 2016. |
U.S. Appl. No. 62/452,437, filed Jan. 31, 2017. |
U.S. Appl. No. 62/485,578, filed Apr. 14, 2017. |
U.S. Appl. No. 62/665,297, filed May 1, 2018. |
U.S. Appl. No. 62/665,302, filed May 1, 2018. |
U.S. Appl. No. 62/665,317, filed May 1, 2018. |
U.S. Appl. No. 62/665,321, filed May 1, 2018. |
U.S. Appl. No. 62/665,331, filed May 1, 2018. |
U.S. Appl. No. 62/665,335, filed May 1, 2018. |
U.S. Appl. No. 62/853,279, filed May 28, 2019. |
U.S. Appl. No. 62/853,889, filed May 29, 2019. |
U.S. Appl. No. 62/864,656, filed Jun. 21, 2019. |
U.S. Appl. No. 62/873,045, filed Jul. 11, 2019. |
U.S. Appl. No. 62/873,048, filed Jul. 11, 2019. |
U.S. Appl. No. 62/876,500, filed Jul. 19, 2019. |
U.S. Appl. No. 62/877,558, filed Jul. 23, 2019. |
U.S. Appl. No. 62/883,172, filed Aug. 6, 2019. |
U.S. Appl. No. 62/889,149, filed Aug. 20, 2019. |
U.S. Appl. No. 62/938,447, filed Nov. 21, 2019. |
U.S. Appl. No. 62/949,187, filed Dec. 17, 2019. |
U.S. Appl. No. 62/956,756, filed Jan. 3, 2020. |
U.S. Appl. No. 62/956,767, filed Jan. 3, 2020. |
U.S. Appl. No. 62/956,770, filed Jan. 3, 2020. |
U.S. Appl. No. 62/994,912, filed Mar. 26, 2020. |
U.S. Appl. No. 63/011,445, filed Apr. 17, 2020. |
U.S. Appl. No. 63/011,487, filed Apr. 17, 2020. |
U.S. Appl. No. 63/011,571, filed Apr. 17, 2020. |
U.S. Appl. No. 63/011,657, filed Apr. 17, 2020. |
U.S. Appl. No. 63/011,760, filed Apr. 17, 2020. |
U.S. Appl. No. 63/012,347, filed Apr. 20, 2020. |
U.S. Appl. No. 63/012,384, filed Apr. 20, 2020. |
U.S. Appl. No. 63/030,685, filed May 27, 2020. |
U.S. Appl. No. 63/033,310, filed Jun. 2, 2020. |
U.S. Appl. No. 63/047,374, filed Jul. 2, 2020. |
U.S. Appl. No. 63/061,241, filed Aug. 5, 2020. |
U.S. Appl. No. 63/061,244, filed Aug. 5, 2020. |
U.S. Appl. No. 63/061,834, filed Aug. 6, 2020. |
U.S. Appl. No. 63/064,017, filed Aug. 11, 2020. |
U.S. Appl. No. 63/064,126, filed Aug. 11, 2020. |
U.S. Appl. No. 63/067,542, filed Aug. 19, 2020. |
U.S. Appl. No. 63/071,438, filed Aug. 28, 2020. |
U.S. Appl. No. 63/071,821, filed Aug. 28, 2020. |
U.S. Appl. No. 63/073,545, filed Sep. 2, 2020. |
U.S. Appl. No. 63/073,553, filed Sep. 2, 2020. |
U.S. Appl. No. 63/074,051, filed Sep. 3, 2020. |
U.S. Appl. No. 63/074,066, filed Sep. 3, 2020. |
U.S. Appl. No. 63/076,032, filed Sep. 9, 2020. |
U.S. Appl. No. 63/076,474, filed Sep. 10, 2020. |
U.S. Appl. No. 63/076,477, filed Sep. 10, 2020. |
U.S. Appl. No. 63/082,261, filed Sep. 23, 2020. |
U.S. Appl. No. 63/088,506, filed Oct. 7, 2020. |
U.S. Appl. No. 63/088,511, filed Oct. 7, 2020. |
U.S. Appl. No. 63/088,539, filed Oct. 7, 2020. |
U.S. Appl. No. 63/094,464, filed Oct. 21, 2020. |
U.S. Appl. No. 63/094,498, filed Oct. 21, 2020. |
U.S. Appl. No. 63/094,594, filed Oct. 21, 2020. |
U.S. Appl. No. 63/094,608, filed Oct. 21, 2020. |
U.S. Appl. No. 63/094,626, filed Oct. 21, 2020. |
U.S. Appl. No. 63/109,066, filed Nov. 3, 2020. |
U.S. Appl. No. 63/109,084, filed Nov. 3, 2020. |
U.S. Appl. No. 63/112,417, filed Nov. 11, 2020. |
U.S. Appl. No. 63/119,161, filed Nov. 30, 2020. |
U.S. Appl. No. 63/124,271, filed Dec. 11, 2020. |
U.S. Appl. No. 63/133,892, filed Jan. 5, 2021. |
U.S. Appl. No. 63/134,287, filed Jan. 6, 2021. |
U.S. Appl. No. 63/134,450, filed Jan. 6, 2021. |
U.S. Appl. No. 63/134,631, filed Jan. 7, 2021. |
U.S. Appl. No. 63/134,632, filed Jan. 7, 2021. |
U.S. Appl. No. 63/134,754, filed Jan. 7, 2021. |
U.S. Appl. No. 63/146,946, filed Feb. 8, 2021. |
U.S. Appl. No. 63/147,013, filed Feb. 8, 2021. |
U.S. Appl. No. 63/147,299, filed Feb. 9, 2021. |
U.S. Appl. No. 63/148,723, filed Feb. 12, 2021. |
U.S. Appl. No. 63/154,248, filed Feb. 26, 2021. |
U.S. Appl. No. 63/155,395, filed Mar. 2, 2021. |
U.S. Appl. No. 63/157,007, filed Mar. 5, 2021. |
U.S. Appl. No. 63/157,014, filed Mar. 5, 2021. |
U.S. Appl. No. 63/159,142, filed Mar. 10, 2021. |
U.S. Appl. No. 63/159,186, filed Mar. 10, 2021. |
U.S. Appl. No. 63/159,210, filed Mar. 10, 2021. |
U.S. Appl. No. 63/159,280, filed Mar. 10, 2021. |
U.S. Appl. No. 63/165,273, filed Mar. 24, 2021. |
U.S. Appl. No. 63/165,384, filed Mar. 24, 2021. |
U.S. Appl. No. 63/171,165, filed Apr. 6, 2021. |
U.S. Appl. No. 63/172,975, filed Apr. 9, 2021. |
U.S. Appl. No. 63/181,695, filed Apr. 29, 2021. |
U.S. Appl. No. 63/192,274, filed May 24, 2021. |
U.S. Appl. No. 63/193,235, filed May 26, 2021. |
U.S. Appl. No. 63/193,406, filed May 26, 2021. |
U.S. Appl. No. 63/193,891, filed May 27, 2021. |
U.S. Appl. No. 63/214,551, filed Jun. 24, 2021. |
U.S. Appl. No. 63/214,570, filed Jun. 24, 2021. |
U.S. Appl. No. 63/215,017, filed Jun. 25, 2021. |
U.S. Appl. No. 63/228,244, filed Aug. 2, 2021. |
U.S. Appl. No. 63/228,252, filed Aug. 2, 2021. |
U.S. Appl. No. 63/228,258, filed Aug. 2, 2021. |
U.S. Appl. No. 63/230,894, filed Aug. 9, 2021. |
U.S. Appl. No. 63/238,457, filed Aug. 30, 2021. |
U.S. Appl. No. 63/238,477, filed Aug. 30, 2021. |
U.S. Appl. No. 63/241,562, filed Sep. 8, 2021. |
U.S. Appl. No. 63/241,564, filed Sep. 8, 2021. |
U.S. Appl. No. 63/241,575, filed Sep. 8, 2021. |
U.S. Appl. No. 63/246,972, filed Sep. 22, 2021. |
U.S. Appl. No. 63/247,375, filed Sep. 23, 2021. |
U.S. Appl. No. 63/247,478, filed Sep. 23, 2021. |
U.S. Appl. No. 63/247,491, filed Sep. 23, 2021. |
Sage's Second Supplemental Invalidity Contentions Regarding U.S. Pat. Nos. 8,287,508, 10,226,375, 10,390,989, and 10,376,407, 292 pages. |
Plaintiff's Identification of Claim Terms and Proposed Constructions, 3 pages. |
Sage's Preliminary Identification of Claim Elements and Proposed Constructions for U.S. Pat. Nos. 8,287,508, 10,226,376, 10,390,989 and 10,376,407, 7 pages. |
Corrected Certificate of Service, 2020, 2 pages. |
Excerpts from the 508 (U.S. Pat. No. 8,278,508) Patent's Prosecution History, 2020, 99 pages. |
Declaration of Diane K. Newman Curriculum Vitae, 2020, pp. 1-199. |
Sage's Supplemental and Initial Invalidity Contentions Regarding U.S. Pat. Nos. 8,287,508; 10,226,375; 10,390,989 and Initial Invalidity Contentions Regarding U.S. Pat. No. 10,376,407, Aug. 21, 2020, 277 pages. |
Decision Granting Institution of Inter Partes Review for U.S. Pat. No. 8,287,508, Feb. 17, 2021, 39 pages. |
Memorandum Order, Feb. 2021, 14 pgs. |
Boehringer CareDry System—Second Generation for Non-Invasive Urinary Management for Females, Mar. 2021, 3 pgs. |
PureWick's Response to Interrogatory No. 9 in PureWick, LLC v. Sage Products, LLC, Mar. 23, 2020, 6 pages. |
Sage's Initial Invalidity Contentions Regarding U.S. Pat. Nos. 8,287,508; 10,226,375; and 10,390,989, May 29, 2020, 193 pages. |
Defendant and Counterclaim Plaintiff Sage Products, LLC's Answer, Defenses, and Counterclaims to Plaintiff's Amended Complaint, Nov. 1, 2019. |
Plaintiff's Opening Claim Construction Brief, Oct. 16, 2020, 26 pages. |
“3 Devices Take Top Honors in Dare-To-Dream Medtech Design Contest”, R+D Digest, Nov. 2013, 1 page. |
“Advanced Mission Extender Device (AMDX) Products”, Omni Medical Systems, Inc., 15 pages. |
“AMXD Control Starter Kit Brochure”, https://www.omnimedicalsys.com/index.php?page=products, 8 pages. |
“AMXDmax In-Flight Bladder Relief”, Omni Medical; Omni Medical Systems, Inc., 2015. |
“AMXDX—Advanced Mission Extender Device Brochure”, Omni Medical, 2 pages. |
“External Urine Management for Female Anatomy”, https://www.stryker.com/us/en/sage/products/sage-primafit.html, Jul. 2020, 4 pages. |
“High Absorbancy Cellulose Acetate Electrospun Nanofibers for Feminine Hygiene Application”, https://www.sciencedirect.com/science/article/abs/pii/S2352940716300701?via%3Dihub, Jul. 2016, 3 pages. |
“How Period Panties Work”, www.shethinx.com/pages/thinx-itworks, 2020, 10 pages. |
“Hydrogel properties of electrospun polyvinylpyrrolidone and polyvinylpyrrolidone/poly(acrylic acid) blend nanofibers”, https://pubs.rsc.org/en/content/articlelanding/2015/ra/c5ra07514a#!divAbstract, 2015, 5 pages. |
“In Flight Bladder Relief”, Omni Medical, 14 pages. |
“Making Women's Sanitary Products Safer and Cheaper”, https://www.elsevier.com/connect/making-womens-sanitary-products-safer-and-cheaper, Sep. 2016, 10 pages. |
“Novel Nanofibers Make Safe and Effective Absorbent for Sanitary Products”, https://www.materialstoday.com/nanomaterials/news/nanofibers-make-safe-and-effective-absorbent/, Oct. 2016, 3 pages. |
“Research and Development Work Relating to Assistive Technology Jun. 2005”, British Department of Health, Nov. 2006, 40 pages. |
“Step by Step How Ur24 WorksHome”, http://medicalpatentur24.com, Aug. 30, 2017, 4 pages. |
“Underwear that absorbs your period”, Thinx!, 7 pages. |
“User & Maintenance Guide”, Omni Medical, 2007, 16 pages. |
“Winners Announced for Dare-to-Dream Medtech Design Challenge”, https://www.mddionline.com/design-engineering/winners-announced-dare-dream-medtech-design-challenge, 2014, 4 pages. |
Hollister , Female Urinary and Pouch and Male Urinary Pouch Brochure, 2011, 1 page. |
Hollister , “Male Urinary Pouch External Collection Device”, http://www.hollister.com/en/products/Continence-Care-Products/Urine-Collectors/Urine-Collection-Accessories/Male-Urinary-Pouch-External-Collection-Device. |
Hollister , “Retracted Penis Pouch by Hollister”, Vitality Medical.com, 6 pages. |
Macaulay , et al., “A Noninvasive Continence Management System: Development and Evaluation of a Novel Toileting Device for Women”, The Wound, Ostomy and Continence Nurses Society, 2007, pp. 641-648. |
Newman , et al., “The Urinary Incontinence Sourcebook”, Petition for Interparties Review, 1997, 23 pages. |
Newton , et al., “Measuring Safety, Effectiveness and Ease of Use of PureWick in the Management of Urinary Incontinence in Bedbound Women: Case Studies”, Jan. 8, 2016, 11 pages. |
Parmar , “10 Finalists Chosen for Dare-to-Dream Medtech Design Challenge (PureWick)”, Design Services, Nov. 10, 2014, 3 pages. |
Purewick , “Incontinence Relief for Women”, Presentation, Sep. 23, 2015, 7 pages. |
Pytlik , “Super Absorbent Polymers”, University of Buffalo. |
Sachtman , “New Relief for Pilots? It Depends”, Wired, 2008, 2 pages. |
Advisory Action for U.S. Appl. No. 16/478,180 mailed Sep. 7, 2023. |
Advisory Action for U.S. Appl. No. 17/051,550 mailed Sep. 8, 2023. |
Advisory Action for U.S. Appl. No. 17/444,792 mailed Aug. 25, 2023. |
Final Office Action for U.S. Appl. No. 16/369,676 mailed Aug. 31, 2023. |
Final Office Action for U.S. Appl. No. 17/051,585 mailed Jul. 27, 2023. |
Final Office Action for U.S. Appl. No. 17/444,792 mailed Jun. 15, 2023. |
Final Office Action for U.S. Appl. No. 17/446,256 mailed Sep. 19, 2023. |
Final Office Action for U.S. Appl. No. 17/448,811 mailed Aug. 3, 2023. |
Final Office Action for U.S. Appl. No. 17/653,137 mailed Sep. 21, 2023. |
Final Office Action for U.S. Appl. No. 17/655,464 mailed Sep. 1, 2023. |
International Search Report and Written Opinion from International Application No. PCT/US2022/043818 mailed Mar. 24, 2023. |
International Search Report and Written Opinion from International Application No. PCT/US2022/044208 mailed May 8, 2023. |
International Search Report and Written Opinion from International Application No. PCT/US2022/049300 mailed Jun. 6, 2023. |
International Search Report and Written Opinion from International Application No. PCT/US2022/050909 mailed Jul. 24, 2023. |
International Search Report and Written Opinion from International Application No. PCT/US2023/012696 mailed Jul. 6, 2023. |
Non-Final Office Action for U.S. Appl. No. 17/051,399 mailed Aug. 18, 2023. |
Non-Final Office Action for U.S. Appl. No. 17/326,980 mailed Jul. 11, 2023. |
Non-Final Office Action for U.S. Appl. No. 17/446,654 mailed Sep. 8, 2023. |
Non-Final Office Action for U.S. Appl. No. 17/657,474 mailed Sep. 12, 2023. |
Non-Final Office Action for U.S. Appl. No. 17/661,090 mailed Jul. 6, 2023. |
Non-Final Office Action for U.S. Appl. No. 17/663,330 mailed Jun. 29, 2023. |
Non-Final Office Action for U.S. Appl. No. 17/664,487 mailed Jun. 8, 2023. |
Non-Final Office Action for U.S. Appl. No. 18/139,523 mailed Aug. 17, 2023. |
Non-Final Office Action for U.S. Appl. No. 18/140,751 mailed Sep. 14, 2023. |
Notice of Allowance for U.S. Appl. No. 16/245,726 mailed Jul. 6, 2023. |
Notice of Allowance for U.S. Appl. No. 17/051,554 mailed Jul. 6, 2023. |
Notice of Allowance for U.S. Appl. No. 17/461,036 mailed Jun. 30, 2023. |
Notice of Allowance for U.S. Appl. No. 17/662,700 mailed Jul. 28, 2023. |
Notice of Allowance for U.S. Appl. No. 18/299,788 mailed Jul. 24, 2023. |
Restriction Requirement for U.S. Appl. No. 17/051,600 mailed Sep. 21, 2023. |
Restriction Requirement for U.S. Appl. No. 17/645,821 mailed Jul. 12, 2023. |
Restriction Requirement for U.S. Appl. No. 17/657,474 mailed Jun. 30, 2023. |
U.S. Appl. No. 17/664,487, filed May 23, 2022. |
U.S. Appl. No. 18/259,626, filed Jun. 28, 2023. |
U.S. Appl. No. 18/260,122 filed Jun. 30, 2023. |
U.S. Appl. No. 18/260,391, filed Jul. 5, 2023. |
U.S. Appl. No. 18/260,394, filed Jul. 5, 2023. |
U.S. Appl. No. 18/263,800, filed Aug. 1, 2023. |
U.S. Appl. No. 18/264,004, filed Aug. 2, 2023. |
U.S. Appl. No. 18/265,736, filed Jun. 7, 2023. |
U.S. Appl. No. 18/335,579, filed Jun. 15, 2023. |
U.S. Appl. No. 18/373,424, filed Sep. 27, 2023. |
U.S. Appl. No. 18/376,274, filed Oct. 3, 2023. |
U.S. Appl. No. 18/548,152, filed Aug. 28, 2023. |
U.S. Appl. No. 18/549,387, filed Sep. 7, 2023. |
U.S. Appl. No. 18/553,625, filed Oct. 2, 2023. |
U.S. Appl. No. 63/150,640, filed Feb. 18, 2021. |
Merriam-Webster Dictionary, , “Embed Definition & Meaning”, https://www.merriam-webster.com/dictionary/ embed last accessed Aug. 3, 2023, 2003. |
Advisory Action for U.S. Appl. No. 16/433,773 mailed Dec. 29, 2023. |
Advisory Action for U.S. Appl. No. 16/449,039 mailed Jan. 25, 2024. |
Advisory Action for U.S. Appl. No. 16/904,868 mailed Jan. 2, 2024. |
Advisory Action for U.S. Appl. No. 17/051,585 mailed Oct. 17, 2023. |
Advisory Action for U.S. Appl. No. 17/179,116 mailed Jan. 8, 2024. |
Advisory Action for U.S. Appl. No. 17/446,256 mailed Dec. 8, 2023. |
Advisory Action for U.S. Appl. No. 17/448,811 mailed Nov. 15, 2023. |
Advisory Action for U.S. Appl. No. 17/451,345 mailed Oct. 20, 2023. |
Advisory Action for U.S. Appl. No. 17/451,354 mailed Jan. 30, 2024. |
Advisory Action for U.S. Appl. No. 17/453,260 mailed Dec. 22, 2023. |
Advisory Action for U.S. Appl. No. 17/501,591 mailed Feb. 22, 2024. |
Advisory Action for U.S. Appl. No. 17/653,137 mailed Dec. 1, 2023. |
Advisory Action for U.S. Appl. No. 17/655,464 mailed Dec. 13, 2023. |
Advisory Action for U.S. Appl. No. 17/661,090 mailed Feb. 26, 2024. |
Advisory Action for U.S. Appl. No. 17/663,330 mailed Feb. 27, 2024. |
Advisory Action for U.S. Appl. No. 18/164,800 mailed Feb. 12, 2024. |
Communication of Notice of Opposition of European Application No. 17807547.9 mailed Jan. 5, 2024. |
Corrected Notice of Allowability for U.S. Appl. No. 16/369,676 mailed Dec. 7, 2023. |
Corrected Notice of Allowability for U.S. Appl. No. 17/326,980 mailed Feb. 8, 2024. |
Final Office Action for U.S. Appl. No. 16/433,773 mailed Oct. 10, 2023. |
Final Office Action for U.S. Appl. No. 16/449,039 mailed Nov. 21, 2023. |
Final Office Action for U.S. Appl. No. 16/452,258 mailed Dec. 21, 2023. |
Final Office Action for U.S. Appl. No. 16/478,180 mailed Feb. 28, 2024. |
Final Office Action for U.S. Appl. No. 16/904,868 mailed Nov. 2, 2023. |
Final Office Action for U.S. Appl. No. 17/051,399 mailed Jan. 8, 2024. |
Final Office Action for U.S. Appl. No. 17/179,116 mailed Oct. 31, 2023. |
Final Office Action for U.S. Appl. No. 17/446,654 mailed Jan. 31, 2024. |
Final Office Action for U.S. Appl. No. 17/450,864 mailed Dec. 28, 2023. |
Final Office Action for U.S. Appl. No. 17/451,354 mailed Oct. 30, 2023. |
Final Office Action for U.S. Appl. No. 17/453,260 mailed Oct. 5, 2023. |
Final Office Action for U.S. Appl. No. 17/501,591 mailed Nov. 14, 2023. |
Final Office Action for U.S. Appl. No. 17/661,090 mailed Dec. 11, 2023. |
Final Office Action for U.S. Appl. No. 17/663,330 mailed Dec. 12, 2023. |
Final Office Action for U.S. Appl. No. 17/664,487 mailed Jan. 4, 2024. |
Final Office Action for U.S. Appl. No. 18/139,523 mailed Dec. 22, 2023. |
Final Office Action for U.S. Appl. No. 18/140,751 mailed Jan. 17, 2024. |
Final Office Action for U.S. Appl. No. 18/164,800 mailed Dec. 6, 2023. |
International Search Report and Written Opinion from International Application No. PCT/US2023/018474 mailed Sep. 11, 2023. |
International Search Report and Written Opinion from International Application No. PCT/US2023/024805 mailed Dec. 14, 2023. |
International Search Report and Written Opinion from International Application No. PCT/US2023/025192 mailed Feb. 7, 2024. |
Issue Notification for U.S. Appl. No. 16/245,726 mailed Oct. 18, 2023. |
Issue Notification for U.S. Appl. No. 17/051,554 mailed Mar. 6, 2024. |
Issue Notification for U.S. Appl. No. 17/461,036 mailed Oct. 11, 2023. |
Issue Notification for U.S. Appl. No. 17/663,046 mailed Dec. 20, 2023. |
Issue Notification for U.S. Appl. No. 18/299,788 mailed Feb. 21, 2024. |
Non-Final Office Action for U.S. Appl. No. 16/369,676 mailed Feb. 29, 2024. |
Non-Final Office Action for U.S. Appl. No. 16/433,773 mailed Feb. 26, 2024. |
Non-Final Office Action for U.S. Appl. No. 16/452,145 mailed Nov. 2, 2023. |
Non-Final Office Action for U.S. Appl. No. 16/478,180 mailed Nov. 7, 2023. |
Non-Final Office Action for U.S. Appl. No. 17/051,550 mailed Oct. 24, 2023. |
Non-Final Office Action for U.S. Appl. No. 17/051,585 mailed Jan. 8, 2024. |
Non-Final Office Action for U.S. Appl. No. 17/051,600 mailed Jan. 17, 2024. |
Non-Final Office Action for U.S. Appl. No. 17/179,116 mailed Feb. 26, 2024. |
Non-Final Office Action for U.S. Appl. No. 17/444,792 mailed Nov. 17, 2023. |
Non-Final Office Action for U.S. Appl. No. 17/446,256 mailed Feb. 13, 2024. |
Non-Final Office Action for U.S. Appl. No. 17/447,123 mailed Jan. 24, 2024. |
Non-Final Office Action for U.S. Appl. No. 17/448,811 mailed Jan. 17, 2024. |
Non-Final Office Action for U.S. Appl. No. 17/451,345 mailed Jan. 17, 2024. |
Non-Final Office Action for U.S. Appl. No. 17/453,560 mailed Oct. 16, 2023. |
Non-Final Office Action for U.S. Appl. No. 17/645,821 mailed Oct. 25, 2023. |
Non-Final Office Action for U.S. Appl. No. 17/653,137 mailed Jan. 18, 2024. |
Non-Final Office Action for U.S. Appl. No. 17/664,914 mailed Jan. 31, 2024. |
Non-Final Office Action for U.S. Appl. No. 17/808,354 mailed Nov. 28, 2023. |
Non-Final Office Action for U.S. Appl. No. 18/134,857 mailed Jan. 25, 2024. |
Non-Final Office Action for U.S. Appl. No. 18/140,163 mailed Nov. 9, 2023. |
Non-Final Office Action for U.S. Appl. No. 18/198,464 mailed Dec. 7, 2023. |
Notice of Allowance for U.S. Appl. No. 16/369,676 mailed Nov. 14, 2023. |
Notice of Allowance for U.S. Appl. No. 17/051,550 mailed Feb. 7, 2024. |
Notice of Allowance for U.S. Appl. No. 17/051,554 mailed Oct. 18, 2023. |
Notice of Allowance for U.S. Appl. No. 17/326,980 mailed Jan. 29, 2024. |
Notice of Allowance for U.S. Appl. No. 17/453,560 mailed Jan. 31, 2024. |
Notice of Allowance for U.S. Appl. No. 17/657,474 mailed Mar. 5, 2024. |
Notice of Allowance for U.S. Appl. No. 17/662,700 mailed Mar. 6, 2024. |
Notice of Allowance for U.S. Appl. No. 17/662,700 mailed Nov. 15, 2023. |
Notice of Allowance for U.S. Appl. No. 18/299,788 mailed Nov. 6, 2023. |
Restriction Requirement for U.S. Appl. No. 18/134,857 mailed Oct. 23, 2023. |
Submission in Opposition Proceedings for European Application No. 17807547.9 filed Jan. 10, 2024. |
Supplemental Notice of Allowance for U.S. Appl. No. 17/051,550 mailed Feb. 21, 2024. |
Supplemental Notice of Allowance for U.S. Appl. No. 17/051,554 mailed Feb. 14, 2024. |
U.S. Appl. No. 17/451,719, filed Oct. 19, 2021. |
U.S. Appl. No. 18/294,370, filed Feb. 1, 2024. |
U.S. Appl. No. 18/294,403, filed Feb. 1, 2024. |
U.S. Appl. No. 18/389,009, filed Nov. 13, 2023. |
U.S. Appl. No. 18/415,080, filed Jan. 17, 2024. |
U.S. Appl. No. 18/426,795, filed Jan. 30, 2024. |
U.S. Appl. No. 18/549,658, filed Sep. 8, 2023. |
U.S. Appl. No. 18/556,945, filed Oct. 24, 2023. |
U.S. Appl. No. 18/558,502, filed Nov. 1, 2023. |
U.S. Appl. No. 18/562,626, filed Nov. 20, 2023. |
U.S. Appl. No. 18/563,672, filed Nov. 22, 2023. |
U.S. Appl. No. 18/569,711, filed Dec. 13, 2023. |
U.S. Appl. No. 18/569,778, filed Dec. 13, 2023. |
U.S. Appl. No. 18/584,002, filed Feb. 22, 2024. |
U.S. Appl. No. 18/681,987, filed Feb. 7, 2024. |
U.S. Appl. No. 18/682,006, filed Feb. 7, 2024. |
U.S. Appl. No. 18/687,117, filed Feb. 27, 2024. |
U.S. Appl. No. 18/688,023, filed Feb. 29, 2024. |
U.S. Appl. No. 63/596,012, filed Nov. 3, 2023. |
U.S. Appl. No. 63/608,553, filed Dec. 11, 2023. |
Wikipedia Article, “Zylinder (Geometrie)”, https://de.wikipedia.org/w/index.php?title=Zylinder (Geometrie)&oldid=154862081, version of Jun. 1, 2016, 7 pages. |
Advisory Action for U.S. Appl. No. 16/452,258 mailed Apr. 8, 2024. |
Advisory Action for U.S. Appl. No. 16/478,180 mailed Jun. 7, 2024. |
Advisory Action for U.S. Appl. No. 17/444,792 mailed Jul. 8, 2024. |
Advisory Action for U.S. Appl. No. 17/446,654 mailed Apr. 15, 2024. |
Advisory Action for U.S. Appl. No. 17/450,864 mailed Mar. 21, 2024. |
Advisory Action for U.S. Appl. No. 17/451,345 mailed Jul. 3, 2024. |
Advisory Action for U.S. Appl. No. 17/645,821 mailed Jul. 2, 2024. |
Advisory Action for U.S. Appl. No. 17/664,487 mailed Mar. 13, 2024. |
Advisory Action for U.S. Appl. No. 17/808,354 mailed Jun. 12, 2024. |
Advisory Action for U.S. Appl. No. 18/139,523 mailed Apr. 24, 2024. |
Advisory Action for U.S. Appl. No. 18/140,163 mailed Jun. 3, 2024. |
Advisory Action for U.S. Appl. No. 18/140,751 mailed Apr. 24, 2024. |
Corrected Notice of Allowability for U.S. Appl. No. 17/501,591 mailed Aug. 9, 2024. |
Corrected Notice of Allowability for U.S. Appl. No. 17/657,474 mailed Mar. 13, 2024. |
Corrected Notice of Allowability for U.S. Appl. No. 17/657,474 mailed May 14, 2024. |
Corrected Notice of Allowability for U.S. Appl. No. 17/664,914 mailed Aug. 9, 2024. |
Final Office Action for U.S. Appl. No. 17/051,585 mailed Jul. 5, 2024. |
Final Office Action for U.S. Appl. No. 17/051,600 mailed Jun. 27, 2024. |
Final Office Action for U.S. Appl. No. 17/444,792 mailed Apr. 3, 2024. |
Final Office Action for U.S. Appl. No. 17/446,256 mailed Aug. 7, 2024. |
Final Office Action for U.S. Appl. No. 17/447,123 mailed May 14, 2024. |
Final Office Action for U.S. Appl. No. 17/451,345 mailed Apr. 18, 2024. |
Final Office Action for U.S. Appl. No. 17/645,821 mailed Apr. 3, 2024. |
Final Office Action for U.S. Appl. No. 17/653,137 mailed Aug. 7, 2024. |
Final Office Action for U.S. Appl. No. 17/653,920 mailed Aug. 14, 2024. |
Final Office Action for U.S. Appl. No. 17/808,354 mailed Apr. 10, 2024. |
Final Office Action for U.S. Appl. No. 18/134,857 mailed Jul. 25, 2024. |
Final Office Action for U.S. Appl. No. 18/140,163 mailed Mar. 27, 2024. |
International Search Report and Written Opinion from International Application No. PCT/US2023/025939 mailed Feb. 7, 2024. |
International Search Report and Written Opinion from International Application No. PCT/US2023/030365 mailed Mar. 13, 2024. |
International Search Report and Written Opinion from International Application No. PCT/US2023/030373 mailed Mar. 13, 2024. |
International Search Report and Written Opinion from International Application No. PCT/US2023/031433 mailed Mar. 4, 2024. |
International Search Report and Written Opinion from International Application No. PCT/US2023/031740 mailed Mar. 4, 2024. |
International Search Report and Written Opinion from International Application No. PCT/US2023/036238 mailed Jul. 22, 2024. |
International Search Report and Written Opinion from International Application No. PCT/US2023/036868 mailed Jun. 5, 2024. |
International Search Report and Written Opinion from International Application No. PCT/US2023/075507 mailed Jun. 13, 2024. |
International Search Report and Written Opinion from International Application No. PCT/US2023/077168 mailed Jun. 24, 2024. |
International Search Report and Written Opinion from International Application No. PCT/US2023/077208 mailed May 10, 2024. |
International Search Report and Written Opinion from International Application No. PCT/US2023/080680 mailed Jul. 22, 2024. |
Issue Notification for U.S. Appl. No. 16/449,039 mailed Jun. 19, 2024. |
Issue Notification for U.S. Appl. No. 17/051,550 mailed Mar. 13, 2024. |
Issue Notification for U.S. Appl. No. 17/326,980 mailed Jul. 10, 2024. |
Issue Notification for U.S. Appl. No. 17/448,811 mailed Jul. 3, 2024. |
Issue Notification for U.S. Appl. No. 17/453,260 mailed Jul. 10, 2024. |
Issue Notification for U.S. Appl. No. 17/453,560 mailed Aug. 7, 2024. |
Issue Notification for U.S. Appl. No. 17/657,474 mailed Jun. 19, 2024. |
Non-Final Office Action for U.S. Appl. No. 16/452,258 mailed Jun. 20, 2024. |
Non-Final Office Action for U.S. Appl. No. 16/478,180 mailed Aug. 7, 2024. |
Non-Final Office Action for U.S. Appl. No. 16/904,868 mailed Mar. 12, 2024. |
Non-Final Office Action for U.S. Appl. No. 17/378,015 mailed Jul. 5, 2024. |
Non-Final Office Action for U.S. Appl. No. 17/446,654 mailed Jun. 25, 2024. |
Non-Final Office Action for U.S. Appl. No. 17/450,864 mailed May 29, 2024. |
Non-Final Office Action for U.S. Appl. No. 17/451,345 mailed Jul. 25, 2024. |
Non-Final Office Action for U.S. Appl. No. 17/451,354 mailed Apr. 4, 2024. |
Non-Final Office Action for U.S. Appl. No. 17/595,747 mailed Jun. 7, 2024. |
Non-Final Office Action for U.S. Appl. No. 17/597,408 mailed Aug. 15, 2024. |
Non-Final Office Action for U.S. Appl. No. 17/597,673 mailed Mar. 20, 2024. |
Non-Final Office Action for U.S. Appl. No. 17/653,920 mailed Mar. 15, 2024. |
Non-Final Office Action for U.S. Appl. No. 17/655,464 mailed Mar. 26, 2024. |
Non-Final Office Action for U.S. Appl. No. 17/661,090 mailed May 22, 2024. |
Non-Final Office Action for U.S. Appl. No. 17/663,330 mailed Jul. 1, 2024. |
Non-Final Office Action for U.S. Appl. No. 17/664,487 mailed Jun. 17, 2024. |
Non-Final Office Action for U.S. Appl. No. 17/749,340 mailed Aug. 14, 2024. |
Non-Final Office Action for U.S. Appl. No. 18/003,029 mailed Mar. 26, 2024. |
Non-Final Office Action for U.S. Appl. No. 18/140,751 mailed Jun. 21, 2024. |
Non-Final Office Action for U.S. Appl. No. 18/164,800 mailed Mar. 22, 2024. |
Non-Final Office Action for U.S. Appl. No. 18/389,009 mailed May 24, 2024. |
Non-Final Office Action for U.S. Appl. No. 18/426,795 mailed Aug. 9, 2024. |
Non-Final Office Action for U.S. Appl. No. 18/451,080 mailed Jul. 30, 2024. |
Notice of Allowance for U.S. Appl. No. 16/369,676 mailed Jun. 17, 2024. |
Notice of Allowance for U.S. Appl. No. 16/449,039 mailed Mar. 28, 2024. |
Notice of Allowance for U.S. Appl. No. 16/452,145 mailed Jul. 11, 2024. |
Notice of Allowance for U.S. Appl. No. 17/326,980 mailed Apr. 5, 2024. |
Notice of Allowance for U.S. Appl. No. 17/447,123 mailed Jul. 26, 2024. |
Notice of Allowance for U.S. Appl. No. 17/448,811 mailed Jun. 14, 2024. |
Notice of Allowance for U.S. Appl. No. 17/453,260 mailed Apr. 8, 2024. |
Notice of Allowance for U.S. Appl. No. 17/501,591 mailed Jul. 31, 2024. |
Notice of Allowance for U.S. Appl. No. 17/657,474 mailed May 2, 2024. |
Notice of Allowance for U.S. Appl. No. 17/662,700 mailed Jun. 12, 2024. |
Notice of Allowance for U.S. Appl. No. 17/664,914 mailed Jul. 26, 2024. |
Notice of Allowance for U.S. Appl. No. 18/140,163 mailed Aug. 21, 2024. |
Notice of Allowance for U.S. Appl. No. 18/198,464 mailed Apr. 17, 2024. |
Notice of Allowance for U.S. Appl. No. 18/198,464 mailed Jul. 30, 2024. |
Restriction Requirement for U.S. Appl. No. 17/527,769 mailed Jun. 17, 2024. |
Restriction Requirement for U.S. Appl. No. 17/625,941 mailed Aug. 7, 2024. |
Restriction Requirement for U.S. Appl. No. 17/667,097 mailed Mar. 20, 2024. |
U.S. Appl. No. 17/013,822, filed Sep. 7, 2020. |
U.S. Appl. No. 17/444,792, filed Aug. 10, 2021. |
U.S. Appl. No. 18/249,577, filed Oct. 19, 2021. |
U.S. Appl. No. 18/610,523, filed Mar. 20, 2024. |
U.S. Appl. No. 18/662,216, filed May 13, 2024. |
U.S. Appl. No. 18/693,638, filed Mar. 20, 2024. |
U.S. Appl. No. 18/694,090, filed Mar. 21, 2024. |
U.S. Appl. No. 18/728,604, filed Jul. 12, 2024. |
U.S. Appl. No. 18/757,964, filed Jun. 28, 2024. |
U.S. Appl. No. 18/758,025, filed Jun. 28, 2024. |
U.S. Appl. No. 18/834,115, filed Jul. 29, 2024. |
U.S. Appl. No. 18/834,176, filed Jul. 29, 2024. |
U.S. Appl. No. 18/834,340, filed Jul. 30, 2024. |
U.S. Appl. No. 18/835,068, filed Aug. 1, 2024. |
U.S. Appl. No. 18/835,444, filed Aug. 2, 2024. |
U.S. Appl. No. 18/836,204, filed Aug. 6, 2024. |
U.S. Appl. No. 63/561,893, filed Dec. 11, 2023. |
U.S. Appl. No. 63/568,615, filed Mar. 22, 2024. |
U.S. Appl. No. 63/683,428, filed Aug. 15, 2024. |
“OBLONG”, Cambridge Dictionary, https://dictionary.cambridge.org/dictionary/english/oblong, 2024, 1 page. |
Britannica, “Polyolefin”, Britannica Online Encyclopedia, T. Editors of Encyclopaedia, https://www.britannica.com/science/polyolefin, Jul. 26, 2012. |
Martin, et al., “Chapter 5 Applications of Polyethylene Oxide (POLYOX) in Hydrophilic Matrices”, Hydrophilic Matrix Tablets for Oral Controlled Release, AAPS Advances in the Pharmaceutical Sciences vol. 16, 2014, pp. 123-141. |
Wikipedia Article, “Decibel”, https://web.archive.org/web/2020041521917/https://en.wikipedia/org/wiki/Decibel last accessed Mar. 11, 2024, 21 pages. |
Wikipedia Article, “Fiberglass”, https://web.archive.org.web/20200309194847/https://en.wikipedia.org/wiki/Fiberglass last accessed Mar. 11, 2024. |
Number | Date | Country | |
---|---|---|---|
20220211536 A1 | Jul 2022 | US |
Number | Date | Country | |
---|---|---|---|
63134450 | Jan 2021 | US |